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ABSTRACT 
Objectives: The objectives of this study were to determine the nutritional content/ contribution of 
intravenous (IV) fluid and electrolyte administration on the total feeding prescription of intensive 
care unit (ICU) patients. 
Methods: Retrospective review of ICU charts of consecutive patients (>18 years) with APACHE II 
scores ≥10 and on ≥72 hours nutrition therapy (NT) admitted to a medical/surgical ICU. Total fluid, 
electrolyte, energy and macronutrient intake from nutritional and non-nutritional sources were 
reviewed from ICU admission until discharge, discontinuation of NT or death for ≤7 days. Energy 
and protein delivery were compared to calculated targets of 25.4 – 28.6kCal/kg and 1.3 – 1.5g/kg 
respectively. Summary statistics, correlation coefficients and appropriate analysis of variance were 
used to describe and analyse the data. 
Results: A total of 71 patients (49% male), average age 49.2 ± 17.1, average APACHE II score 
21.0 ± 6.1, 68% medical and 32% surgical, were included. Fluid and nutrient intake were reviewed 
over a mean of 5.7 ± 1.1 days.  
Mean daily fluid delivery was 3.2 ± 0.6L. IV fluid therapy (IVFT) contributed 32.0 ± 12.0% to total 
fluid delivery (TFD), whereas IV drug administration, including fluids used for reconstitution and 
dilution purposes, contributed 20.7 ± 8.1% to TFD. 
Balanced electrolyte solutions (BES) were the crystalloid of choice, prescribed in 91.5% of patients 
with a mean daily volume (MDV) of 0.5 ± 0.4L. Hypertonic low molecular weight (LMW) 130/0.4kD 
hydroxyethyl starch (HES) was the colloid of choice, prescribed in 78.9% of patients with a MDV of 
0.2 ± 0.1L. Potassium salts were the most frequently prescribed IV electrolyte supplement (IVES), 
prescribed in 91% of patients (±20 – 60mmol per administration). 
NT was initiated within 14.5 ± 14.1 hours. The majority (80%) received enteral nutrition (EN). The 
mean daily energy delivered was 1613 ± 380kCal (25.1kCal/kg), meeting 93.6 ± 17.7% of mean 
target range (MTR). Mean daily protein delivery (PD) was 72 ± 22g (1.1g/kg), meeting 82.8 ± 
19.9% of MTR. Non-nutritional energy sources (NNES), mostly derived from carbohydrate-
containing IV fluids, contributed 10.1 ± 7.5% to total energy delivered (156kCal/d). Mean 
cumulative energy and protein balance was -674.0 ± 1866.1kCal and -86.0 ± 106.9g respectively. 
The majority (73%) received >90% of the minimum energy target but only 49% >90% of minimum 
protein target; 59% of those with energy intake 90-110% of target had adequate protein intake. A 
significant negative correlation was found between cumulative energy/protein balance and the time 
to initiation of NT (energy: r=-0.28, p=0.02; protein: r=-0.32, p=0.01).  
Conclusion: In this ICU BES are the crystalloid of choice and hypertonic LMW 130/0.4kD HES the 
colloid of choice for IVFT. Potassium salts are the most frequently prescribed IVES. NNES added 
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significantly to energy delivery and should be included in the calculation of feeding prescriptions to 
avoid the harmful effects of overfeeding. Early initiation of EN with conventional products which are 
energy rich is insufficient to achieve adequate PD. EN formulae with a more favorable nitrogen to 
non-protein energy ratio could help to optimise PD during the first week of ICU care. 
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OPSOMMING 
Doelwitte: Die doelwit van hierdie studie was om die voedingswaarde/ bydrae van intraveneuse 
(IV) vog en elektroliet toediening tot die totale voedings voorskrif van pasiënte in ‘n intensiewe sorg 
eenheid (ISE) te bepaal. 
Metodes: Retrospektiewe bestudering van die ISE kaarte van agtereenvolgende pasiënte (>18 
jaar) opgeneem in ‘n mediese/chirurgie ISE en met APACHE II tellings ≥10 en ≥72 ure 
voedingsterapie (VT). Totale vog, elektroliet, energie en makronutriënt inname vanaf 
voedingsverwante en nie-voedingsverwante bronne is vanaf ISE opname tot en met ontslag, 
staking van VT of sterfte, vir ≤7 dae hersien. Energie en proteiën inname is vergelyk met 
berekende doelwitte van 25.4 – 28.6kKal/kg en 1.3 – 1.5g/kg onderskeidelik. Beskrywende 
statisitiek, korrelasie koeffisiënte en toepaslike analises van variansie is gebruik vir data analise. 
Resultate: 71 pasiënte (49% mans), gemiddelde ouderdom 49.2 ± 17.1, gemiddelde APACHE II 
telling 21.0 ± 6.1, 68% medies en 32% chirurgie, is ingesluit. Vog en voedingstof inname is hersien 
oor ‘n gemiddelde tydperk van 5.7 ± 1.1 dae. Gemiddelde vog inname was 3.2 ± 0.6L/dag. IV vog 
terapie (IVVT) het 32.0 ± 12.0% bygedra tot totale vog inname (TVI). IV medikasie toediening, 
insluitende die herkonstruksie en verwatering van medikasie, het 20.7 ± 8.1% bygedra tot TVI. 
Die mees voorgeskrewe kristalloiëd en kolloiëd vir IVVT was gebalanseerde elektroliet oplossings 
(GEO), voorgeskryf in 91.5% van pasiënte (gemiddeld 0.5 ± 0.4L/dag), en hipertoniese lae 
molekulêre gewig (LMG) 130/0.4kD hidroksie-etiel stysel (HES), voorgeskryf in 78.9% van 
pasiënte (gemiddeld 0.2 ± 0.1L/dag), onderskeidelik. Die mees voorgeskrewe IV elektroliet 
supplement was kalium soute, voorgeskryf in 91% van pasiënte (±20 – 60 mmol per toediening). 
VT is binne 14.5 ± 14.1 ure geinisieër. Die meerderheid (80%) het enterale voeding (EV) ontvang. 
Die gemiddelde daaglikse energie inname van 1613 ± 380kCal (25.1kKal/kg) het 93.6 ± 17.7% van 
die gemiddelde doelwit rykwydte (GDR) bereik. Die gemiddelde daaglikse proteiën inname van 72 
± 22g (1.1g/kg) het 82.8 ± 19.9% van die GDR bereik. Nie voedings-verwante energie bronne 
(NVEB), meestal vanaf koolhidraat-bevattende IV vloeistowwe, het 10.1 ± 7.5% tot totale energie 
inname (TEI) bygedra (156kKal/d). Die gemiddelde kumulatiewe energie en proteiën balans was -
674.0 ± 1866.1kKal en -86.0 ± 106.9g onderskeidelik. Die meerderheid (73%) het >90% van die 
minimum energie doelwit (ED) bereik. Slegs 49% het >90% van die minimum proteiën doelwit (PD) 
bereik. Slegs 59% van pasiënte met genoegsame energie inname (90-110% van ED) het hul 
minimum PD bereik. Daar was ‘n beduidende negatiewe korrelasie tussen kumulatiewe 
energie/proteiën balans en die tyd tot inisiëring van VT (energie: r=-0.28, p=0.02; proteiën: r=-0.32, 
p= 0.01).   
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Opsomming: Die kristalloiëd en kolloiëd van keuse vir IVT is GEO en hipertoniese LMG 
130/0.4kD HES onderskeidelik. Kalium soute word mees algemeen voorgeskryf. NVEB dra 
beduidend by tot TEI en moet inaggeneem word tydens die berekening van voedingsvoorskrifte 
ten einde oorvoeding te voorkom. Vroeë inisiëring van EV met konvensionele energie-ryke EV 
produkte is onvoldoende om genoegsame proteiën inname te verseker. EV produkte met ‘n 
gunstiger stikstof tot nie-proteiën energie verhouding sal help om proteiën inname gedurende die 
eerste week van intensiewe sorg te optimaliseer.  
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DEFINITION OF TERMS 
APACHE II score A scoring system for use in ICU patients to assess the severity of 
disease and provide an estimation of in-hospital mortality.1 
Colloid A solution composed of larger, more insoluble molecules that do not 
readily cross semipermeable membranes 2 and can either be semi-
synthetic or naturally occurring human plasma derivatives.3 
Crystalloid A solution consisting of small water-soluble molecules that can 
easily diffuse across semi-permeable membranes and with ion 
concentrations equal or close to to that of the extracellular space.2,4 
Dipeptiven A concentrate of the dipeptide N(2)-L-alanyl-L-glutamine indicated 
as part of an intravenous nutrition regimen as a supplement to 
amino acid solutions.5 
Enteral nutrition Nutrition provided through the gastrointestinal tract via a tube, 
catheter or stoma that delivers nutrients distal to the oral cavity.6 
Intravenous drug dilution Dilution of certain intravenous drugs to prevent irritation of veins. 
These medications are diluted according to the pharmacy references 
and administered intermittently or continuously.7 
Intravenous electrolyte 
supplements 
Intravenous infusion of electrolyte preparations (e.g. potassium 
phosphate, calcium gluconate and magnesium sulphate).8 
Intravenous fluids Fluids that are administered intravenously.9 
Intravenous fluid therapy The administration of intravenous fluids; namely crystalloids, colloids 
and blood products, to achieve and maintain hemodynamic stability 
and optimise organ function.3,10 
Intravenous infusion The slow intravenous injection of a substance. This is a common 
method for replacing water, electrolytes, and blood products and is 
also used for the continuous administration of drugs (e.g. antibiotics) 
or nutrition.9 
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DEFINITION OF TERMS 
Nutrition therapy The provision of nutrients via an artificial route, i.e. enteral and/or 
parenteral nutrition.11 Nutrient provision is no longer regarded as 
supportive care in ICU, but rather as a therapeutic intervention.12 
Parenteral nutrition Provision of nutrients intravenously.13 
Polygam Polyvalent human normal immunoglobulin used in the treatment of 
Guillian-bare syndrome. Polygam contains sucrose as stabiliser.14 
Propofol An intravenous sedative-hypnotic agent administered as a lipid 
emulsion for the induction and maintenance of anesthesia or for 
sedation of critically ill patients in the ICU.15,16 
Recumbent height A patient’s body is aligned so that the lower extremities, trunk, 
shoulders, and head are in a straight line. A mark is made on the 
bed sheet at the base of the heels and top of the crown. The 
distance between these two lines is measured using a non-elastic 
tape measure.17 
Sepsis The systemic inflammatory response syndrome (SIRS) in the 
presence of infection.18 
Septic shock The presence of severe sepsis and hemodynamic instability.18 
Severe sepsis/SIRS The presence of sepsis/SIRS with one or more organ dysfunction.18 
SIRS A clinical syndrome that can be caused by a variety of insults, 
including infection, severe trauma, pancreatitis, ischemia, and burn 
injury. It is characterized by fever, tachycardia, tachypnoea, and an 
elevated white cell count as well as organ dysfunction and 
hypotension in severe cases.18 
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1.1 Significance of the study 
Critical illness encompasses a wide range of physiological abnormalities that are related to 
impaired fluid regulation, hence putting the critically ill patient at risk of fluid and electrolyte 
imbalance.10 Intravenous (IV) fluid and volume management play a crucial role in achieving and 
maintaining this balance,10,19 however, intensive care unit (ICU) physicians do face daily difficulty in 
management of fluid status.20 This is of concern to the ICU dietician, since nutrition therapy (NT) 
and fluid and electrolyte balance are closely related in critical illness.21-22 
Fluid and electrolyte status is influenced, purposefully or involuntarily, by the provision of NT.23 
Likewise, the delivery and tolerance of NT is influenced by a patient’s fluid and electrolyte status. 
Published evidence suggests that fluid overload delays gastric emptying and intestinal transit time, 
prolongs post-operative ileus and delays achievement of nutritional targets.21-22 On the other hand, 
severe acute hypovolemia is associated with impaired microvascular blood flow in vascular beds 
such as the splanchnic circulation,23 resulting in decreased tolerance of enteral nutrition (EN). Fluid 
and electrolyte balance also play an important role in patients fed via the parenteral route and 
determination of fluid status is a prerequisite for calculating parenteral nutrition (PN) fluid 
requirements, especially if a fluid imbalance is clinically suspected.24 
Achieving and maintaining fluid and electrolyte balance therefore plays a crucial role in obtaining 
the full benefit from EN and/or PN.22 Daily monitoring of fluid and electrolyte status, as well as 
determination of fluid and electrolyte requirements will assist in the successful management of 
patients receiving NT.25 Fluid and electrolyte intake via the parenteral, enteral and oral route 
should be considered to ensure timely and appropriate adjustment of the volume or electrolyte 
content of NT regimens.24 Assessing input and output charts provide valuable information on fluid 
status, however, frequent errors in the measurement and recording of specific volumes, combined 
with a failure to estimate insensible losses, often results in a large cumulative error in fluid 
balance.25-26 Furthermore, IV electrolyte replacement, a routine ICU practice, lacks standardization, 
and the dosing, timing and monitoring of electrolyte replacement varies considerably from clinician 
to clinician.27 The volume and composition of IV fluids used for IV drug dilution and flushing of IV 
lines may also impact on total daily fluid and electrolyte intake. There is currently a lack of studies 
with an accurate assessment of total fluid and electrolyte delivery via all routes, including additional 
fluid delivery from drug administration (i.e. liquid drugs, fluids used for reconstitution and dilution 
purposes), as well as flushing of IV lines. 
IV fluid therapy (IVFT) and drug administration not only influences total fluid and electrolyte intake, 
but also total energy intake. The extent to which such routine ICU practices contribute to total 
energy intake is of concern as there is strong evidence that overfeeding negatively impacts on 
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clinical outcomes.28-30 Several previous studies that have assessed energy intake among critically 
ill patients failed to take into account additional energy delivery from inadvertent non-nutritional 
energy sources (NNES). According to a recent review article by Berger and Pichard 29 the concept 
of counting only non-protein energy (NPE), as well as failing to take into account the energy 
derived from NNES, such as glucose 5% solutions and fat soluble sedatives, might have been 
responsible for systematic overfeeding in several studies. Several authors have therefore 
suggested that the energy content of inadvertent NNES should be taken into account when 
prescribing energy targets.29,31-32  
Heidegger et al 32 have estimated that NNES provide an additional energy delivery of 100 – 
400kCal per day. According to a study by Villet et al 33 energy delivery from propofol infusion and 
glucose-containing IV fluids administered for sundry purposes provided as much as 150 – 
600kCal/day. Similarly Hise et al 34 reported a clinically relevant amount of kilocalories (on 
average, approximately 250kCal/day) derived from propofol infusions and glucose-containing IV 
fluids in surgical ICU patients. These studies 33-34 did not take into account all of the existing 
inadvertent NNES, including the infusion of hydroxyethyl starches (HES), albumin solutions, 
immunoglobulin therapy (polygam), as well as the administration of dextrose water as part of 
standard ICU protocols (e.g. treatment of hyperkalemia). The extent to which these sources 
contribute to total energy intake is unknown and there is an urgent need for an accurate 
assessment of total energy delivery from both nutritional and non-nutritional energy sources to be 
performed in the ICU.  
In conclusion, routine ICU therapeutic practices; i.e. IVFT, IV drug dilution, flushing of IV lines, as 
well as IV electrolyte replacement may significantly impact on total nutritional and fluid and 
electrolyte intake. The inappropriate administration of IV fluids is known to be a significant cause of 
patient morbidity and mortality.2,4,35 Electrolyte disturbances, depending on the degree, may also 
have serious clinical consequences including significant impact on delivery and tolerance of NT.8 In 
addition the impact of inadvertent NNES on total energy intake is of great concern since both over- 
and underfeeding are associated with adverse outcomes.29-30 An accurate assessment of the 
contribution of NNES to total energy delivery is therefore paramount. 
This study was undertaken to assess the impact of routine ICU therapeutic practices, i.e. IVFT, IV 
drug dilution, flushing of IV lines, IV electrolyte replacement, lipids delivered with sedatives 
(propofol), sucrose delivered with immunoglobulin therapy (polygam infusion), and dextrose water 
administered as part of standard ICU protocols on a patient’s total fluid, electrolyte, energy and 
macronutrient intake. 
Stellenbosch University  http://scholar.sun.ac.za
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2  
 LITERATURE OVERVIEW 
 
2.0 CHAPTER 2 - LITERATURE OVERVIEW 
Stellenbosch University  http://scholar.sun.ac.za
22 
 
2.1 Intravenous (IV) fluid and volume management 
2.1.1 Indications 
IV fluid and volume management, also known as IVFT, is one of the most basic interventions in the 
ICU and plays a crucial role in achieving and maintaining fluid and electrolyte balance in critically ill 
patients.10,19 The primary goal of IVFT is to achieve adequate circulating blood volume and cardiac 
output in order to ensure adequate tissue oxygenation for the prevention of multiple organ 
failure.2,3,10,19 Furthermore it aids in the prevention of cerebral oedema in acute or chronic 
hyponatraemia and also plays an important role in correcting modest extracellular fluid (ECF) 
depletion, replacing ongoing losses, avoiding oligouria and providing maintenance fluids to replace 
insensible fluid and electrolyte losses (e.g. in sweat and via gastrointestinal (GI)-tract).19 Yet 
according to Cannesson 20 ICU physicians face difficulty in optimising patients’ fluid status on a 
daily basis. 
2.1.2 Fluid and electrolyte imbalances in critical illness 
Fluid balance can be defined as the difference between intake and output and requires 
consideration of the total body water (TBW), its compartmental distribution and plasma 
composition. The volume status of a patient is influenced by several parameters. Critical illness 
encompasses a wide range of physiological abnormalities that are related to impaired fluid 
regulation, putting the critically ill patient at high risk of fluid and electrolyte imbalances.10 
2.1.2.1 Conservation of sodium and water and increased potassium excretion 
The physiological stress response to critical illness, surgery or trauma leads to an antidiuretic effect 
manifesting with oliguria mediated by the release of vasopressin and catecholamines, as well as 
the activation of the renin-angiotensin-activating-system (RAAS). This results in water and sodium 
retention often in the setting of fluid overload.2 Sodium excretion is further hampered by an 
increase in potassium excretion caused by the activated RAAS system. Increased nitrogen 
excretion due to the stress-induced catabolic state competes with that of sodium and chloride, 
resulting in increased water and sodium retention and worsening of interstitial oedema.2 The 
reduced physiological capacity to excrete water and sodium is further aggravated by starvation.22 
2.1.2.2 Increased capillary permeability 
Sepsis or the systemic inflammatory response syndrome (SIRS) is associated with increased 
capillary permeability and leakage of plasma proteins, water and electrolytes from the 
intravascular- to the interstitial compartment.2,10,23 The leakage of albumin into the interstitial space 
reduces the intravascular oncotic pressure causing a net fluid shift from the intravascular to the 
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interstitial compartment. This in turn leads to intravascular hypovolemia, 2,10,23 as well as pulmonary 
and peripheral oedema.23 Intravascular hypovolemia also leads to further activation of the RAAS 
system worsening sodium retention and potassium excretion. 2 
2.1.2.3 Shedding of the endothelial glycocalyx 
The endothelial glyococalyx (EG) consists of membrane-bound proteoglycans and glycoproteins 
found on the luminal side of the endothelium which together with bound plasma constituents, bind 
approximately one litre (1L) of non-circulating plasma volume. The EG plays a major role in 
vascular barrier function, reducing inflammation and tissue oedema 36 and is important with regard 
to fluid management in inflammation and in the perioperative phase.4 However, there are certain 
physiological and pathophysiological processes which can lead to shedding of the glycocalyx.4,36 
These include: 
 Ischaemia/reperfusion 4,36 
 Proteases 36 
 Inflammatory cytokines, such as tumour necrosis factor (TNF)-alpha 4,36 and 
bacterial lipopolysaccharide (LPS) 4 
 Oxidised low density lipoproteins (LDL) 36 
 Hypervolemia 3-4,36 
Under normal circumstances, water and small solutes pass through the intact glycocalyx, while 
colloids and proteins remain intravascularly. Flooding of the vascular system with excessive 
amounts of IV fluids contributes to EG shedding and increases vascular permeability, followed by 
plasma extravasation and interstitial oedema.3-4 This is not merely a direct effect of the volume 
itself, but also due to anti-natriuretic protein (ANP)-mediated enzymatic breakdown of integral 
components of the EG. There is still an ongoing debate on the upper threshold for fluid 
administration above which extra fluid will result in glycocalyx disruption.4,36  
2.1.2.4 Other contributing factors 
Mystical third space losses 
The third space essentially refers to the transcellular space consisting of endothelial lined 
compartments like the pleural and intraperitoneal spaces or the anterior and posterior eye 
chambers.4 The third space was previously thought to be anatomically separated and not in 
dynamic equilibrium with the interstitial space and intravascular compartment 36 and has been 
divided into anatomical and non-anatomical parts. Anatomical losses were regarded as 
pathological fluid accumulations in the interstitial space which, together with the plasma, forms the 
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functional extracellular volume. On the other hand, non-anatomical losses represented what was 
described as the classical “third-space” fluid shift and was thought to be mainly caused by major 
surgery and trauma.3,36 Examples of classical “non-anatomic” third space losses are fluid 
accumulation in transcellular fluid spaces, such as traumatized tissues, bowel, and peritoneal and 
pleural cavities, which normally contain insignificant amounts of fluid.3 Fluid trapped into this third 
space was believed to be permanently lost for extracellular exchange.3,36 Traditional perioperative 
fluid management therefore exceeded normal requirements to account for losses into this space 
and consequently to achieve hemodynamic stability.4 An excessively positive fluid balance was 
considered to be unavoidable if one was to maintain the functional ECF volume.36 It was also 
regarded to be essential in order to treat unmeasured fluid losses caused by a preoperative fluid 
deficit and insensible losses.36 In spite of intensive research, a classic third space has not been 
identified.3 According to Brettner et al,4 bearing in mind the negative consequences of artificial 
hypervolemia on the EG another explanation other than “fluid shift into the third space” is required. 
Jacob et al 36 further suggests that the classical “third space” is most likely pure fiction and that 
perioperative fluid shifts consist rather of losses from the intravascular to the interstitial space, 
which in turn is to a large degree caused by inappropriate perioperative fluid management; i.e. 
infusing the wrong IV fluid in an excessive amount. Jacob et al 36 concluded that perioperative fluid 
shifts can be qualitatively divided into two types; namely the physiological and the pathological. 
The physiological (type-1) fluid shift refers to a leak of protein-free fluids across an intact barrier 
caused by crystalloid hypervolemia whereas the pathological (type-2) fluid shift refers to leak of 
protein-rich fluid related to disruption of the EG.3,36 Avoiding hypervolemia will therefore protect the 
vascular barrier and minimize perioperative fluid shifts.36  
Pre-operative fasting 
According to Heckel et al 3 hypovolemia and extravascular dehydration frequently occurs as a 
result of pre-operative fasting, however, Brettner et al 4 point out that the impact of overnight 
fasting on intravascular volume is less than previously thought and is probably practically 
negligible. The body is able to compensate for short term fasting by recruiting fluid from the 
interstitial to the vascular space and the traditional practice of infusing crystalloids and colloids to 
compensate for an assumed intravascular deficit may actually lead to ANP-mediated shedding of 
the EG.4 Although patients receiving bowel preparation prior to intestinal surgery are at risk of 
intravascular depletion,4 the need for bowel preparation is controversial and most authorities feel 
that it is unnecessary. The ingestion of carbohydrate-rich clear fluids up to two hours prior to 
general anaesthesia, with re-initiation of oral fluids as soon as possible post-operatively, is now 
widely recommended and led to a reduction in the incidence of preoperative fluid and salt 
depletion.4,37-38 
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Insensible perspiration and evaporation from wounds and exposed gut 
Insensible losses which include perspiration, faecal loss and evaporation from wounds and 
exposed gut add to fluid losses in the immediate postoperative period.3 However, these losses are 
much less than previously thought and are estimated to be between 0.5ml/kg/hr in minor to 
1ml/kg/hr in major abdominal surgery.4 
Nutrition therapy (NT) 
Critical illness-related fluid and electrolyte abnormalities are further influenced, purposefully or 
involuntary, by the provision of NT.23 
Fluid resuscitation 
Fluid resuscitation may further contribute to fluid and electrolyte imbalances and, depending on the 
composition of the resuscitation fluids, may lead to acid-base and electrolyte abnormalities, such 
as hyper- or hyponatraemia.10 Special caution should be taken in patients at high risk of fluid and 
electrolyte imbalances, such as perioperative patients and those with pre-existing renal or 
cardiopulmonary disease.39 
2.1.3 Complications of hypo- and hypervolemia 
According to Hilton et al 35 a patient’s ability to tolerate relative hypo- or hypervolemia decreases 
with increasing severity of acute illness. 
2.1.3.1 Hypovolemia 
Hypovolemia, defined as an ECF deficit, may occur as a decrease in water volume, with or without 
an electrolyte deficit.40 
Hypovolemia as a water deficit alone is generally caused by an inability to regulate water intake 
(e.g., concentrated EN or loss of the thirst mechanism).40 In this setting, treatment is aimed at 
replacing water in order to regain sodium homeostasis and restore serum osmolality to normal. IV 
fluid replacement should be administered as 5% dextrose in water or as a hypotonic solution in the 
case of hypotension.40 
Hypovolemia, with a combined water and electrolyte deficit is caused by excessive losses (e.g., GI 
losses, diuretic therapy, or postoperative fluid sequestration). The sodium and volume deficit is 
calculated in order to determine the need for fluid and electrolyte replacement. Treatment includes; 
(1) treating the primary problem, (2) water restriction and (3) sodium replacement. An isotonic 
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solution (e.g. normal saline) is often indicated and vasopressin-receptor antagonists are used to 
help inhibit the action of the anti-diuretic hormone (ADH).40 
The consequences of hypovolemia are determined by the extent of fluid lost, the timing and 
adequacy of volume replacement, as well as the patient’s clinical context. Minor hypovolemia 
ranges from thirst and postural hypotension, worsening of perioperative nausea and vomiting, and 
the potential for prolonged hospital stay.35 Severe acute hypovolemia clinically manifests as 
shock.3,35 It leads to circulatory and tissue hypoperfusion with subsequent tissue hypoxemia, 
cellular dysfunction and organ injury.3,41 This in turn increases the risk of organ failure.3 For this 
reason hypovolemia is often associated with oliguria and occasionally with acute kidney injury 
(AKI). Furthermore it may also impair microvascular blood flow in vascular beds such as the 
splanchnic circulation 23 which may negatively impact on tolerance for EN. The target of volume 
resuscitation is therefore to maintain adequate tissue perfusion and oxygenation.2-3,10,19 
2.1.3.2 Hypervolemia 
Hypervolemia, defined as an ECF volume expansion, may occur as a result of altered renal 
function, plasma to interstitial fluid shift, or excessive fluid administration.40 According to Hilton et al 
35 the signs and symptoms of fluid overload are determined by the extent to which the fluid balance 
is positive, the severity of underlying cardio-respiratory disease, as well as the nature and severity 
of critical illness. 
There is a strong link between crystalloid overload and the presence of pulmonary oedema, both 
cardiogenic in the presence of myocardial dysfunction, and as it occurs in the acute respiratory 
distress syndrome (ARDS), in critical illness.10,35,41 Compared to an otherwise healthy patient, the 
acute physiological changes seen in critical illness and major surgery (primarily the capillary leak 
as described above) decrease the ability to tolerate excessive infusion of crystalloids, putting the 
patient at risk of symptomatic respiratory failure.35 Crystalloid overload is also associated with 
cerebral oedema in patients with concomitant head injury, abdominal compartment syndrome 
(ACS), and peripheral and gut oedema.10,23   
Postoperative fluid overload is associated with a range of serious complications. Soft tissue 
oedema decreases lymphatic drainage and local oxygenation, leading to tissue hypoxemia and 
delayed wound and anastomotic healing. Gut oedema may result in EN intolerance, translocation 
of endotoxin or bacteria, with potentially detrimental consequences such as sepsis and multi-organ 
failure. It may also result in prolonged post-operative ileus. Furthermore, crystalloid infusion may 
augment coagulation increasing the risk of postoperative thrombosis.41    
Treatment of hypervolemia includes the restriction of fluid and/or sodium with or without the use of 
diuretics. Biochemical abnormalities associated with hypervolemia often include hyponatremia and 
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hypo-osmolality and may require sodium restriction to prevent further worsening of fluid retention. 
Patients who are hypervolemic and hyponatraemic require free water- and sodium restriction and 
in some cases the use of diuretics to achieve effective fluid mobilization.40 
2.1.4 Solutions available for IV fluid therapy (IVFT) 
Table 2-1 indicates the most commonly used IV fluids for IVFT; namely crystalloids, colloids and 
blood products. For the purposes of this study the composition of blood products will not be 
discussed.   
 
Table 2-1 Commonly used intravenous (IV) fluids 3 
 
Crystalloids Colloids Blood products 
Natural Artificial 
Glucose solutions Albumin Gelatin Whole blood 
Sodium chloride 
solutions 
 Dextran Erythrocyte concentrate 
Electrolyte solutions, 
balanced 
 HES 130 Fresh frozen plasma 
Electrolyte solutions, 
unbalanced 
 HES 200  
Abbreviations: HES: Hydroxyethyl starch 
 
2.1.4.1 Crystalloids 
Crystalloid solutions consist of small, water-soluble molecules that can easily move across the 
intact vascular barrier into the interstitial space.2,4 The main solute is either sodium chloride (saline) 
or glucose.37 Crystalloids can be isotonic, hypotonic, or hypertonic with respect to plasma.37 Table 
2-2 gives a breakdown of the commonly used crystalloid solutions.  
Isotonic crystalloids have an osmolarity equal or close to that of human plasma (280 – 300 
mOsm/L). Isotonic crystalloids can either have a “normal” sodium concentration, i.e. a sodium 
concentration nearer to that of human plasma (136 – 145mmol/L), such as sodium chloride 0.9% 
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(“normal” saline) and Hartmann’s solution or a “low” sodium content such as sodium chloride 
0.18%/glucose 4% or glucose 5%. Fluids with “normal” sodium content freely move within the ECF 
compartment causing little alteration in sodium concentration and osmolarity. This restricts the 
movement of water out of the ECF into the intracellular ﬂuid (ICF) compartment and vice versa.2 
‘Normal’ saline contains more chloride than the ECF and inappropriate administration may lead to 
hyperchloraemic acidosis.2,4 Balanced crystalloids, e.g. Hartmann’s solution, have ion 
concentrations and tonicity nearer to that of human plasma and are more “physiological” and do 
not cause hyperchloraemic acidosis.4 Isotonic crystalloids with low sodium content are ideal for 
rehydration since they freely move between the ICF and ECF compartments once the glucose 
component has been metabolised. Excess administration may however result in hyponatremia.2  
Non-isotonic crystalloids can either be hypo- or hypertonic and are normally reserved for special 
conditions where manipulation of plasma osmolarity is needed.2 Hypertonic formulations may offer 
potential benefit with regard to the formation of tissue oedema, fluid balance, and intracranial or 
ACS.23 Mannitol is currently the first-line drug for osmotherapy in intracranial hypertension, but 
hypertonic saline can be added as an adjunctive treatment modality in cases where raised 
intracranial pressures are not adequately controlled by mannitol.23 It causes an increase in the ECF 
sodium concentration resulting in a net fluid shift from the ICF to the ECF, hence reducing cerebral 
oedema.2 
Stellenbosch University  http://scholar.sun.ac.za
29 
 
Table 2-2 Composition of commonly used crystalloid solutions (per litre) 2,38,42 
Crystalloid 
Solution 
Na 
 
K Cl Ca/ 
Mg 
Lactate 
 (g/L) 
HCO3 
(g/L) 
Osmolarity 
(mOsm/L) 
pH Dextrose 
(g/L) 
Energy 
kJ/L 
Saline 0.9%/ 
Normal saline 
154 - 154 - - - 308 
 
5.5 - - 
Hartmann’s/ 
Ringer Lactate 
131 5 111 Ca 
1.8 
29 - 275 6.0 - - 
Modified 
Ringer Lactate 
131 5.4 108 - 29 - 273 6.0 - - 
Balsol 130 4 110 Mg 
1.5 
- 27 
 
273 7.4 - - 
Dextrose 5% - - - - - - 278 4.5 50 840 
Saline 0.45%  77 - 77 - - - 154 5.5 - - 
Dextrose 5% in 
saline 0.45% 
77 - 77 - - - 432 4.0 50 840 
Dextrose 4% in 
saline 0.18% 
30 - 30 - - - 154 4.0-
5.0  
40 680 
Bicarbonate 
-8.4% 
1000 - - - - 1000 - 
 
8.0 - - 
Bicarbonate 
-1.26% 
150 - - - - 150 - 7.0 - - 
Units are in mmol/litre unless otherwise stated. 
Abbreviations: Na: Sodium; K: Potassium; Cl: Chloride; Ca: Calcium; Mg: Magnesium; HCO3:Hydrogen 
carbonate 
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2.1.4.2 Colloids 
Colloids are composed of larger, more insoluble molecules that do not readily cross 
semipermeable membranes.2 Colloids are either semi-synthetic (e.g. gelatins, dextrans, and HES) 
or naturally occurring human plasma derivatives (e.g. human albumin solutions, plasma protein 
fraction, fresh frozen plasma, and immunoglobulin solution).3 Movement of colloid out of the 
intravascular space is determined by the molecular weight (MW), shape, ionic charge of the 
constituents and capillary permeability.2 Whereas most colloids are suspended in 0.9% sodium 
chloride solutions, several balanced colloid solutions are now available.2 Table 2-3 gives a 
breakdown of commonly used colloid solutions. 
Albumin is the only natural colloid used clinically.2-3 It is derived from human plasma by 
fractionation. Under normal physiologic conditions, albumin is the primary determinant of the 
intravascular osmotic pressure. It is therefore seen as an ideal colloid to restore protein losses 
from the vasculature.3 Albumin solutions are available as 4.5%, 5% or 20% solutions.2 Despite 
albumin’s low vascular permeability in the healthy patient due to its negative charge, losses occur 
in critical illness as a result of the capillary leak associated with inflammation.2 Over the past 
decade there has been considerable debate over the use of albumin in critically ill patients.2 It has 
been linked to severe allergic reactions and immunologic complications and has previously been 
shown to worsen outcomes in patients with traumatic brain injury (TBI).3,43 However, Marsh and 
Brown 2 point out that the Saline versus Albumin Fluid Evaluation (SAFE) study by Finfer et al 
(2004) found no association between albumin infusion and increased mortality in critically ill 
patients as a group. 
Gelatins are polydispersed polypeptides synthesized from the degradation of bovine collagen and 
therefore carry the risk of anaphylaxis.2,3 According to Heckel et al 3 all gelatin preparations are 
considered safe with regard to organ function and coagulation. However, there is still considerable 
debate regarding the effect of gelatins on renal function. 
Dextrans are colloids made with large glucose polymer molecules. They are rarely used due to 
potential side effects including osmotic diuresis, abnormal platelet function, renal failure, 
coagulopathy and interference with blood cross-matching.2 
Hydroxy-ethyl starches (HES) are artificial polymers derived from amylopectin, a highly branched 
chain of amylopectin (glucose) molecules obtained from waxy maize or potatoes, linked with 
hydroxyl-ethyl groups making the resultant polymer similar to glycogen.2,3 Negative effects of high 
molecular HES on the coagulation system have been reported. Preparations above 200kDa cause 
a reduction in von Willebrand factor and factor VIII, leading to decreased platelet adhesion. 2 HES 
colloids have also been linked to serious adverse events, such as hemostasis due to platelet 
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coating 4 and to particularly impaired renal function.2,4 According to Heckel et al 3 the most probable 
link between colloid infusion and impaired renal function is the potential to increase urine viscosity 
from the infusion of hyperoncotic colloids in dehydrated patients. These adverse effects on renal 
function and coagulation are not as conspicuous with the use of low molecular weight (LMW) HES 
(e.g. 6% 130/0.4) compared to the older high molecular weight starches.2-4 Nevertheless, the use 
of HES IV fluids in ICU remains controversial and even more so after the publication of recent trials 
and review articles.44-50 Further research should therefore be undertaken to clarify the extent to 
which HES IV fluids may be associated with adverse events, particularly impaired renal function.2 
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Table 2-3 Composition of commonly used colloids (per litre) 2,42 
Colloid Solution Na 
 
K Cl Ca Mg Other  
(g/L) 
Osmolarity 
(mOsm/L) 
pH Energy 
(kJ/L) 
A: Gelatins  
Gelofusine  
MW 30 000 
154 0.4 125 0.4 0.4 Gelatin  
40g 
290 7.4 - 
 
Haemacel 
MW 30 000 
145 5.1 145 6.25 - Gelatin  
35g 
301 7.3 - 
 
B: Dextrans 
Dextran 70 in 
dextrose 5% 
MW 70 000 
- - - - - Dextran/ 
Dextrose: 
60g/50g 
287 5 – 6 1841 
Dextran 70 in 
saline 0.9% 
MW 70 000 
154 - 154 - - Dextran 
60g 
287 4 – 5 1004 
C: Hydroxyethyl starches (HES) 
Hespan  6% 
MW 200 000 
154 - 154 - - Starch 
60g 
310 5.5 1020 
Voluven HES 6% 
(130/0.4) 
MW 130 000 
154 - 154 - - Starch  
60g 
308 5.5 1004 
Voluven 
Balanced 
137 4 110 - 1.5 -  286.5 6.5 1004 
Voluvyte HES 6% 
(130/0.4) 
137 4 110 - - Starch  
60g 
286 - 1004 
HES 10% 
(200/0.5) 
154 - 154 - - Starch 
100g 
308 - 1674 
HES 6%  
(450/0.6) 
154 - 154 - - Starch  
60g 
308 - 1004 
D: Human albumin solutions (HAS) 
HAS 4.5% 100-160 <2 100 - 
160 
- - Albumin/
Citrate: 
45g/<15g 
270 – 300 6.4-7.4 753 
HAS 5%  150 - 150 - - Albumin 
50g 
300 - 837 
HAS 20% 50–120 <10 <40 - - Albumin 
200g 
135-138 6.4-7.4 3348 
Units are in mmol/litre unless otherwise stated.  
Abbreviations: Na: Sodium; K: Potassium; Cl: Chloride; Ca: Calcium; Mg: Magnesium  
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2.1.5 Available intravenous (IV) fluid regimens  
IVFT can be divided into two basic strategies, i.e. 1) fixed fluid replacement regimens; and 2) 
variable, algorithmic approaches.35 
2.1.5.1 Fixed fluid replacement regimens 
Fixed fluid regimens are most commonly used in clinical settings. It is adjusted according to 
individualised assessment of fluid losses and can be subdivided into the following three categories:  
1. Standard perioperative fixed fluid replacement regimens. This usually advocates 3 
litres per day of fluid of varying composition. These are often associated with fluid 
overload and the complications mentioned above. Hilton et al 35 therefore suggests 
substituting the “fixed 3 L per day” prescription for maintenance fluid requirements with a 
more restrictive approach, unless clearly indicated otherwise. 
2. Restrictive fluid regimens. This is commonly used for postoperative management of 
pneumonectomy and lobectomy, and more recently for bowel surgery. 35  
3. Liberal acute fluid resuscitation. This is used to correct severe acute hypovolemia, e.g. 
burns.35 
2.1.5.2 Algorithmic approaches 
Algorithmic approaches to volume replacement are mostly restricted to critically ill patients in ICUs. 
These regimens target specific circulatory parameters and may improve patient outcomes. Targets 
previously included invasive monitoring of cardiac chamber filling pressures with central venous 
pressure (CVP) and pulmonary artery wedge pressure and today more frequently use noninvasive 
techniques such as measurement of stroke volume variation and measurement of cardiac output 
(CO) by pulse contour analysis.35 According to Marsh and Brown 2 there is an increasing body of 
evidence supporting the use of CO monitoring to guide fluid therapy and that such “goal-directed” 
fluid therapy may have significant benefits. According to Cannesson 20 dynamic parameters of fluid 
responsiveness, based on cardiopulmonary interactions in patients under general anaesthesia and 
mechanical ventilation, are superior to static indicators (e.g. CVP). The concept of fluid 
responsiveness refers to the ability of the circulation to increase CO in response to volume 
expansion. These dynamic parameters can be obtained from a single arterial pressure waveform 
(systolic pressure variations (SPVs) and pulse-pressure variations (PPVs)). It allows for 
optimization of the dynamic indicators of fluid responsiveness and offers an alternative to CO 
monitoring and optimization. According to recent studies this approach has the ability to improve 
postoperative outcomes. However, dynamic parameters of fluid responsiveness can only be used 
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in mechanically ventilated patients under general anaesthesia. It also requires a tidal volume of 8 
mL/kg of body weight with a positive end-expiratory pressure between 0 and 5cmH2O to be able to 
use these indices. If unable to use these indices, alternative dynamic parameters can be used, 
such as echocardiography, passive leg raising to determine its effect on stroke volume and 
assessing preload dependence. Further studies are required to better define how these 
parameters can be implemented in clinical protocols for perioperative fluid management.20 
2.1.6 The use of crystalloids versus colloids in the treatment of acute hypovolemia and 
dehydration 
Considerable debate revolves around matters such as the use of crystalloids versus colloids in the 
treatment of acute intravascular hypovolemia and extravascular dehydration. According to Marsh 
and Brown 2 any IV ﬂuid should be seen as a drug with potential beneﬁts and side effects. No 
single IV fluid has the ability to offer appropriate ﬂuid and electrolyte components on its own. 
Crystalloids and colloids should therefore be seen as two separate classes of IV fluids and that 
each has its own unique part to play in terms of fluid management.20 The type of IV ﬂuid 
administered should always reﬂect the given patient’s volume and electrolyte status, as well as the 
clinical goal at hand.2 Firstly it is important to differentiate between dehydration of the extravascular 
compartment and acute intravascular hypovolemia, since the type of fluid used in the treatment of 
each differs.3  
Dehydration of the extravascular compartment is caused by fasting, urine production and 
insensible losses resulting in a loss of electrolytes and colloid-free fluid initially from the interstitial 
space. Only thereafter does it influence the intravascular compartment. In this setting dehydration 
should be treated by refilling the interstitial space and replacing additional losses by crystalloid 
infusions. In practice, since only the intravascular compartment is directly accessible, balanced 
crystalloids which freely distribute between the interstitial and intravascular compartments are 
suitable for this purpose.3 According to Heckel et al 3 treating extravascular dehydration with 
colloids in a normovolemic patient may result in iatrogenic hypervolemia and subsequent 
glycocalyx damage and tissue edema.  
On the other hand, acute intravascular hypovolemia primarily affects the intravascular 
compartment and is therefore potentially life-threatening.3 There is ongoing debate regarding the 
use of crystalloids (isotonic) versus colloids (roughly iso-oncotic) for the treatment of hypovolemia 
and shock.51 Large clinical trials and systematic reviews suggest no superiority of one over the 
other with regard to effects on overall mortality. However, it is important to consider the 
heterogeneity of critically ill patients and that the effects on hemodynamics, adverse effects and 
outcomes may differ among different patient populations.51 
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According to Bauer et al 23 isotonic crystalloids are probably superior to artificial colloids in the 
septic patient. Crystalloids are cheap, easily available and have a low risk of anaphylaxis, but on 
the other hand are less effective than colloids at refilling the intravascular compartment.2,51 
According to Heckel et al 3 only one fifth of the intravenously infused crystalloid solution remains in 
the intravascular compartment and should therefore not be used for volume resuscitation in acute 
hypovolemia. Treating hypovolemia with crystalloids may result in persistent hypovolemia with a 
concomitant reduction in intravascular oncotic pressure leading to the formation of interstitial 
edema.3,51 Table 2-4 indicates the proposed colloid to crystalloid volume ratios as published by 
several authors.  
Table 2-4 Colloid to crystalloid volume ratio 
Proposed volume ratio (colloid to crystalloid) Reference 
1 : 3 Trof and Groeneveld (2011)
 51
 
1: 4 Heckel et al (2011)
 3
 
1 : 1.5 Bauer et al (2009) 
23
 
 
As a consequence various authors recommend the use of colloids for the treatment of acute 
hypovolemia, since they remain essentially within the intravascular space and maintain oncotic 
pressure.2-4,51 It is however debatable whether the theory behind colloid use for the management of 
acute hypovolemia applies to critically ill septic patients who suffer from capillary leak and impaired 
glycocalyx barrier function. One could assume that a severely impaired vascular barrier will result 
in both colloids and crystalloids being able to distribute freely across the vascular barrier. It is 
questionable however whether this finding can be generalized to every critically ill patient. There is 
unfortunately no bedside parameter for measuring vascular barrier function.3 There is a currently a 
large amount of research being performed on albumin and starch molecules in the management of 
hypovolemia in patients presenting with hyperinflammatory conditions.51 According to Trof and 
Groeneveld 51 the electrostatic properties of albumin enable it to penetrate and bind to the overlying 
luminal glycocalyx. This subsequent “sealing effect” may decrease fluid movement into the 
interstitium independently of the colloid oncotic pressure by albumin.51 The benefits of albumin 
infusion may however be patient specific. Albumin may offer benefit to those presenting with 
hypoalbuminemia (e.g. sepsis, ALI) but may worsen outcome in patients with TBI.43 TBI patients 
may therefore rather benefit from the use of iso-and/or hypertonic saline.23 
Large HES molecules have also been claimed to have a similar “sealing” effect, but the clinical 
significance is uncertain if it occurs at all. In animal experiments and clinical studies, the use of 6% 
HES 130/0.4 lead to a reduction in typical perioperative complications, e.g. wound infection, 
pneumonia and anastomotic leak, and improved bowel tissue oxygenation and microcirculatory 
blood flow.3 On the other hand a number of recent trials and reviews showed an association 
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between the use of HES and impaired renal function 44-46,50 and led to international regulatory 
bodies issuing recent statements that HES IV fluids should be withdrawn from clinical use; (2) its 
clinical use reviewed; or (3) used with extreme caution in ICU, cardiac surgery and patients with 
known kidney disease or coagulopathy.52-54 Based on these recommendations the Western Cape 
Department of Health withdrew all IV fluids containing HES from hospitals in the Western Cape,55 
with similar action contemplated in the Free State and Gauteng. Of great concern, however, is that 
the recommendations have been based on flawed scientific evidence and applied to clinical 
settings not included in the studies. In these studies HES were mostly administered to critically ill 
patients with sepsis,44-46,50 outdated hyperoncotic HES solutions were used 44,50 and were 
administered in excessive amounts over prolonged periods of time.4,50 Furthermore the use of HES 
in patients with trauma or those undergoing major elective or emergency surgery for non-septic 
disease were not addressed by these studies. According to a randomised controlled trial (RCT) 47 
comparing HES with 0.9% saline in trauma patients, renal injury occurred more frequently in the 
saline group than the HES group (16% vs. 0%; P = 0.018). A recent meta-analysis has also 
demonstrated the efficacy of colloid solutions, including HES, as a fluid replacement agent during 
caesarean sections.48 The Enhanced Recovery After Surgery (ERAS) program for major elective 
surgery, such as colectomy, also support the use of colloids such as HES for replacement of 
intraoperative blood loss in preference to crystalloids.49 On the contrary two recent studies 
published in 2012, the 6S study 45 from Scandinavia and the CHEST study from Australia,46 found 
HES to be associated with an increased risk of renal replacement therapy (RRT) particularly in 
elderly, critically ill septic patients.  
Based on these two trials the conclusion can be drawn that HES should be avoided in elderly, 
critically ill patients with sepsis.45,46  On the other hand there seems to be no evidence that HES 
should be avoided in non-septic patients without critical illness who require intravascular volume 
replacement, but not transfusion. Until stronger evidence is available the prescription of these 
ﬂuids is likely to be based on personal choice and clinical indication.2   
2.2 Management of electrolyte disturbances 
Critically ill patients often present with electrolyte and metabolic disturbances.56 Depending on the 
degree, electrolyte disturbances may have serious clinical manifestations and require urgent 
replacement or removal with measures specific to the abnormality. In most ICUs abnormal values 
are generally corrected by the patient’s physician during rounds. However, this practice lacks 
standardization and the dosing, timing and monitoring of electrolyte replacement varies 
considerably from clinician to clinician. The implementation of multi-disciplinary electrolyte 
replacement protocols may therefore improve overall electrolyte replacement and its 
effectiveness.8 Important to consider is that the use of replacement fluids in the management of 
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electrolyte disturbances provide volume and potentially nutrients. For example, (1) hypernatremia 
is often treated by the administration of free water in the form of 5% dextrose water; 57 and (2) 
hyperkalemia is often treated by a concomitant administration of dextrose with insulin.40  
 
2.3 Dilution of IV medications and -supplements 
IV medication administration refers to the infusion of medication directly into a patient’s vein. The 
main purpose of giving IV medication is to initiate a quick systemic response to medication. IV 
medication can be administered as a bolus (“push-in”), intermittently or continuously.7 “Push-in” 
drugs are usually diluted in 10ml of sterile water unless otherwise stated and given through a freely 
running IV line over a period of not less than three minutes. Drugs administered intermittently or 
continuously require specific dilution or are pre-diluted by the manufacturer and require specific 
infusion time.58 Furthermore the IV tubing or cannula should be flushed with saline before and after 
drug administration.7 
The volume and composition of the IV solutions used for IV drug dilution and flushing of IV lines 
contribute to total fluid, electrolyte and potentially energy intake. Many studies assessing energy 
intake among ICU patients did not account for the use of dextrose containing IV fluids in the 
dilution of IV drugs, for example in hypernatraemic patients. 
2.4 Link between nutrition and fluid and electrolyte balance 
Nutrition and fluid and electrolyte balance are closely linked through ingestion, digestion, 
absorption and intermediary metabolism.21,22 The intake of food by natural or artificial means 
cannot be separated from that of fluid and electrolytes.21,25 Furthermore, the physiological 
processes of digestion and nutrient absorption in the small and large intestines are closely linked to 
the secretion and absorption of water and electrolytes. Lastly, fluid and electrolytes play a crucial 
role in intermediary metabolism and cellular function. In clinical practice nutrient, water, mineral 
and electrolyte balance are closely related in the treatment of disease. 21   
2.4.1 Enteral nutrition (EN) 
Fluid and electrolyte balance influences GI function and subsequent tolerance of EN.22 Published 
evidence suggests that fluid overload delays gastric emptying and intestinal transit, prolongs post-
operative ileus and delays feeding via the enteral route.21,22,25 According to Allison 22 even a 
moderate saline overload may result in prolonged post-operative ileus. Furthermore, clearance of 
oedema (via salt restriction and diuretics) appears to be coupled with a return in GI function, 
allowing nutrition via the oral or enteral route.21,22 Lobo hypothesizes that fluid and electrolyte 
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balance, and not the serum albumin concentration per se, is the primary determinant of recovery 
from post-operative ileus.21 There is a close relationship between serum albumin concentration, 
illness, nutrition and fluid balance.22 Avoidance of fluid and sodium overload, reduced fasting times 
pre- and postoperatively, pre-operative carbohydrate loading and early initiation of post-operative 
EN all form part of the ERAS guidelines on reducing the stress induced by surgery and facilitate 
the return of GI function 26 and subsequent EN tolerance.  
According to Lobo 21 a study by Wilkes et al (2001) found that hyperchloraemic acidosis caused by 
excessive saline infusions reduces gastric blood flow and decreases gastric intra-mucosal pH in 
elderly surgical patients. Fluid overload may also result in splanchnic or gut oedema.21,22 
Splanchnic oedema may lead to increased abdominal pressure, ascites, and ACS. This in turn 
causes a reduction in mesenteric blood flow and increases the risk for complications, such as ileus 
(acute intestinal failure) with subsequent intolerance of EN, functional obstruction of anastomoses, 
increased gut permeability, intestinal failure and anastomotic dehiscence.21,22 Potassium 
supplementation may play a beneficial role in the prevention of post-operative ileus. Therefore 
routine IV potassium supplementation starting from theatre is recommended and regarded safe.39 
Figure 2-1 illustrates the possible link between fluid overload an impaired GI function. 
 
 
Figure 2-1 Hypothesis for the effects of salt and fluid overload on GI function 21 
On the other hand, severe fluid and electrolyte abnormalities may develop as a result of existing 
intestinal failure, e.g. short bowel syndrome. These fluid and electrolyte abnormalities can be life 
threatening in the case of inappropriate or delayed treatment. Treatment should be based on a 
multidisciplinary assessment of the underlying disease process, fluid status, absorptive capacity of 
the GI tract and renal function involving the attending physician, nurse, dietician and pharmacist.40 
The electrolyte concentration of most EN products are based on the assumption that the patient’s 
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macronutrient requirements will be met using that feed, e.g., 2000 ml/day. If a patient is unable to 
tolerate adequate EN, the intake of electrolytes will be similarly reduced and inadequate. 
Furthermore, intestinal absorption of minerals (especially calcium, magnesium and phosphate) is 
often compromised. It can therefore be challenging to restore electrolyte deﬁciencies in patients 
with pre-existing deficiencies (e.g., electrolyte deficiencies caused by sepsis, trauma or previous 
malnutrition), increased extra-renal losses and high output fistulas or stomas, by the enteral route 
alone. These conditions may require additional enteral or IV fluid and electrolyte administration.25  
2.4.2 Parenteral nutrition (PN) 
It is essential to determine the exact fluid and electrolyte requirements when prescribing PN for 
critically ill patients, especially for those with fluid and electrolyte imbalances in the presence of 
shock, sepsis and renal insufficiency. This necessitates daily monitoring of fluid and electrolyte 
status and also requires a multidisciplinary approach, especially if teams are mutually exclusive. 
Prompt treatment of the underlying condition responsible for the fluid imbalance is paramount. The 
symptoms of fluid imbalance can be managed by means of individually adapted PN, for e.g., in 
critically ill patients with renal failure or chronic renal, lung, heart or liver insufficiency. Fluid and 
electrolyte intake via all routes, as well as additional losses (e.g. diarrhoea) should be strictly 
monitored and appropriate changes in fluid and electrolyte intake made in patients who are at risk. 
Intake should be individually determined when electrolyte balance is acutely altered (e.g. due to 
chronic diarrhoea, recurring vomiting, renal insufficiency, etc.). Many commercially available multi-
chamber bags and amino acid solutions contain electrolytes in various doses, which may not 
always meet the long-term PN patient’s requirements. It is important to take these quantities into 
account when determining electrolyte intake and when calculating additional needs.24 
2.4.3 Monitoring fluid and electrolyte status in patients receiving nutrition therapy (NT) 
Achieving and maintaining fluid and electrolyte balance plays a crucial role in obtaining the full 
benefit from NT.22 Calculation of fluid and electrolyte requirements is as important as determining a 
patient’s macro- and micronutrient needs when prescribing NT.21,25 Daily monitoring of fluid and 
electrolyte status should therefore be incorporated into the dietician’s daily ICU round to ensure 
successful management of fluid and electrolyte balance in patients receiving NT.25 Assessing input 
and output charts provide valuable information on fluid status,25 however, frequent errors in the 
measurement and recording of fluid input and output, e.g. urine output and GI losses, combined 
with neglect of insensible losses, often results in a large cumulative error in fluid balance. 
Monitoring of charts should therefore be combined with other indicators of fluid balance to obtain a 
more accurate reflection of a patient’s fluid status. For example, combining input and output charts 
with daily weighing will give a better indication of changes in fluid balance25-26 However, ICU 
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patients are mostly bedridden and seldom weighed.59 Even with the use of electronic bed scales, 
Schneider et al 59 found that obtaining daily body weights were difficult and that compliance was 
poor. Daily evaluation for evidence of dehydration, oedema or ileus, combined with daily 
monitoring of changes in urea, creatinine, sodium, potassium, magnesium, calcium and phosphate 
is recommended and will assist in adjusting the volume or electrolyte content of NT 
appropriately.25-26 
2.5 Fluid, electrolyte, energy and macronutrient requirements of the critically ill 
patient 
2.5.1 Fluid and electrolyte requirements 
Table 2-5 indicates the normal daily fluid and electrolyte requirements during maintenance of NT in 
critically ill and/or perioperative patients as recommended by various authors. The electrolyte 
recommendations serve as a general guideline for patients with normal renal and liver function and 
for those with normal serum electrolyte concentrations.38 Electrolyte intake frequently requires 
adjustment during maintenance NT based on the clinical condition 25 and additional replacement 
may be required during the acute resuscitation of a hypovolemic patient.21 Table 2-6 shows 
examples of conditions that frequently require electrolyte adjustment. 
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Table 2-5 Maintenance fluid and electrolyte requirements of critically ill patients requiring NT 
  Allison 
2004
 22
 
Lobo 
2004 
21
 
Rassam 
2005 
39
 
Madsen  
2006 
13
 
    EN               PN 
Shields 
2008 
41 (A)
 
Powel-Tuck 
2008 
38
 
 
Sobotka 
2009 
25
 
EN               PN 
Biesalski  
2009 
24 (B)
 
Mer M  
2012 
42
 
Marsh 
2012 
2
 
Fluid* mL/kg/d 30–40  
+10ml/kg/1˚C 
>37 ˚C  
25–35 
 
35 
 
- - 25–35 
 
- - - - 35 (18–60 yr) 
30 (>60 yr) 
+ 2 – 2.5 
ml/kg/1˚C  
>37 ˚C 
- 
L/d - 2 – 2.5 2.5 – 3 - - ≤ 5 (median 3) 1.5 – 2.5 - - - - - 
mL/kg/hr - - - - - - - - - - 1.5 1.5 
Na  
 
mmol/kg/d - 1–1.2 2 - - 1 - - - - - 1 - 1.5 
mmol/d - 60–100 - 0–200 100–150 242 (median) 50-100 80 -100 80 -100 60 – 150 100 - 
K mmol/kg/d - 1–1.2 1 - - - - - - - - 1 
mmol/d - - - 0–240 60–120 - 40–80 
©
 60 – 150 60 – 150 40 – 100 75 - 
Cl mmol/kg/d - - - As needed to maintain 
acid-base balance 
- - - - - - 1.5 
mmol/d - - - - - - - - 120 - 
P mmol/kg/d - - - - - - - - - - - 0.2 - 0.5 
mmol/d - - - 0 – 60 15 – 30 - - 15 – 30 20 – 40 10–30 - - 
Mg mmol/kg/d - - - - - - -     0.1 - 0.2 
 mmol/d - - - 0 – 48 8 – 24 - - 8 – 12 10 – 18 4 – 12 8 
Ca mmol/kg/d - - - - - - - - - - - 0.1 - 0.2 
mmol/d - - - 0 – 25 9 – 22 - - 2.5 – 5 25 – 50 2.5 – 7.5 - - 
(A) 
Postoperative guidelines; 
(B) 
Standard daily dose in PN. Additional amounts should only be given to correct deficits or ongoing losses; 
(C)
 Unless kidney disease or hyperkalemia 
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Table 2-6 Conditions requiring adjustment of normal electrolyte requirements25 
Fluid/electrolyte abnormality Condition 
Fluid and Na deficiency 
 
Extra-renal ﬂuid losses:  
GI ﬁstulas; Water and electrolyte losses from gastric aspiration; Severe 
diarrhoea; Toxic megacolon; Ileus with pooling in the gut; Short bowel 
syndrome; Increased skin losses (sweat) during febrile episodes or in a hot 
environment; Severe burns  
Increased renal losses: 
Polyuric renal failure (tubular impairment)  
Fluid and sodium sequestration into extracellular or transcellular 
compartment: 
Severe acute pancreatitis; Severe trauma and sepsis; Sequestration of 
ﬂuid in intestine 
Fluid and sodium restriction Oliguric renal failure; Cardiac failure; Oedema in the post-acute phase of 
injury 
K, Mg and P deﬁciency Convalescence phase after trauma, sepsis or severe injury; Severe 
malnutrition with risk of refeeding syndrome; Severe losses of extracellular 
ﬂuid (GI tract, burns); Treatment with diuretics 
K, Mg, P restriction 
 
Oliguric renal failure; Acute catabolic situations (e.g. sepsis) particularly if 
combined with renal failure 
Abbreviations: Na: Sodium; K: Potassium; Mg: Magnesium; P: Phosphate 
 
2.5.2 Energy and macronutrient requirements 
Despite numerous observational studies, small randomized trials, systematic reviews and 
consensus guidelines on NT in critical illness, many issues remain controversial; including the most 
appropriate substrates to use, the optimal time to initiate NT, the ideal method for assessing 
energy requirements and optimal nutritional targets.  
Accurate determination of energy requirements in the critically ill is difficult. Firstly, resting energy 
expenditure is highly variable during the course of critical illness due to changes induced by shock, 
fever, sedation, surgical procedures and loss of lean body mass (LBM).29,60 Secondly, accurate 
determination of energy targets requires knowledge of pre-illness weight and body height, data 
which is often missing. Thirdly, actual body weight is frequently inaccurate due to fluid 
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accumulation post resuscitation,29,60 while dry body weight is a poor indicator of LBM, especially in 
the obese patient where body weight is increased by excess fat mass.29  
Currently, the gold standard for predicting energy requirements is by means of measuring energy 
expenditure on an individual basis by indirect calorimetry.28-29,60-62 However, this method is fairly 
expensive, time-consuming and remains unavailable in most ICUs.29,62 Predictive equations are 
therefore frequently used as surrogates to estimate energy requirements.28-29,62 Most of these were 
developed for use in the healthy population and there is currently no consensus as to the most 
accurate equation for estimating energy requirements in the critically ill.28 The Harris & Benedict 
equation (adjusted or not for ideal body weight), and the equations of Mifflin, Owen, the American 
College of Chest Physicians (ACCP), Ireton-Jones 1992 and 1997, Penn State 1998 and 2003, 
and Swinamer 1990 are the most commonly used. However, the results from these correlate 
poorly with those of indirect calorimetry.29 The most significant source of error in these equations is 
the use of estimated, rather than measured weight.28 Berger and Pichard 29 suggest that the 
Toronto equation for major burns and the Faisy-Fagon equation for patients on mechanical 
ventilation were developed specifically for critically ill patients and are clinically more accurate than 
other predictive equations for metabolically stable, mechanically ventilated patients.29 The last 
method for determining energy requirements is the use of a fixed daily prescription, usually in the 
range of 20 – 35 kCal/kg.28,62 Despite the greater ease of applying this method at the patient’s 
bedside, accuracy is generally regarded as poor. Accuracy might be improved by using 
metabolically active weight, instead of actual weight, but currently there is no reliable definition of 
metabolically active weight.28 A number of professional organizations and authors have developed 
consensus guidelines for the determination of nutritional requirements in critical illness (Table 2-7). 
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Table 2-7 Published guidelines for nutrient intake in critically ill patients 
Society Year Energy 
kCal/kg/day 
Protein 
g/kg/day 
Carbohydrates 
g/kg/day 
Lipid 
g/kg/day 
ACCP 
63
 
 
1997 25 - - - 
CCCPG 
64
 2003 No recommendation 
(insufficient evidence) 
- - - 
ESPEN 
65-66
 2006 Enteral nutrition: 
Acute phase:  
20 – 25 (Grade C) 
 
Recovery phase:  
25 – 30 (Grade C) 
 
Malnutrition: 
25 – 30 (Grade C) 
- - - 
2009 Parenteral nutrition: 
25 if IC not available 
(Grade C) 
1.3 – 1.5  
(+ 0.3 – 0.6 alanyl-
glutamine dipeptide) 
Minimum: 2 
 
0.7 – 1.5 over  
12 – 24 hours 
ASPEN 
67
 2009 25 or predictive 
equations if IC not 
available  
1.2 – 2.0 
(BMI<30kg/m2) 
Increase in burns 
and polytrauma.  
- - 
Abbreviations: ACCP: American College of Chest Physicians; CCCPG: Canadian Critical Care Practice 
Guidelines; ESPEN: European Society of Parenteral and Enteral Nutrition; ASPEN: American Society of 
Parenteral and Enteral Nutrition; IC: Indirect calorimetry. 
Evidence grades: B, supported by at least one well-designed randomized controlled trial or other with sound 
methodology; C, based on expert opinion or advice.
65-66
 
 
2.5.3 Hypo- versus hypercaloric feeding 
Considerable debate revolves around the optimal quantity of nutrition (energy and protein) that 
should be provided to critically ill patients in relation to clinical outcomes.34,68 According to Berger 
and Pichard 29 the recent publication of studies with apparently conflicting results regarding the 
respective merits of hypo- and hypercaloric feeding has caused further confusion among ICU 
specialists. There is a general consensus that both over- and underfeeding have well defined 
adverse effects and should be avoided.29,60,68 Feeding strategies suggesting that permissive 
underfeeding may be adequate are based on several studies that found that suboptimal provision 
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of calories actually improves patient outcomes compared to goal directed feeding. Table 2-8 shows 
a breakdown of some of the landmark studies in favour of permissive underfeeding.  
 
Table 2-8 Landmark studies in favour of permissive underfeeding 
Study reference Study design Level of caloric intake Results 
Krishnan 2003 
69
 Observational 33 – 65% of ACCP target 
(9-18kCal/kg) 
Improved survival 
Hise 2007 
34
 Observational < 81% of energy target Shorter ICU and hospital 
LOS 
Arabi 2011 
70
 RCT Permissive underfeeding  
versus target feeding  
(59% vs 71%) 
Lower hospital mortality 
in permissive 
underfeeding group 
Rice 2012 
71
 RCT Trophic feeding versus 
target feeding during first 
6 days in ALI patients 
No difference in clinical 
outcomes More GIT 
disturbances in target 
feeding group 
Abbreviations: ACCP: American College of Chest Physicians; RCT: Randomized controlled trial; ICU: 
Intensive care unit; LOS: Length of stay; ALI: Acute lung injury; GIT: Gastrointestinal 
 
However, most of these studies did not take into account the additional calories derived from 
NNES (i.e. dextrose-containing IV solutions or lipid-based sedatives), thus limiting the conclusions 
made regarding energy goals for critically ill patients.28 In addition the controls fed according to 
traditional protocols 70-71 did not receive sufficient protein which is perhaps more important than 
calories alone.72 Dickerson 30 recommends further research to determine the minimum amount of 
nutrition (calories and protein) needed to achieve a therapeutic benefit and to determine at what 
intake no further benefit accrues. According to Peake et al 28 short periods of hypocaloric feeding 
are considered a normal response to acute illness, usually involving anorexia and reduced intake, 
and might not negatively impact clinical outcomes. It is also possible that some variation in calories 
within a defined range, delivered over a variable time frame, might not influence clinical outcomes. 
However, prolonged underfeeding may result in a cumulative energy/protein debt that cannot be 
compensated for later during ICU stay due to complications related to overfeeding.28,33 Hence, at 
some point in time cumulative malnutrition and loss of muscle mass will influence recovery.28  
Table 2-9 is a summary of previous studies reporting that underfeeding has a negative impact on 
clinical outcomes. 
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Table 2-9 Studies reporting negative impact of underfeeding on clinical outcomes 
Study reference Study design Level of calorie intake Results 
Rubinson 2004 
73
 Observational < 25 % of energy target Increased risk of blood 
stream infections 
Villet 2005 
33
 Observational Negative cumulative 
energy balance  
Increased risk of ICU 
complications, especially 
infections  
Alberda 2009 
74
 Observational + 1000 kCal/day 
+ 30g Prot/day 
Reduced mortality 
(Limited to BMI < 25 or ≥ 
35) 
Pichard 2008 
75
 Observational Energy delivery greater 
than 1500 kCal over first 
3 days 
Reduced ICU and 
hospital mortality 
Tsai 2010 
68
 Observational < 60 % of energy target Increased mortality 
Weijs 2012 
76
 Observational Meeting energy & 
protein targets 
50% reduction in 
mortality 
Abbreviations: BMI: Body mass index (kg/m2) 
 
There are problems with some of these studies. Specifically, Alberda et al 74 and Villet et al 33 did 
not adjust for illness severity and as such these observational data may simply point out the 
association between illness severity and difficulties with feeding. Furthermore, all of the above 
studies are observational and a causal relationship can therefore not be established. On the other 
hand, overfeeding is associated with a range of complications, including altered hepatic function, 
hyperglycemia, hypercapnia, increased infectious rates, increased inotropic support, increased 
body temperature, increased metabolic rate and measured energy expenditure.28-30 Berger and 
Pichard 29 reported on a large multicentre Spanish study by Grau et al (2007) that found 
overfeeding at values as low as 110 – 120% of true requirements to be one of the determinants of 
altered hepatic function. 
In conclusion, the provision of NT should be based on the Latin phrase “primum non nocere”, 
translated as “first, do no harm”.30 Each patient should be closely monitored for signs and 
symptoms of overfeeding, as well as feeding intolerance and appropriate measures taken to avoid 
these complications. On the other hand, severe underfeeding can also be harmful and justifies 
continuous efforts to optimise nutrient delivery and feeding tolerance.30 
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2.5.4 Patient-specific recommendations 
2.5.4.1 Obesity 
Obesity (BMI > 30kg/m2) may be present in up to 30% of ICU patients. The metabolic and 
endocrine consequences, such as glucose intolerance, insulin resistance, type 2 diabetes mellitus, 
metabolic syndrome, dyslipidemia, non-alcoholic fatty liver disease, and steatohepatosis, are 
further exacerbated by critical illness. Obese critically ill patients present with a greater increase in 
net glucose and protein oxidation and reduction in fat oxidation compared with their non-obese 
counterparts.28,77-78 Problems with futile cycling, insulin resistance, and poor fuel utilization may 
predispose these patients to greater losses of lean body mass when in stressed situations and are 
therefore at greater risk of protein malnutrition.28,78 They are also at increased risk of overfeeding 
due to the presence of comorbidities, such as diabetes, fatty liver and obesity-related 
hypoventilation syndrome. In fact many obese critically ill patients may present with worsened 
stress-induced hyperglycemia. In this setting, excessive calorie and glucose delivery may increase 
the risk of lipogenesis, hepatic steatosis, increased carbon dioxide production and increased work 
of breathing. Therefore special attention should be paid to the nutritional goals of obese patients in 
ICU.28 Determination of the most appropriate energy target is difficult. However although conclusive 
evidence is lacking, expert opinion currently suggests restriction of energy intake to <70% of 
targeted energy intake 77 and high-protein feeding is recommended to preserve lean body mass, 
facilitate loss of fat mass and improve insulin sensitivity.67,78 Table 2-10 indicates the nutritional 
guidelines for obese critically ill patients as published by the SCCM and ASPEN in 2009.67 
 
Table 2-10 Nutritional guidelines (ASPEN) for obese critically ill patients 67 
 Recommendation 
Energy 60 – 70 % of energy requirements 
11 – 14 kcal/kg/day actual body weight 
22 – 25 kcal/kg/day ideal body weight 
(Grade D recommendation) 
Protein ≥ 2.0 g/kg ideal body weight/ day (Class I & II) (BMI 30 – 40) 
≥ 2.5 g/kg ideal body weight/ day (Class III) (BMI ≥ 40) 
Abbreviation: BMI: Body mass index 
  
Adequately powered RCTs are recommended to address the unresolved controversy regarding the 
amount of calories to be delivered to these patients, as well as the most accurate method to 
estimate energy requirements. Obesity-related changes in body composition and resting energy 
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expenditure, especially the reduced metabolic demands of adipose tissue and the variable 
increase in LBM with increasing body weight, makes the determination of both actual and ideal 
body weight (IBW) problematic. This puts the obese patient at risk of both under- and over-feeding. 
Using actual body weight has been shown to overestimate energy requirements, while IBW 
generally underestimates measured energy expenditure. Using an adjusted IBW takes into account 
the increase in metabolically active LBM mass that occurs with obesity. However, there is currently 
no consensus regarding which of these weights (actual, ideal, adjusted) should be used to predict 
energy requirements and some authors have proposed the use of a fixed amount of calories (e.g. 
21kCal/kg actual body weight in obese ventilated patients).28   
2.5.4.2 Malnutrition 
There is also an increased incidence of malnutrition among ICU patients. Malnutrition is both a 
cause and consequence of disease and greatly impacts on clinical outcomes. NT in critical illness 
should therefore aim at preventing malnutrition 28 and providing more aggressive NT to those who 
are the most nutritionally at risk.79 Accurate determination of the energy requirements of 
malnourished patients are however challenging. A certain subgroup of malnourished patients are 
also at risk of refeeding syndrome. High risk patients are those with a low body weight or BMI 
<18kg/m2, a history of severe weight loss of ≥10% over 3 months, poor oral intake for >5 days and 
a history of poor nutritional intake or conditions that may be associated with malnutrition (e.g. 
alcoholism).28  
2.5.4.3 Acute kidney injury (AKI) 
AKI is a well-recognized hypermetabolic, pro-inflammatory and pro-oxidative state with distinct 
alterations in protein, carbohydrate and lipid metabolism.80,81 This, together with coexisting 
catabolic illness leads to accelerated skeletal muscle breakdown with a negative nitrogen balance, 
insulin resistance, hyperglycemia, altered lipid metabolism, and water, electrolyte and acid-base 
imbalances.81 Metabolic alterations and nutrient balances are further influenced by the modality 
and intensity of RRT (Grade B).80 Currently the treatment modalities of choice in critically ill 
patients with AKI are continuous renal replacement therapies (CRRT), and especially continuous 
veno-venous hemofiltration (CVVH), veno-venous hemodiafiltration (CVVHD-F) or sustained low-
efficiency dialysis (SLED). These therapies are known to exert a negative influence on electrolyte 
and nutrient balance due to their continuous or prolonged nature and high efficiency.82  
Electrolyte and acid-base imbalances, such as hypo- and hypernatremia, hyperkalemia, 
hyperphosphatemia and metabolic acidosis are often seen in AKI.80-82 These abnormalities can be 
resolved by appropriate regulation of the intensity of RRT and the composition of 
hemodialysis/hemofiltration fluids used.80-82 Hypophosphatemia and hypomagnesemia caused by 
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the highly efficient modalities of RRT can be prevented by adequate electrolyte 
supplementation.80,81,82 Potassium, magnesium and phosphate restrictions in PN are usually not 
needed if the patient is on daily RRT (CRRT, hemodialysis or SLED).80 In enterally fed patients, the 
electrolyte content of most 1500–2000 kcal enteral formulae is usually adequate. However, 
electrolyte requirements can differ and requires individual assessment. Plasma electrolyte 
monitoring should aim at avoiding hypokalaemia and/or hypophosphataemia after the initiation of 
EN to prevent the so-called refeeding syndrome.83  
Energy and macronutrient requirements in AKI are determined rather by the severity of the 
underlying disease, type and intensity of extracorporeal RRT, pre-existing nutritional status and 
acute/chronic comorbidities, than by the AKI per se.81-83 A patient’s tolerance of excessive 
substrate delivery (e.g. amino acids, trace elements, vitamins, etc) is severely reduced due to 
impaired renal regulatory function (C) 80 and overfeeding should therefore be avoided.81 Saxena 81 
suggests that a target of 25 – 30 kCal/kg during the first week of ICU care is appropriate for most 
stable patients. The energy target can then be increased to 35 kCal/kg/d if the patient is stable, in a 
low inflammatory state and weight gain is required.81 According to Cano 80 energy targets should 
be adapted to the level of catabolism and tailored to individual needs in patients that are 
underweight or obese. 
The optimal amount of protein intake in AKI patients is unknown. The use of high-flux filters and/or 
highly efficient modalities (such as CRRT or SLED) is associated with increased protein losses.80,82 
In CVVH/CVVHD-F there is a loss of ~0.2 g amino acids/L of ultrafiltrate (up to 10–15 g/day of 
amino acids), and 5 - 10 g/day of protein, depending on RRT modality and filter type. 
Approximately 10 – 15% of infused amino acids are lost in the dialysate/ultrafiltrate.80 AKI patients 
on RRT should therefore receive at least 1.5g/kg/day of protein and an additional 0.2g/kg/day to 
compensate for protein and amino acid losses during RRT.80,82 In non-catabolic AKI patients with 
milder non-oligouric forms of the syndrome that do not need RRT and who are likely to regain renal 
function in a few days lower protein intakes (up to 0.8 g/kg/d) will suffice for short periods of time, 
combined with adequate calorie intake (30 kcal/kg/d).82 Table 2-11 indicates the nutritional 
requirements of patients with AKI as recommended by several authors. 
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Table 2-11 Nutritional requirements of patients with AKI 
 NPE 
kCal/kg/d 
PROTEIN 
g/kg/d 
CHO 
g/kg/d 
LIPID 
g/kg/d 
Cano 2006 & 2009 
 (PN & EN) 
80,83
 
20 – 30 Conservative therapy/ 
mild catabolism: 
0.6 – 0.8  (Max 1.0) 
 
3 – 5 
(Max 7) 
0.8 – 1.2  
(Max 1.5) 
Extracorporeal therapy/ 
moderate catabolism: 
1.0 – 1.5  
 
CRRT/severe catabolism:  
Up to max of 1.7 
 
Fiaccadori 2010 
82
 
 
20 – 25  
(Max 30) 
 
BEE X 1.3 
 
Nitrogen: 
Min of 0.25  
 
Protein: 
1.5 – 2.0 g/kg/d  
- ~ 30 – 35% of 
NPE 
 
0.8 – 1.2 over  
18 – 24hr 
(Stop lipid 
infusion if s-TG 
>400mg/dL) 
Martindale 2009 
67
 - RRT:  
Increase up to a max of 2.5  
 
- - 
Ziegler 2009 
84
 - No RRT: 
0.6 – 1.0 (based on renal function) 
 
- - 
RRT: 
1.2 – 1.5  
 
KDOQI 
85
 
(NKF 2012) 
25 – 35 Non-catabolic/ no dialysis: 
0.8 – 1.0 
 
- - 
AKI on RRT: 
1.0– 1.5  
 
CRRT/hypercatabolic: 
Up to a max of 1.7  
 
Saxena 2012 
81
 25  CT/mild catabolism: 
0.8 
 
5 0.8 – 1.2 
Extracorporeal therapy/  
moderate catabolism: 
1 – 1.5 
 
CRRT/SLED/severe catabolism:  
1.5–2.0  
 
Abbreviations: AKI: Acute kidney injury; NPE: Non protein energy; CHO: Carbohydrates; PN: Parenteral 
nutrition; EN: Enteral nutrition; CRRT: Continuous renal replacement therapy; BEE: Basal energy 
expenditure according to Harris Benedict equation; s-TG: serum triglycerides; RRT: Renal replacement 
therapy; SLED: Sustained low efficiency dialysis 
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2.6 Impact of intravenous fluid therapy (IVFT) on actual nutrient intake 
Most previous studies assessing energy intake among critically ill patients did not account for 
energy delivery from non-specific sources, such as dextrose water and propofol.  Table 2-12 
shows a summary of the NNES that were taken into account by observational studies that were 
published prior to the data collection phase of our study. This table is based on the energy sources 
that were reported by the respective authors. 
 
Table 2-12 NNES taken into account by previously published observational studies 
 IV fluid therapy Drug 
dilution 
50% 
dextrose 
water 
Propofol Polygam 
Crystalloids HES Albumin     
Villet 2005 
33
 X   X  X  
Hise 2007 
34
 X     X  
Alberda 2009 
74
      X  
Tsai 2011 
68
 X        
Arabi et al 2011 
70
 X     X  
This study X X X X X X X 
 
The prospective cohort study by Hise et al 34 found that medical ICU patients received less 
propofol and significantly less dextrose-containing IV fluids when compared to surgical ICU 
patients. On average, patients in the surgical ICU received 250 kcal per day from propofol and 
dextrose-containing fluids. These NNES contributed a clinically relevant amount of kilocalories in 
surgical ICU patients.34 Both Hise et al 34 and Taylor et al 86 found propofol to be a significant 
source of lipids in ICU patients and they recommend that close monitoring of propofol 
administration when calculating feeding prescriptions is essential to prevent excessive lipid 
intake.34,86 According to Hise et al 34 the significantly higher energy intake derived from dextrose-
containing IV fluids in their surgical ICU was attributed to the greater need for fluid resuscitation in 
perioperative patients, as well as differences among ICU physician practices regarding volume and 
duration of dextrose-containing IV fluid administration. They recommended routine monitoring of all 
NNES. In a RCT by Arabi et al 70 the average daily caloric intake derived from propofol and 
dextrose infusions was 34kCal/day and 116kCal/d respectively. The authors did not specify the 
sources of dextrose energy that were evaluated. 
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According to Byrnes et al 31 additional energy delivery from NNES is of great concern in patients at 
risk of refeeding syndrome. According to a recent review article by Berger and Pichard 29 the 
concept of counting only NPE, as well as not taking into account the energy derived from NNES, 
such as glucose 5% solutions and fat soluble sedatives, might have been responsible for 
systematic overfeeding in several studies. The authors strongly suggest taking into account the 
energy content of inadvertent NNES when prescribing energy targets.  
2.7 Conclusion 
Optimal fluid and electrolyte administration forms a cornerstone in the successful management of 
critical illness-induced fluid and electrolyte imbalances. Nevertheless, ICU physicians face difficulty 
in optimising patients’ fluid status on a daily basis.20 Nutrient, water, mineral and electrolyte 
balance are all closely related 21 and achieving and maintaining balance plays a crucial role in 
obtaining the full benefit from NT.22 NT also directly impacts on a patient’s fluid and electrolyte 
status, since the delivery of NT cannot be separated from that of fluid and electrolytes.21,25 Excess 
fluid intake from multi-drug infusions, PN or EN or antibiotics requiring large volume infusions, 
should be subtracted from the maintenance fluid regimen in order to avoid fluid overload.39 
Similarly IVFT in patients receiving CRRT for AKI should also compensate for increased fluid given 
to provide adequate nutrition and drugs, however most ICUs do not take into account fluid delivery 
in their prescription of fluid removal.10   
Calculation of fluid and electrolyte requirements is as important as determining a patient’s macro- 
and micronutrient needs when prescribing NT 21,25 and daily monitoring of fluid and electrolyte 
status should be incorporated into the dietician’s daily ICU round.  Input and output charts provide 
valuable information on fluid status,25 however, frequent errors in the measurements and records 
often result in a large cumulative error in fluid balance. There are currently few studies that have 
recorded accurately total fluid and electrolyte delivery.  
In addition most studies that have assessed energy intake among critically ill patients did not take 
into account additional energy delivery from inadvertent NNES. The small number that did, did not 
include all the NNES that form part of daily routine ICU practices. As such it is not known to what 
extent the latter would have further contributed to total energy intake. An accurate determination of 
the contribution of NNES to total energy delivery is paramount, since both over- and underfeeding 
are associated with detrimental effects.  
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3.1 Aim 
To determine the nutritional content / contribution of IV fluid and electrolyte administration on the 
total feeding prescription of ICU patients admitted to a multidisciplinary ICU. 
3.2 Specific objectives 
 To determine the volume and types of IV fluids most often prescribed to ICU 
patients 
 To determine the IV electrolyte supplements (type and dosing) most often 
prescribed to ICU patients 
 To determine the contribution of the following routine ICU practices on a patient’s 
total fluid, electrolyte, energy and macronutrient intake: 
- Crystalloids, colloids and blood products used for IVFT 
- Crystalloids used for IV drug dilution and flushing of IV lines 
- IV electrolyte replacement 
- Lipids delivered with sedatives (propofol)  
- Dextrose water used in the treatment of hypoglycaemia and hyperkalaemia 
- Sucrose delivered with immunoglobulin therapy (polygam) 
 To compare a patient’s total energy and protein intake inclusive of nutritional and 
non-nutritional sources with his/her estimated energy and protein targets. 
3.3 Implementation objectives 
The results from this study will aid clinical dieticians to optimise the nutritional care of critically ill 
patients by taking into account the contribution of IV fluid and electrolyte administration to a 
patient’s total fluid, electrolyte, energy and macronutrient intake. It will also function as an audit of 
actual delivery. 
3.4 Study design 
A retrospective descriptive observational study was conducted.  
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3.5 Study population and sampling 
3.5.1 Study population 
The study population consisted of critically ill adult (i.e. ≥ 18 years of age) patients admitted to the 
general intensive care unit (GICU) of Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH).  
3.5.2 Sampling method 
All patients discharged from ICU or who demised on or after the first day of data collection, were 
screened for eligibility. Consecutive patients meeting the inclusion criteria were enrolled in the 
study until the required sample size was reached. Data collection commenced on the 19th of 
March 2012 and was completed on the 17th of July 2012. 
3.5.3 Inclusion and exclusion criteria 
3.5.3.1 Inclusion criteria 
 Adults (≥ 18 years of age) 
 Must have been admitted to the GICU of CMJAH 
 APACHE II score ≥10 on admission to ICU 
 Must have received NT (i.e. EN and/or PN) for at least 72 hours. 
 Must have had an ICU length of stay of at least 72 hours. 
3.5.3.2 Exclusion criteria 
 Skeletal abnormalities, contractures and spinal cord injuries (quadriplegia and 
paraplegia) 
 NT discontinued within 72 hours after ICU admission. 
 Patients that were discharged from ICU or that demised within 72 hours after ICU 
admission.  
3.5.4 Sample size 
A total of seventy one patients (n=71) were included in the final sample size. This was based on a 
precision of Cp= 12% and a confidence interval of 95% (Appendix A).  
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3.6 Methods of data collection 
Data collection was carried out in the 12-bed GICU of CMJAH.  All patients discharged from ICU or 
who demised on or after the first day of data collection were screened for eligibility, i.e. all data 
were collected retrospectively. ICU charts and hospital files of eligible patients’ were reviewed to 
collect data from ICU admission until ICU discharge, or until discontinuation of NT or death, 
whichever occurred first. All relevant data were entered into standardised case report forms 
following a standardised data collection protocol (Appendix B). If a study participant remained in 
ICU for more than 7 days data were collected until day 7 in ICU.  
3.6.1 Baseline patient data 
Study participants’ ICU charts and hospital files were reviewed retrospectively in order to obtain the 
following baseline information: 
 Age, sex, ICU admission date/time, type of admission (medical versus surgical) and 
primary ICU diagnosis. 
 As an indicator of the severity of disease on admission to ICU, data from the first 24 
hours after ICU admission was used to calculate the patient’s Acute Physiology and 
Chronic Health Evaluation (APACHE II) score. For each APACHE variable, the 
single worst value out of all values from the first 24 hours after ICU admission was 
used. If variables were not available from the first 24 hours, data outside the 24 hour 
window but closest to ICU admission were used.  
 Additional medical information was charted if applicable to the study participant’s 
feeding prescription (e.g. comorbidities or nutrition-related problems, medical 
history, arterial blood gas values, biochemistry, fluid balance, gastric residual 
volumes, prescribed medication/s, tests/procedures, clinical presentation and 
feeding tolerance).   
 Renal function and the presence of severe sepsis or septic shock were reviewed 
over the entire study period; i.e. from ICU admission until study exit. The presence 
of severe sepsis/SIRS or septic shock was based on the charted diagnoses and/or 
reviewing study participants’ ICU charts for the presence of sepsis criteria 87 as 
specified in the standardised data collection protocol (Appendix B). The presence of 
AKI was based on the charted diagnoses by the attending physician. 
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3.6.2 Baseline anthropometrical data  
3.6.2.1 Height 
Height charted on the study participant’s ICU chart was used. Height is routinely estimated and 
charted by the registered dietician for all ICU patients according to the “recumbent height” 
method.17 
3.6.2.2 Body weight (BW) 
Weight charted on the study participant’s ICU chart was used. Estimated dry weight is routinely 
charted by the registered dietician for all patients in the ICU. Weight charted for patients with fluid 
retention or amputation/s are routinely estimated according to standardized methods (Appendix 
C).17 
3.6.3 Daily feeding prescription/s 
The daily feeding prescription/s as charted by the registered dietician (RD) or the study 
participant’s attending physician were recorded retrospectively for each study participant. 
3.6.4 Daily fluid and nutritional data 
3.6.4.1 Type of nutrition delivered 
The type and route of nutrition delivered to a study participant (EN and/or PN and/or oral nutrition) 
was recorded. 
3.6.4.2 Fluid, electrolyte, energy and macronutrient intake 
 The type and volume of IV fluids used for IVFT 
 The volume of liquid drugs administered via the IV, enteral or oral route 
 The type and volume of IV fluids used for reconstitution and dilution of IV drugs 
 The type and volume of IV fluids used for flushing of IV lines 
 The type and dosing of IV electrolyte replacement (if prescribed) 
 The dose of propofol, dipeptiven and/or polygam infused (if prescribed) 
 The type and volume of dextrose water administered as part of standard ICU 
protocols  
 The type and volume of EN and/or PN 
 The type and volume of fluids and/or feeds taken orally (if applicable) 
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3.7 Pilot study 
A pilot study was undertaken in the GICU of CMJAH to determine the completeness and accuracy 
of the following: 
 Patients’ ICU charts for data collection purposes 
 Data entry procedure (case report forms) 
 Data coding procedure  
Ten patients (n=10) were included in the pilot study and they were subsequently excluded from the 
main study. 
3.8 Data management and analysis 
3.8.1 Statistical analysis 
MS Excel was used to capture the data and STATISTICA version 9 (StatSoft Inc. (2009) 
STATISTICA (data analysis software system), www.statsoft.com.) was used to analyse the data.  
Summary statistics were used to describe the variables.  Distributions of variables are presented 
with histograms and/or frequency tables. Medians or means were used as the measures of central 
location for ordinal and continuous responses and standard deviations and quartiles as indicators 
of spread. 
Relationships between two continuous variables were analysed with regression analysis and the 
strength of the relationship measured with Pearson correlation, or Spearman correlation if the 
continuous variables were not normally distributed. The relationships between continuous 
response variables and nominal input variables (like different diets) were analysed using 
appropriate analysis of variance (ANOVA).When ordinal response variables were compared versus 
a nominal input variable, non-parametric ANOVA methods were used. For completely randomized 
designs the Mann-Whitney test or the Kruskal-Wallis test were used. The relation between nominal 
variables were investigated with contingency tables and appropriate chi-square tests like the 
likelihood ratio chi-square test. 
A p-value of p < 0.05 represented statistical significance in hypothesis testing and 95% confidence 
intervals were used to describe the estimation of unknown parameters. 
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3.8.2 Analysis of anthropometrical data 
3.8.2.1 Ideal body weight 
Ideal body weight was calculated as follows (Table 3-1): 
 
Table 3-1 Ideal body weight calculations: 88 
Males: Height2 (m) X 20 – 25 
Females:  Height2 (m) X 19 - 24 
(Height obtained from ICU charts) 
 
3.8.2.2 Nutritional status 
Nutritional status was determined by using the body mass index (BMI) classification system (Table 
3-2): 
 
Table 3-2 Nutritional status according to BMI classification system 17 
Nutritional status BMI classification* 
Undernourished Grade I 17 ≤ BMI < 18.5 
Grade II 16 ≤ BMI < 17 
Grade III  BMI < 16 
Normal 18.5 ≤ BMI < 25 
Overweight 25 ≤ BMI < 30 
Obese Class I 30 ≤ BMI < 35  
Class II 35 ≤ BMI < 40 
Class III  
(Morbid obesity) 
BMI ≥ 40 
* BMI (kg/m2) =  weight/ (height)
2
 
(Weight and height obtained from ICU charts) 
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3.8.3 Analysis of fluid and nutritional data 
Daily fluid and nutritional data were used to determine the following: 
 Total fluid delivery 
Total fluid delivery included fluid administered via the IV route (i.e. IVFT, IV drug administration, 
reconstitution and dilution of IV drugs, IV electrolyte and vitamin supplementation, flushing of IV 
lines, dextrose water administered in the treatment of hypoglycemia and hyperkalemia, PN), 
enteral route (i.e. EN, water, flushing of feeding tube, drugs administered via the enteric tube, 
including the mixing of crushed medication with water) and oral route if applicable.   
 Total electrolyte delivery 
Total electrolyte delivery included electrolytes administered via the intravenous route (i.e. 
electrolyte-containing IV solutions used for IVFT, drug dilution and flushing of IV lines, IV 
electrolyte replacement, PN), enteral route (EN and/or fluids administered via feeding tube) and 
oral route if applicable. 
 Total energy delivery with delineation of energy sources 
Total energy delivery included energy delivery from NT (EN, PN and/or dipeptiven), additional oral 
intake (if applicable), NNES (crystalloids and colloids used for IVFT, drug dilution and flushing of IV 
lines), lipids delivered with sedatives (propofol), sucrose delivered with immunoglobulin therapy 
(polygam) and IV dextrose administration in the treatment of hypoglycemia and hyperkalemia. 
 Macronutrient distribution 
The percentage (%) macronutrient distribution of mean daily energy intake was determined.    
 Estimated energy and protein balance 
Estimated energy/protein balance was calculated on a daily basis as total energy/protein delivery – 
total energy/protein target*. The cumulative energy/protein balance (total energy/protein delivery – 
total energy/protein target* for the total study period) was then calculated.33-34  
 Energy and protein delivery in relation to estimated targets 
For energy/protein analyses comparing delivery of nutrition in relation to estimated targets*, the 
outcome variable were mean energy/protein delivery in the ICU relative to estimated targets*. Each 
study participant’s actual energy/protein intake in kilocalories/grams per day was divided by the 
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target value in kilocalories/grams per day. The mean percent target per ICU day was calculated as 
follows (Table 3-3): 
 
Table 3-3 Calculation of mean percent target: 34 
Mean percent target (energy):  
= ∑ (Each day’s energy intake/target energy intake) X 100 
                          7 days 
Mean percent target (protein): 
= ∑ (Each day’s protein intake/target protein intake) X 100 
                          7 days 
 
*Estimated energy and protein targets: 
The charted daily feeding prescriptions did not always reflect the study participants’ actual energy 
and protein targets for the following reasons: 
 Feeding prescriptions written by the attending doctor in the absence of the RD was 
not based on calculated nutritional targets. The RD’s ICU round takes place in the 
mornings and henceforth patients admitted in the afternoon or at night had feeding 
prescriptions written by the attending doctor until the next RD round.  
 In some instances more than one feeding prescription was charted on a particular 
day. 
 Certain specialised feeding prescriptions did not reflect the patient’s actual energy 
and protein targets, e.g.  
- Trickle/trophic feeding  
- Low electrolyte feeding prescription in the presence of severe electrolyte 
derangements (e.g. hypernatremia > 160mmol/L)  
Henceforth the study participants’ daily energy and protein targets, expressed in ranges (e.g. 20 – 
25kCal/kg and 1.2 – 1.5g/kg protein), were standardized retrospectively according to a 
standardized procedure, as indicated in the standardized data collection protocol (Appendix B). 
This procedure was based on the evidence-based recommendations made by the European 
Society of Enteral and Parenteral Nutrition (ESPEN), 65-66 American Society of Parenteral and 
Enteral Nutrition (ASPEN) 67 and the Canadian Clinical Practice Guidelines (CCPG).64 The weight 
used for calculating nutritional targets were based on the standardized procedure as indicated in 
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the standardized data collection protocol (Appendix B).88-90 Meeting 100% of energy/protein target 
was defined as an energy/protein delivery falling between 90% of the minimum and 110% of the 
maximum target. Underfeeding was defined as meeting less than 90% of the minimum 
energy/protein target and overfeeding as meeting more than 110% of the maximum energy/protein 
target. 
 
3.9 Time schedule 
 
Table 3-4 Time schedule 
2011 – 2012 
  
Nov-
11 
Dec-
11 
Jan-
12 
Feb-
12 
Mar-
12 
Apr-
12 
May-
12 
Jun-
12 
Jul-
12 
Aug-
12 
 
Sep-
12 
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12 
 
Nov-
12 
 
Dec-
12 
  
Week Week Week Week Week Week Week Week Week Week 
 
Week 
 
Week 
 
Week 
 
Week 
  
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
 
1 
 
2 
 
3 
 
4 
 
1 
 
2 
 
3 
 
4 
 
1 
 
2 
 
3 
 
4 
 
1 
 
2 
 
3 
 
4 
Finalise protocol  
& ethics approval 
  
                                        
                
Pilot study                                                            
Data collection                                                           
Preparing data for analysis                                                           
Analysing data                                                           
2013 
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13 
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13 
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13 
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13 
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13 
Jun-
13 
Jul-
13 
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13 
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13 
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14 
Feb-
14 
  
Week Week Week Week Week Week Week Week Week Week 
 
Week 
 
Week 
 
Week 
 
Week 
  
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
 
1 
 
2 
 
3 
 
4 
 
1 
 
2 
 
3 
 
4 
 
1 
 
2 
 
3 
 
4 
 
1 
 
2 
 
3 
 
4 
Analysing data                                                           
Write thesis                                                           
Submit final thesis                                                           
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3.10 Ethical and legal considerations 
The study was approved by the University of Stellenbosch Health Research Ethics Committee 2 
(S12/01/001) and the University of the Witwatersrand Human Research Ethics Committee 
(M120240). 
Written permission has been granted by the following respective persons at CMJAH (letters of 
permission available on request): 
 Director of Critical Care and Head of GICU where study was conducted (Prof GA 
Richards)  
 Chief Executive Officer of CMJAH (Dr TE Selebano)  
Study participants’ identities (names and hospital numbers) were known to the data collector since 
they are routinely charted. However, identifiable data were coded and “links” kept separate. All 
patients discharged from ICU or who demised on or after the first day of data collection were 
entered into a screening log (Appendix B). Each patient’s name and hospital number were 
recorded on the screening log. Screening log columns represented eligibility criteria for purposes of 
data collection. A research number was allocated to all eligible patients and recorded on the 
screening log. Research numbers were allocated consecutively from R1 to R71 as patients were 
entered into the study. Each eligible patient’s data were then recorded on an individual data entry 
form coded with only his or her unique research number. The screening log is kept safe and only 
the investigators have access to it. The screening log will help track down which patient 
corresponds to which research number in case there are data queries at a later date. All data were 
handled with strict confidentiality and none other than the investigators had access to the data. 
Data was made anonymous for analysis. 
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4.1 Baseline characteristics 
Seventy-seven patients were enrolled out of three-hundred and nine consecutive admissions 
(24.9%): six patients were excluded due to incomplete data or missing charts, leaving seventy-one 
patients for analysis. Figure 4-1 shows a detailed flow chart for the inclusion of study participants.  
 
 
309 consecutive admissions during study period 
(19 March 2012 – 17 July 2012) 
Screened for eligibility 
232 patients excluded: 
 
227 patients less than 72 hours ICU stay and/or nutrition therapy 
2 patients APACHE II score < 10 
2 patients skeletal abnormalities 
1 patient age < 18 years 
2 patients ICU charts missing 
4 patients incomplete data 
 
71 PATIENTS INCLUDED IN FINAL SAMPLE SIZE 
 
 
77 patients eligible 
 
Figure 4-1 Flow chart for inclusion of study participants 
 
Stellenbosch University  http://scholar.sun.ac.za
  
66 
 
The final sample size (n=71, mean age 49.2 ± 17.1 years) had an equal gender distribution with 
49% being male and 51% female.  Of the seventy-one study participants, 68% were medical and 
32% surgical admissions. Study participants were mostly admitted for severe sepsis (28.2%), 
respiratory (23.9%), neurological (18.3%) and gastrointestinal conditions (14.1%). On admission to 
ICU study participants had an average APACHE II score of 21.0 ± 6.1 and an average body mass 
index (BMI) of 28.5 ± 8.1 kg/m2. Study participants’ fluid and nutrient intake were reviewed over a 
mean of 5.7 ± 1.1 days (median 6.3, range 3.5 – 7.0); i.e. the time elapsing from ICU admission 
until study exit. Study participants’ baseline characteristics are reported in Table 4-1.  
 
Table 4-1 Baseline characteristics of study participants (n=71) 
Variables Unit Mean ± SD (median) Range 
Sex (N, %)   
    Male  35 (49)  
    Female  36 (51)  
Age Years 49.2 ± 17.1 (47.4) 18.0 – 85.0 
APACHE II, admission  21.0 ± 6.1 (22.0) 10.0 – 34.0 
Admission category  (N, %)   
    Medical                                   48 (68)  
    Surgical   23 (32)  
Primary admission diagnosis  (N, %)   
     Gastrointestinal  10 (14.1)  
     Sepsis  20 (28.2)  
     Neurological  13 (18.3)  
     Respiratory  17 (23.9)  
     Other  11 (15.5)  
Body height cm 167.3 ± 8.6 (166.0) 150.0 – 186.0 
Body weight kg 79.1 ± 20.6 (75.0) 45.0 – 150.0 
BMI  kg/m
2
 28.5 ± 8.1 (26.8) 16.7 – 55.1 
Ideal body weight kg 61.6 ± 7.3 (61.0) 48.4 – 78.0 
Data are presented as N (%), mean ± SD (median) and ranges. 
Abbreviations: APACHE II: Acute Physiology and Chronic Health Evaluation II; BMI: Body mass index  
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4.2 Presence of severe sepsis, septic shock and AKI 
The presence of severe sepsis, septic shock and AKI throughout the study period is reported in 
table 4-2. Fifty-eight study participants (81.7%) presented with severe sepsis/SIRS or septic shock 
during the period of observation. A total of thirty-one study participants (43.6%) presented with AKI. 
Sixteen participants (22.5%) received dialysis in the form of SLED or CVVHD (Table 4-2). A 
significant association was found between severity of illness (APACHE II score) on admission to 
ICU and the presence of AKI, as well as the probability of receiving subsequent dialysis 
(p=0.00009) (Table 4-2). 
 
Table 4-2 Severe sepsis, septic shock and AKI during study period 
Variables N %  APACHE II score (mean ± SD)  
Presence of severe sepsis/shock 58 81.7 - 
Presence of acute kidney injury    
     AKI- no dialysis 15 21.1 22.3 ± 5.7 
     AKI- dialysis 16 22.5 25.8 ± 4.7 
     Normal renal function                      40 56.3 18.6 ± 5.5 
Data are presented as N (%), mean ± SD (median). 
Abbreviations: AKI: Acute kidney injury; APACHE II: Acute Physiology and Chronic Health Evaluation II  
 
The incidence of AKI was similar among medical and surgical participants. Ten (44%) of the 
twenty-three surgical participants and twenty-one (44%) of the forty-eight medical participants 
presented with AKI (including dialysed and non-dialysed participants). A greater percentage of 
medical participants received dialysis compared to surgical participants (29% versus 19% 
respectively, p= 0.045, chi-square test).  
 
4.3 Fluid delivery 
Table 4-3 shows a breakdown of the following: 
(1) Total cumulative fluid delivery over the entire study period  
(2) Mean daily fluid delivery 
(3) Breakdown of fluid delivery according to route of delivery (IV, enteral and oral) 
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Table 4-3 Breakdown of total cumulative fluid delivery 
Variables N-size Cumulative delivery (litres) % of total cumulative fluid delivery 
  Mean ± SD (median) Range Mean ± SD (median) Range 
TOTAL CUMULATIVE DELIVERY 
A 
 71 18.3 ± 4.8 (18.0) 7.0 – 31.1 - - 
    Mean daily delivery (L/d) 71 3.2 ± 0.6 (3.2) 1.7 – 5.2 - - 
    Mean daily delivery (mL/kg/d) 71 50.0 ± 11.6 (48.0) 29.0 – 86.4 - - 
BREAKDOWN ACCORDING TO ROUTE OF DELIVERY      
INTRAVENOUS 71 11.8 ± 5.6 (10.5)  2.1 – 30.9 62.5 ± 18.2 (58.0) 30.4 - 100 
Fluid therapy 71 6.0 ± 3.2 (5.2) 0.3 – 15.0  32.0 ± 12.0 (31.4) 4.3 – 55.4 
   Crystalloid 70 4.5 ± 2.5 (3.8) 0.6 – 10.7  24.0 ± 10.7 (23.9) 4.6 – 49.5 
   Colloid 56 1.2 ± 0.9 (1.0) 0.3 – 3.3  6.2 ± 3.9 (5.7) 1.0 – 17.5 
   Blood products 41 1.2 ± 1.6 (0.6)  0.3 – 8.0  6.0 ± 6.1 (3.7) 1.3 – 25.8  
Drug administration 
B
 71 3.9 ± 2.0 (3.9) 0.7 – 11.2  20.7 ± 8.1 (21.4) 4.2 – 49.2  
Flushing of lines 71 0.5 ± 0.1 (0.5) 0.2 – 1.0 2.9 ± 0.9 (2.7) 1.7 – 7.0 
Electrolyte & vitamin supplementation 70 0.1 ± 0.1 (0.1) 0 – 0.7 0.7 ± 0.5 (0.6) 0.0 – 2.5  
Nutrition 16 4.8 ± 2.8 (4.0) 0.8 – 10.0  23.9 ± 15.5 (23.1) 3.2 – 51.3 
Propofol 7 0.8 ± 0.7 (0.6) 0.1 – 2.2  5.2 ± 4.5 (3.3) 1.4 – 13.6 
Other 
C
 41 0.1 ± 0.1 (0.1) 0 – 0.4 0.6 ± 0.4 (0.4)  0.1 – 1.7 
ENTERAL 70 6.5 ± 3.1 (6.4) 0.1 – 12.9  37.8 ± 17.8 (41.2) 0.7 – 69.6 
Nutrition 67 6.3 ± 2.7 (5.9) 0.4 – 10.8  36.9 ± 16.0 (38.6) 1.9 – 68.5  
Flushing of enteric tube 63 0.1 ± 0.1 (0.1) 0.0 – 0.3  - - 
Tap water for hypernatremia 5 1.0 ± 0.8 (0.9) 0.1 – 1.8  - - 
Other enteral fluids  69 0.3 ± 0.2 (0.2) 0 – 1.3 - - 
ORAL 
D
 15 0.3 ± 0.6 (0.2) 0.0 – 2.3 1.5 ± 2.2 (1.1) 0.2 – 9.0 
Data are presented as mean ± SD (median) and ranges.  
A
Total cumulative delivery: Total cumulative fluid delivery (litres) over total study hours. 
B
Drug administration: Volume of drugs in liquid form, as well as fluids used for reconstitution and dilution purposes  
C
Other: Administration of 50% dextrose water in the treatment of hyperkalemia and hypoglycaemia 
D
Oral: Nutrition (e.g. sipfeeds), water and liquid drugs (e.g. Ulsanic, Mist KCl) 
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4.3.1 Routes of fluid delivery 
Figure 4-2 shows the contribution of IV, enteral and oral fluid administration to total cumulative fluid 
delivery. IV fluid administration (n=71) contributed 62.5 ± 18.2% (median 58.0, range 30.4 - 100) to 
total fluid delivery (TFD). Enteral fluid administration (n=70) contributed 37.8 ± 17.8% (median 
41.2, range 0.7 – 69.6) to TFD whereas oral fluids (n = 15) only contributed 1.5 ± 2.2% (median 
1.1, range 0.2 – 9.0). 
 
 
Figure 4-2 Breakdown of total cumulative fluid delivery according to route of administration 
 
4.3.2 IV fluid delivery 
IV maintenance or resuscitation crystalloids, colloids and blood products contributed 52.0 ± 16.0% 
(median 54.7, range 10.6 – 82.1) to total cumulative IV fluid delivery. IV drug administration 
contributed a further 35.2 ± 13.5% (median 32.1, range 10.7 – 68.7). This included the volume of 
liquid drugs, as well as fluids used for reconstitution and dilution purposes. PN and IV line flushing 
contributed 5.8 ± 13.1% (median 0 – 53.7) and 5.2 ± 3.1% (median 4.4, range 1.9 – 23.1) 
respectively. The remaining IV fluid volume was derived from electrolyte/vitamin supplementation 
and 50% dextrose water with a mean contribution of 1.1 ± 1.1% (median 0.8, range 0 – 7.2) and 
0.6 ± 0.9% (median 0.3, range 0 – 5.64) respectively. Fifty percent (50%) dextrose water was 
administered as part of the unit’s protocol for the management of hypoglycemia and/or 
hyperkalemia. Figure 4-3 shows a breakdown of total cumulative IV fluid delivery across all study 
participants who received IV fluids (n=71).  
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Figure 4-3 Mean percentage breakdown of cumulative IV fluid delivery (n=71) 
 
4.3.2.1 IV fluid therapy (IVFT) 
Figure 4-4 shows a breakdown of total cumulative IVFT across all study participants who received 
IVFT (n=71). 
 
Figure 4-4 Mean percentage breakdown of total cumulative IV fluid therapy (n=71) 
More than two-thirds of the cumulative IVFT volume was derived from crystalloids with a mean 
contribution of 73.2 ± 20.3% (median 76.6, range 0 – 100). Colloids contributed 15.6 ± 12.3% 
(median 16.1, range 47.5) and blood products 11.2 ± 18.1% (median 4.7, range 0 – 100).          
Table 4-4 shows the mean daily volume of the different IV fluids administered as part of IVFT. 
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Table 4-4 Mean daily volume of different IV fluids used for IV fluid therapy (IVFT) 
Variables Unit N-size
A
 Mean ± SD (median) Range 
Mean daily IVFT volume L/d 71 1.1 ± 0.5 (1.0) 0.1 – 2.5 
 Crystalloids L/d 70 0.8 ± 0.4 (0.7) 0.1 – 1.9 
    Glucose solutions
B
 L/d 39 0.4 ± 0.3 (0.3) 0.02 – 1.2 
    Sodium chloride solutions
C
 L/d 13 0.3 ± 0.3 (0.2) 0.005 – 1.2 
    Gluco-saline solutions
D
 L/d 13 0.3 ± 0.3 (0.3) 0.009 – 1.2 
    Electrolyte solutions
E
  L/d 65 0.5 ± 0.4 (0.4) 0.01 – 1.5 
  Colloids L/d  56  0.2 ± 0.1 (0.2) 0.04 – 0.6 
  Blood products L/d 41 0.2 ± 0.3 (0.1) 0.04 – 1.3 
    Platelets L/d 4 0.2 ± 0.1 (0.2) 0.1 – 0.3  
    Erythrocyte concentrate L/d 40 0.1 ± 0.1 (0.1) 0.04 – 0.7 
    Fresh frozen plasma L/d 11 0.2 ± 0.1 (0.2) 0.04 – 0.4  
Data are presented as mean ± SD (median) and ranges.    
A 
N-size: Number of study participants who received the given IV fluid 
B 
Glucose solutions: 5% dextrose water & anticoagulant citrate dextrose solution 
C 
Sodium chloride solutions: Normal and hypertonic saline 
D 
Gluco-saline solutions: Rehydration solution (Dextrose 5% in 0.45% saline) 
E 
Electrolyte solutions: Balsol/Plasmalyte B and Ringer’s lactate/Hartman’s solution 
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Crystalloids 
Crystalloid solutions were administered to seventy (98.6%) of the seventy-one study participants 
(n=70) with a mean daily volume of 0.8 ± 0.4 litres (Table 4-4). Electrolyte solutions (balanced) 
were most often prescribed with a mean contribution of 61.2 ± 34.8 % (median 61.6, range 0 – 
100) to total cumulative crystalloid delivery. The percentage contribution of glucose-, gluco-saline- 
and sodium chloride solutions were 26.0 ± 30.4% (median 12.4, range 0 – 100), 7.9 ± 21.9% 
(median 0, range 0 – 100) and 4.9 ± 15.0% (median 0, range 0 – 100) respectively. Figure 4-5 
shows the mean percentage breakdown of total cumulative crystalloid delivery (n=70).  
 
Figure 4-5 Mean percentage breakdown of total cumulative crystalloid delivery (n=70) 
 
Colloids 
Colloid solutions were administered to fifty-six (78.9%) of the seventy-one study participants (n=56) 
with a mean daily volume of 0.2 ± 0.1 litres (Table 4-4). The primary colloid used was non-
hypertonic LMW 130/0.4 KD hydroxyethyl starch (HES) with a mean contribution of 99.4 ± 3.1 % 
(median 100, range 81.3 – 100) to total colloid delivery. IV albumin and gelatin solutions (n=2) 
contributed a negligible 0.6 ± 3.1 % (median 0, range 0 – 18.7) and were therefore not considered 
for statistical analyses (Figure 4-6).  
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Figure 4-6 Mean percentage breakdown of total cumulative colloid delivery (n=56) 
 
Blood products 
Blood products were administered to forty-one (57.7%) of the seventy-one study participants 
(n=41) with a mean daily volume of 0.2 ± 0.3 litres (Table 4-4).  Figure 4-7 shows a breakdown of 
the blood products used for IVFT (n=41).  
 
Figure 4-7 Mean percentage breakdown of total cumulative blood product delivery (n=41) 
Erythrocyte concentrate was most often prescribed with a mean contribution of 85.7 ± 25.7 % 
(median 100, range 0 – 100) to total cumulative blood product delivery. Fresh frozen plasma and 
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platelets contributed a further 11.7 ± 22.5 % (median 0, range 0 – 100) and 2.5 ± 9.1 % (median 0, 
range 0 – 51.1) respectively.  
4.3.3 Fluid delivery according to admission category and renal function 
Surgical participants received a significantly higher mean daily fluid delivery (L/day: p<0.01; 
mL/kg/d: p=0.002) compared to their medical counterparts and was due to significantly more IVFT 
administered to the former group (p=0.00002). Daily crystalloid, colloid and blood product delivery 
were significantly higher among surgical participants (p=0.02, p=0.01, p=0.01, respectively) with a 
significantly higher percentage contribution of IVFT to TFD in this patient subgroup (39.5 vs 28.4%, 
p=0.001) (Table 4-5). 
 
Table 4-5 Total fluid delivery and intravenous fluid therapy according to admission category 
 Unit Surgical N Medical N p-value 
TFD       
  Total cumulative L 19.6 ± 5.0  23 17.6 ± 4.6  48 0.099 
  Mean daily L/d 3.6 ± 0.6 23 3.0 ± 0.6 48 <0.01 
  Mean daily mL/kg/d 56.1 ± 12.0 23 47.1 ± 10.3 48 0.002 
Mean daily IVFT L/d 1.4 ± 0.6 23 0.9 ± 0.4 48 0.00002 
   Crystalloids L/d 0.9 ± 0.4 23 0.7 ± 0.4 47 0.02 
   Colloids L/d 0.30 ± 0.2 19 0.16 ± 0.1 37 0.01 
   Blood products L/d 0.29 ± 0.33 19 0.14 ± 0.15 22 0.01 
Contribution to TFD (%)       
    IVFT % 39.5 ± 11.8   23 28.4 ± 10.4  48 0.0001 
Data are presented as mean ± SD. Statistical analyses based on ANOVA F-test/Mann-Whitney test.  
Abbreviations: TFD: Total fluid delivery; IVFT: Intravenous fluid therapy 
 
Non-dialysed AKI participants (AKI-ND) received a significantly higher total cumulative (litres: 
p=0.005) and mean daily fluid delivery (L/d: p=0.01) compared to their dialysed (AKI-D) and normal 
renal function (NRF) counterparts. AKI-ND participants had a significantly higher mean daily 
crystalloid delivery compared to AKI-D and NRF participants (L/d: p<0.01) (Table 4-6). 
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Table 4-6 Total fluid delivery (TFD) and IV fluid therapy (IVFT) according to renal function 
 Unit NRF N AKI-ND N AKI-D N p-value 
TFD         
  Total cumulative L 16.8 ± 4.7 40 21.3 ± 4.6 15 19.0 ± 3.6 16 0.005 
  Mean daily L/d 3.0 ± 0.6 40 3.7 ± 0.7 15 3.1 ± 0.4 16 0.01 
  Mean daily mL/kg/d 48.3 ± 11.6 40 56.1 ± 13.4 15 48.6 ± 8.0 16 0.11 
Mean daily IVFT L/d 1.0 ± 0.4 40 1.5 ± 0.7 15 0.8 ± 0.3 16 <0.01 
   Crystalloids L/d 0.8 ± 0.4 39 1.1 ± 0.5 15 0.5 ± 0.2 16 <0.01 
   Colloids L/d 0.2 ± 0.1 31 0.3 ± 0.2  13 0.2 ± 0.1 12 0.06 
   Blood products L/d 0.1 ± 0.1 18 0.3 ± 0.4  11 0.3 ± 0.3  12 0.20 
Contribution to 
TFD (%) 
        
    IV fluid therapy % 31.8 ± 11.2 40 39.6 ± 12.9  25.2 ± 9.0 16 0.003 
Data are presented as mean ± SD. Statistical analyses are based on ANOVA F-test/Kruskal-Wallis test.  
Abbreviations: IVFT: Intravenous fluid therapy; TFD: Total fluid delivery; NRF: Normal renal function;  
AKI-ND: Acute kidney injury with no dialysis; AKI-D: Acute kidney injury with dialysis; N: Sample size 
 
4.4 Electrolyte delivery: 
4.4.1 IV electrolyte supplementation 
In total seventy (n=70) study participants received IV electrolyte supplementation. Figure 4-8 
shows the type of IV electrolyte supplements (IVES) most often prescribed to the study 
participants.  
 
Figure 4-8 Percentage of study participants receiving IV electrolyte supplementation (n=70) 
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Potassium salts (i.e. potassium chloride or potassium phosphate) were prescribed to sixty-four 
(91.4%) of the seventy study participants who received IV electrolyte supplementation. Calcium- 
(i.e. calcium chloride or calcium gluconate), magnesium- (i.e. magnesium sulphate) and sodium 
bicarbonate salts (i.e. sodium bicarbonate 8.5%) were prescribed to thirty-six (51.4%), twenty-four 
(34.3%) and fifteen (21.4%) study participants respectively. Table 4-7 shows the dosing of the 
IVES that were most often prescribed to the study participants. This is based on observation, since 
the calculation of mean doses are not a true reflection of prescribed single doses.  
Table 4-7 Often prescribed dosing of IV electrolyte supplements 
 Indications Dosing per single administration 
 
Prescribed dose Provides 
 
Potassium chloride 15% Hypokalemia 10 – 30ml (1.5 – 3g)  K
+
 20 – 60 mmol  
Cl
-
 20 – 60 mmol  
 
Potassium phosphate Hypokalemia 
Hypophosphatemia 
10 – 30ml (2.14 – 6.42g)  
 
K
+
 20 - 60 mmol  
HPO4
-
 14 – 42 mmol  
 
Calcium chloride 10% Hypocalcemia 10ml (1g) Ca
2+
 6.8 mmol   
Cl
-
 13.6 mmol  
 
Calcium gluconate 10% Hyperkalemia 
Hypocalcemia 
10ml  Ca
2+
 2.325 mmol  
Magnesium sulphate Hypomagnesemia 
Refractory hypokalemia 
4ml (2g) Mg
2+
 8mmol  
Sodium bicarbonate 8.5% Metabolic acidosis 150ml  
 
Na
+
 150 mmol  
 
4.4.2 Total electrolyte delivery 
Mean daily sodium and chloride delivery was 3.7 ± 1.2 and 3.6 ± 1.2mmol/kg/d respectively. This 
was more than double the maintenance requirement of 1 – 1.5 and 1.5mmol/kg/day respectively.2 
The greatest contributor was IVFT contributing 42% and 38% to total sodium and chloride delivery 
respectively. This was followed by the use of saline for the reconstitution and dilution of IV drugs 
which contributed a further 28% to both sodium and chloride delivery.  
The mean daily potassium delivery of 1.3 ± 0.4mmol/kg/d was slightly higher than the maintenance 
requirement of 1mmol/kg/d. The greatest contributor to total potassium intake was EN with a mean 
contribution of 62%. This was followed by IV electrolyte supplementation which contributed a 
further 35% to total potassium delivery.  
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The mean daily magnesium delivery of 0.2 ± 0.1mmol/kg/d met the maintenance requirement of 
0.1 – 0.2mmol/kg/d. The greatest contributor was once again EN contributing 88% to total 
magnesium delivery. The mean daily calcium and phosphate delivery of 0.4 ± 0.2 and 0.7 ± 0.4 
mmol/kg/d exceeded the maintenance requirements of 0.1 – 0.2 and 0.2 – 0.5 mmol/kg/d 
respectively.2 EN contributed 88% to total calcium delivery, whereas EN and the administration of 
fleet enemas contributed 93% to total phosphate delivery. Table 4-8 – table 4-13 provides a 
summary of sodium, potassium, chloride, calcium, magnesium and phosphate delivery according 
to the following: 
(1) Cumulative delivery over entire study period (mmol)  
(2) Mean daily delivery (mmol/d and mmol/kg/d) 
(3) Breakdown according to route of delivery (IV, enteral and oral) 
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Table 4-8 Breakdown of total cumulative sodium delivery 
 
Variables N-size Cumulative delivery (mmol) % of total sodium delivery 
  Mean ± SD (median) Range Mean ± SD (median) Range 
TOTAL CUMULATIVE DELIVERY 
A
 71 1347.3 ± 471.0 (1296.7) 428.6 – 2526.1 - - 
    Mean daily delivery (mmol/d) 71 237.1 ± 72.4 (238.0) 100.5 – 384.7 - - 
    Mean daily delivery (mmol/kg/d) 71 3.7 ± 1.2 (3.7) 1.6 – 6.4  - - 
BREAKDOWN ACCORDING TO ROUTE OF  DELIVERY      
INTRAVENOUS 71 1053.7 ± 463.4 (981.9) 188.9 – 2194.9 76.9 ± 13.9 (76.6)  42.8 – 100.0  
Fluid therapy 69 578.6 ± 323.8 (497.9) 120.1 – 1379.2 41.6 ± 15.5 (40.4) 11.2 – 79.2 
   Crystalloid 69 432.8 ± 286.4 (347.1) 10.5 – 1337.6   
   Colloid 56 179.7 ± 132.2 (154.0) 38.5 – 500.5   
Drug administration
B
 71 373.1 ± 218.5 (336.9) 8.9 – 1160.6 27.7 ± 13.0 (25.7) 1.1 – 56.9 
Flushing of IV lines 71 78.4 ± 22.8 (77.8) 27.3 – 155.2 6.4 ± 2.7 (5.9) 3.2 – 17.2  
Electrolyte supplementation
C
  15 175.8 ± 188.5 (109.0) 27.4 – 602.2 10.2 ± 9.0 (5.3) 2.3 – 30.0 
Nutrition 5 39.8 ± 46.0 (17.4) 8.1 – 118.0 2.2 ± 2.5 (1.5) 0.5 – 6.5 
ENTERAL 68 306.0 ± 182.8 (282.9) 39.9 – 813.6 24.1 ± 13.3 (24.5) 1.9 – 57.2  
Nutrition 67 277.4 ± 175.7 (246.7) 16.2 – 813.6 21.9 ± 13.0 (19.4) 1.3 – 57.2 
Fleet enema 27 82.3 ± 61.9 (64.4) 16.1 – 289.8 - - 
ORAL 
D
 7 4.7 ± 3.6 (4.4) 0.1 – 11.0 0.3 ± 0.2 (0.3) 0 – 0.5 
Data are presented as mean ± SD (median) and ranges. 
A
Total cumulative delivery: Total cumulative sodium delivery (mmol) over total study hours. 
B
Drug administration: Sodium derived from fluids used for reconstitution and dilution purposes, as well as sodium-containing blood derivatives; i.e. polygam and 
hemosolvex 
C
Electrolyte supplementation: Sodium bicarbonate 8.5% 
D
Oral: Nutrition (e.g. sipfeeds) 
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Table 4-9 Breakdown of total cumulative potassium delivery 
Variables N-size Cumulative delivery (mmol) % of total potassium delivery 
  Mean ± SD (median) Range Mean ± SD (median) Range 
TOTAL CUMULATIVE DELIVERY
A
  71 462.8 ± 168.8 (446.1) 133.9 – 850.4 - - 
    Mean daily delivery (mmol/d) 71 81.7 ± 26.3 (81.5) 22.0 – 164.8  - - 
    Mean daily delivery (mmol/kg/d) 71 1.3 ± 0.4 (1.3) 0.4 – 2.4  - - 
BREAKDOWN ACCORDING TO ROUTE OF  DELIVERY      
INTRAVENOUS 70 158.7 ± 116.1 (139.7) 4.0 – 516.2 35.7 ± 25.2 (30.3) 0.7 – 100 
Fluid therapy 66 12.8 ± 9.4 (10.4) 0.4 – 49.2 3.1 ± 2.5 (2.6) 0.1 – 13.5  
   Crystalloid 66 12.8 ± 9.4 (10.4) 0.4 – 49.2 ± ± 
   Colloid 2 1.2 ± 1.6 (1.2) 0.1 – 2.3  ± ± 
Electrolyte supplementation
B
 64 158.1 ± 105.2 (140.0) 20.0 – 500.0 34.6 ± 21.1 (29.8) 4.7 – 96.1  
Nutrition 5 29.6 ± 34.1 (12.9) 6.0 – 87.5 15.9 ± 27.7 (3.6) 1.1 – 65.4 
ENTERAL 67 323.7 ± 139.9 (306.1) 30.4 – 672.0 68.5 ± 20.2 (71.6) 9.9 - 100 
Nutrition 67 292.4 ± 137.3 (292.1) 15.8 – 609.7 61.7 ± 21.4 (64.3) 4.4 – 100.0 
Mist KCl 35 57.4 ± 38.9 (48.0) 16.0 – 192.0 - - 
ORAL 
C
 6 10.0 ± 14.6 (3.3) 1.5 – 38.6 2.0 ± 3.0 (0.8) 0.2 – 7.9  
Data are presented as mean ± SD (median) and ranges. 
A
Total cumulative delivery: Total cumulative potassium delivery (mmol) over total study hours. 
B
Electrolyte supplementation: Potassium salts (Potassium chloride 15% and -phosphate) 
C
Oral: Nutrition (e.g. sipfeeds) and Mist KCl supplementation 
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Table 4-10 Breakdown of total cumulative chloride delivery 
Variables N-size Cumulative delivery (mmol) % of total chloride delivery 
  Mean ± SD (median) Range Mean ± SD 
(median) 
Range 
TOTAL CUMULATIVE DELIVERY
A
  71 1307.1 ± 436.5 (1270.4) 388.0 – 2458.1 - - 
    Mean daily delivery (mmol/d) 71 230.6 ± 68.4 (220.3) 92.2 – 373.6 - - 
    Mean daily delivery (mmol/kg/d) 71 3.6 ± 1.2 (3.3) 1.5 – 7.1  - - 
BREAKDOWN ACCORDING TO ROUTE OF  DELIVERY      
INTRAVENOUS 71 1102.5 ± 448.1 (1001.8) 208.9 – 2458.1 82.8 ± 11.1 (83.7) 41.7 – 100 
Fluid therapy 69 524.6 ± 296.6 (445.0) 120.1 – 1266.5 38.4 ± 13.7 (38.3) 10.0 – 71.5 
   Crystalloid 69 379.1 ± 259.3 (293.7) 9.0 – 1228.0 - - 
   Colloid 56 179.2 ± 132.1 (154.0) 38.5 – 500.5 - - 
Drug administration
B
 71 372.2 ± 217.3 (336.9) 8.9 – 1160.6 27.8 ± 12.4 (28.1) 1.8 – 56.5  
Flushing of lines 71 78.4 ± 22.8 (77.8) 27.3 – 155.2  6.5 ± 2.8 (6.0) 3.1 – 19.5  
Electrolyte supplementation
C
 65 150.9 ± 96.8 (140.0) 13.6 – 500.0 11.9 ± 7.3 (10.8) 1.7 – 39.4 
Nutrition 5 57.8 ± 66.8 (25.2) 11.7 – 171.2 3.3 ± 4.0 (2.2) 0.7 – 10.3 
ENTERAL 67 216.1 ± 114.6 (193.7) 15.6 – 466.5 18.2 ± 10.5 (16.5) 0.8 – 58.3  
Nutrition 67 184.8 ± 110.7 (167.3) 15.6 – 466.5 15.5 ± 10.1 (15.4) 0.8 – 58.3 
Mist KCl 35 59.9 ± 39.6 (48.0) 16.0 – 192.0 - - 
ORAL
D
 6 9.1 ± 13.9 (2.5) 0.8 – 36.2 0.7 ± 1.1 (0.2) 0.1 – 2.8 
Data are presented as mean ± SD (median) and ranges.  
A
Total cumulative delivery: Total cumulative chloride delivery (mmol) over total study hours. 
B
Drug administration: Chloride derived from fluids used for reconstitution and dilution purposes (excluding chloride-containing drugs) 
C
Electrolyte supplementation: Potassium chloride 15% & Calcium chloride 10% 
D
Oral: Nutrition (e.g. sipfeeds) and Mist KCl supplementation 
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Table 4-11 Breakdown of total cumulative calcium delivery 
Variables N-size Cumulative delivery (mmol) % of total calcium delivery 
  Mean ± SD (median) Range Mean ± SD 
(median) 
Range 
TOTAL CUMULATIVE DELIVERY
A
 71 149.5 ± 78.6 (156.6)  0 – 314.4 - - 
    Mean daily delivery (mmol/d) 71 26.2 ± 13.0 (27.5) 0 – 57.5 - - 
    Mean daily delivery (mmol/kg/d) 71 0.4 ± 0.2 (0.4) 0 – 0.8  - - 
BREAKDOWN ACCORDING TO ROUTE OF  DELIVERY      
INTRAVENOUS 54 9.3 ± 7.0 (7.2) 0.2 – 31.3 13.7 ± 21.4 (6.1) 0.1 - 100 
Fluid therapy 36 4.2 ± 3.7 (2.7) 0.1 – 14.9 6.9 ± 14.7 (2.0)  0.1 – 80.1 
   Crystalloid 36 4.2 ± 3.7 (2.7) 0.1 – 14.9 - - 
   Colloid 1 0.1  -  - - 
Electrolyte supplementation
B
 36 9.4 ± 6.1 (6.8) 2.3 – 29.5 11.6 ± 13.2 (6.8) 1.1 – 63.6  
Nutrition 5 2.6 ± 3.0 (1.1) 0.5 – 7.6  15.1 ± 18.6 (6.4) 0.5 – 45.5 
ENTERAL
C
 67 150.6 ± 75.4 (155.1) 7.0 – 314.1 88.4 ± 12.9 (96.3) 32.7 - 100 
ORAL
D
 6 4.0 ± 4.1 (2.8) 0.5 – 10.2 4.5 ± 5.5 (3.0) 0.2 – 15.0  
Data are presented as mean ± SD (median) and ranges.  
A
Total cumulative delivery: Total cumulative calcium delivery (mmol) over total study hours. 
B
Electrolyte supplementation: Calcium chloride 10%, calcium gluconate 10% 
C
Enteral: EN  
D
Oral: Nutrition (e.g. sipfeeds) 
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Table 4-12 Breakdown of total cumulative magnesium delivery 
Variables N-size Cumulative delivery (mmol) % of total energy 
  Mean ± SD (median) Range Mean ± SD (median) Range 
TOTAL CUMULATIVE DELIVERY
A
  71  68.9 ± 30.7 (65.6)  6.4 – 138.6 - - 
    Mean daily delivery (mmol/d) 71 12.0 ± 4.7 (12.6) 1.0 – 21.1  - - 
    Mean daily delivery (mmol/kg/d) 71 0.2 ± 0.1 (0.2) 0.0 – 0.3 - - 
BREAKDOWN ACCORDING TO ROUTE OF DELIVERY      
INTRAVENOUS 56 9.1 ± 10.2 (5.7) 0.2 – 48.0  21.0 ± 28.5 (7.5) 0.1 - 100 
Fluid therapy
B
 50 3.1 ± 2.3 (2.6) 0.2 – 9.0 7.7 ± 10.4 (3.7) 0.1 – 49.8 
Electrolyte supplementation
C
 24 13.3 ± 11.8 (8.0) 4.0 – 48.0 26.2 ± 19.3 (21.9) 3.8 – 68.0  
Nutrition 5 5.1 ± 5.9 (2.2) 1.0 – 15.2  26.7 ± 32.0 (8.8) 1.5 – 79.2 
ENTERAL
D
 67 65.3 ± 28.6 (64.9) 3.4 – 129.1 88.1  ± 17.9 (95.9) 28.0 - 100 
ORAL
E
 6 1.2 ± 1.1 (1.1) 0.1 – 2.5 3.0 ± 2.9 (2.5) 0.1 – 6.6  
Data are presented as mean ± SD (median) and ranges. 
A
Total cumulative delivery: Total cumulative calcium delivery (mmol) over total study hours. 
B
Fluid therapy: Crystalloids 
C
Electrolyte supplementation: Magnesium sulphate 50% 
D
Enteral: EN 
E
Oral: Nutrition (e.g. sipfeeds) 
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Table 4-13 Breakdown of total cumulative phosphate delivery 
Variables N-size Cumulative delivery (mmol) % of total energy 
  Mean ± SD (median) Range Mean ± SD (median) Range 
TOTAL CUMULATIVE DELIVERY
A
  71 241.1 ± 165.4 (197.8) 44.2 – 999.7 - - 
     Mean daily delivery (mmol/d) 71 42.2 ± 27.1 (33.4) 7.2 – 154.8  - - 
     Mean daily delivery (mmol/kg/d) 71 0.7 ± 0.4 (0.5) 0.1 – 2.1  - - 
BREAKDOWN ACCORDING TO ROUTE OF DELIVERY      
INTRAVENOUS 20 51.8 ± 33.2 (43.5) 8.2 – 140.0  39.2 ± 32.7 (27.8) 6.6 - 100 
Electrolyte supplementation
B
 10 65.8 ± 37.4 (63.0) 14.0 – 140.0 37.4 ± 15.1 (31.2) 16.7 – 62.2  
Nutrition 14 27.0 ± 12.5 (28.5) 8.2 – 54.9 29.2 ± 29.1 (16.1) 6.6 – 100 
ENTERAL
C
  68 236.2 ± 165.8 (199.8) 20.3 – 999.7 92.7 ± 16.2 (100) 29.4 - 100 
ORAL
D
 6 3.3 ± 3.2 (3.0) 0.3 – 7.8 1.8 ± 2.3 (1.0) 0 – 6.2 
Data are presented as mean ± SD (median) and ranges. 
A
Total cumulative delivery: Total cumulative phosphate delivery (mmol) over total study hours. 
B
Electrolyte supplementation: Potassium phosphate 
C
Enteral: EN and fleet enemas 
D
Oral: Nutrition (e.g. sipfeeds) 
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4.5 Contribution of non-nutritional fluids to total fluid and electrolyte delivery 
Total fluid, sodium and chloride delivery were mostly derived from non-nutritional sources (60%, 
79% and 85% respectively), whereas NT was the greatest contributor to total potassium, calcium, 
magnesium and phosphate delivery (60%, 88%, 85% and 75% respectively).  Table 4-14 and 
Figure 4-9 show the mean percentage contribution of non-nutritional fluids versus NT to total fluid 
and electrolyte delivery across all study participants (n=71). In this study unit the contribution of NT 
to electrolyte delivery was influenced by the routine use of electrolyte-free PN regimens. NT may 
therefore be a greater contributor to electrolyte delivery in units where PN is not restricted to the 
use of electrolyte-free PN regimens. 
Non-nutritional sodium sources included sodium-containing crystalloids, HES, blood derivatives 
(i.e. hemosolvex, polygams), sodium bicarbonate supplementation and the administration of fleet 
enemas. Non-nutritional chloride sources included chloride-containing crystalloids, HES, polygam 
infusions and potassium chloride supplementation. Interestingly, a significant correlation was found 
between severity of illness (APACHE II score) on admission to ICU and the percentage 
contribution of IVFT to total chloride delivery (n=69, spearman R: -0.246754, p=0.040956). Hence 
the higher the APACHE II score, the lower the percentage contribution of IVFT to total chloride 
delivery. Despite potassium salts being the most commonly prescribed IVES, NT was still the 
greatest contributor to total potassium delivery (60%).  
Important to take note is that the electrolyte content of the prescribed drugs (e.g. sodium-
containing antimicrobial agents) were not taken into account and could have further contributed to 
total electrolyte intake. 
 
Table 4-14 Contribution of non-nutritional fluids versus NT to fluid and electrolyte delivery 
 % Non-nutritional sources % Nutrition therapy 
Fluid 59.8 ± 12.1 (58.2) 31.5 – 87.8 40.2 ± 12.1 (41.8) 12.2 – 68.5 
Sodium 79.2 ± 13.4 (81.6) 42.8 – 100 20.8 ± 13.4 (18.4) 0 – 57.2  
Potassium 40.5 ± 23.8 (36.3) 0 – 100 59.5 ± 23.8 (63.7) 0 – 100 
Chloride 85.1 ± 10.2 (86.7) 41.7 – 100 14.9 ± 10.2 (13.3) 0 – 58.3 
Calcium 12.2 ± 21.4 (3.8) 0 - 100  87.8 ± 21.6 (96.2) 0 – 100 
Magnesium 14.7 ± 22.9 (4.2) 0 – 100 85.3 ± 22.9 (95.8) 0 – 100 
Phosphate 25.2 ± 29.9 (0) 0 – 91.3  74.8 ± 29.9 (100) 8.7 - 100 
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Figure 4-9 Contribution of NT versus non-nutritional fluids to total fluid and electrolyte 
delivery 
4.6 Energy and macronutrient delivery 
4.6.1 Nutrition therapy 
Nutrition therapy (NT) was most commonly provided via the enteral route: Fifty-four (76.1%) study 
participants were fed exclusively via the enteral route, three (4.2%) received combined EN and oral 
nutrition, ten (14.1%) received a combination of EN and PN, while only four patients (5.6%) 
received sole PN (Table 4-15). Patients who received a combination of EN and oral nutrition were 
initially fed orally and enteral nutrition (EN) initiated at a later stage due to; (1) inadequate oral 
nutrition or (2) no longer able to take feeds orally (e.g. post-intubation). Hence a total of fifty-seven 
study participants (80.3%) were fed via the enteral route without the use of supplemental PN.  
NT was initiated within 14.5 ± 14.1 hours (median 11, range 0 – 69) after admission to ICU. Table 
4-16 shows a breakdown of the time to initiation of NT according to the primary admission 
diagnosis. There was a non-significant trend (p=0.23) towards a longer nil per os (NPO) period in 
gastrointestinal patients compared to the other primary admission diagnoses (24 hours versus 12 – 
15 hours).  
The average duration of NT; i.e. from initiation of NT until study exit was 5.1 days (median 5.4, 
range 3.0 – 6.6 days) (Table 4-15). A significant association was found between study participants’ 
age and the time (hours) to initiation of NT (n=71, Spearman R=0.24, p=0.04). This indicates that 
NT was initiated earlier in older patients. There was no significant association between the time 
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(hours) to initiation of NT and gender, nutritional status (BMI) on admission to ICU, admission 
category or primary admission diagnosis. 
 
Table 4-15 Breakdown of nutritional parameters 
Variables Unit Mean ± SD (median) Range 
Study duration
A
    
      Hours 136.9 ± 25.3 (152.0) 83.0 – 168.0 
    Days 5.7 ± 1.1 (6.3) 3.5 – 7.0 
Time to initiation of NT    
    Hours 14.5  ± 14.1 (11.0) 0 – 69.0 
NT duration
B
    
 Hours                              122.5 ± 24.8 (129.0) 71.0 – 158.0 
 Days 5.1 ± 1.0 (5.4) 3.0 – 6.6 
Route of NT    
    EN only n (%) 54 (76.1)  
    EN & Oral  3 (4.2)  
    PN only  4 (5.6)  
    PN & EN  10 (14.1)  
Calculated requirements    
    Weight used for calculations kg 64.9 ± 8.5 (65.0) 46.0 – 92.0 
Data are presented as N (%), mean ± SD (median) and ranges. 
A
Study duration: Time from admission until study exit (hours/days) 
B
NT duration: Time from initiation of NT until study exit (hours/days) 
Abbreviations: NT: Nutrition therapy, EN: Enteral nutrition; PN: Parenteral nutrition 
. 
Table 4-16 Hours to initiation of NT according to primary admission diagnosis (p=0.23) 
Primary admission 
diagnosis 
n-size Mean ± SD (median) Range 
All 71 14.5  ± 14.1 (11.0) 0 – 69 
Gastrointestinal 10 24.2 ± 18.1 (25.5) 0 – 65 
Sepsis 20 14.9 ± 16.2 (10.5) 1 – 69 
Neurological 13 11.5 ± 12.0 (10.0) 1 – 43 
Respiratory 17 12.5 ± 11.0 (9.0) 2 – 45 
Other 11 11.5 ± 10.2 (10.0) 1 – 38 
Data are presented as means ± SD (median) and ranges. Statistical analyses based on ANOVA F-test. 
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4.6.2 Energy parameters 
The mean daily energy delivered was 1613 ± 380kCal (25.1kCal/kg), meeting 93.6 ± 17.7% of the 
mean target range of 25.4 – 28.6kCal/kg/d. The mean cumulative energy balance was -674.0 ± 
1866.1kCal. NNES contributed 10.1 ± 7.5% to total energy delivered (Table 4-17). 
 
Table 4-17 Breakdown of energy delivery parameters 
Variables Mean ± SD (median) Range 
CALCULATED ENERGY TARGET 
Minimum target 
  
    Total kCal
A
 9431.7 ± 2432.2 (9464.6) 4604.2 – 15706.7 
    kCal/kg/d 25.4 ± 3.0 (25.0) 20.0 – 40.0  
Maximum target   
    Total kCal 10594.2 ± 2663.6 (10875.0) 4958.3 – 17670.0 
    kCal/kg/d 28.6 ± 3.5 (28.5) 24.8 – 45.0 
ACTUAL ENERGY DELIVERY   
    Total kCal 9199.2 ± 2826.3 (9169.2) 3466.8 – 16584.9 
    Mean kCal/d 1612.6 ± 379.8 (1642.0) 740.4 – 2618.7 
    Mean kCal/kg/d 25.1 ± 6.1 (25.7) 9.7 – 42.2 
ACTUAL DELIVERY VERSUS TARGET   
    Mean percent target
B
 93.6 ± 17.7 (100) 39.41 – 133.0 
    Cumulative balance  -674.0 ± 1866.1 (0) -7231.3 – 2835.6 
CONTRIBUTION OF NNES   
   % Nutrition therapy  89.9 ± 7.477 (91.793) 70.860 – 100 
   % Non-nutritional sources 10.1 ± 7.477 (8.207) 0.00 – 29.14 
Data are presented as mean ± SD (median) and ranges. 
A
Total kCal: Cumulative energy delivery over entire study period 
B
Mean percent target: Refer to section 3.8.3 for calculation of mean percent target 
Abbreviations: kCal: kilocalories; NNES: Non-nutritional energy sources 
 
Females (n=36) had a significantly lower mean daily energy intake (kCal/d: 1491.5 ± 353.7 vs 
1737.1 ± 369.8, p<0.01) compared to males (n=35). Mean daily energy delivery was not 
significantly influenced by the APACHE II score on admission to ICU. A significant negative 
correlation was found between nutritional status (BMI) on admission to ICU and mean daily energy 
delivery expressed as kCal/kg/d (n=71, R= -0.32925, p=0.005052). Hence the higher the BMI, the 
lower the weight-based mean daily energy delivery.  Furthermore, a significant negative correlation 
was found between the time (hours) to initiation of NT and mean daily energy delivery (kCal/d: 
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n=71, R= -0.35386, p=0.002467; kCal/kg/d: n=71, R=-0.27066, p=0.022437). Hence the longer it 
takes to initiate NT, the lower the overall mean daily energy delivery.  
4.6.3 Macronutrient breakdown 
Table 4-18 shows the total carbohydrate, protein and lipid delivery derived from both nutritional and 
non-nutritional sources. Total energy delivery (TED) was mostly derived from carbohydrate 
sources (51%), while lipid and protein sources contributed a further 31% and 18% respectively. 
The mean daily carbohydrate and lipid delivery (g/kg/d) fell within the recommended daily weight-
based range of 3 – 5g/kg and 0.7 – 1.5g/kg respectively.13,66,80 The mean daily protein delivery of 
1.1g/kg/d was below the general ICU recommendation of 1.2 – 2.0 g/kg per day.67  
 
Table 4-18 Macronutrient breakdown of energy delivery 
Variables N-size Mean ± SD (median) Range 
CARBOHYDRATE DELIVERY    
   Total delivery (g) 71 1164.0 ± 372.1 (1169.9) 473.8 – 2096.8 
   Mean daily delivery (g/d) 71 203.5 ± 49.1 (207.2) 105.3 – 312.6 
   Mean daily delivery (g/kg/d) 71 3.2 ± 0.8 (3.2) 1.6 – 5.2 
   % of total energy  50.9 ± 6.4 (50.9) 33.6 – 66.3 
PROTEIN DELIVERY    
   Total delivery (g) 71 406.8 ± 143.9 (401.0) 119.8 – 853.0 
   Mean daily delivery (g/d) 71 71.5 ± 21.5 (75.0) 20.8 – 134.7 
   Mean daily delivery (g/kg/d) 71 ± 0.3 (1.1) 0.3 – 2.2 
   % of total energy  17.6 ± 2.9 (18.0) 11.3 – 25.3 
LIPID DELIVERY    
   Total delivery (g) 71 324.0 ± 116.5 (319.7) 77.1 – 607.0 
   Mean daily delivery (g/d) 71 56.9 ±  17.9 (57.5) 16.1 – 108.2 
   Mean daily delivery (g/kg/d) 71 0.9 ± 0.3 (0.9) 0.2 – 1.5 
   % of total energy  31.4 ± 5.6 (30.9) 19.3 – 45.4 
Data are presented as mean ± SD (median) and ranges. 
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4.6.4 Protein parameters 
Table 4-19 shows the mean daily protein target range, actual protein delivery, mean percent target 
and cumulative protein balance for all study participants (n=71). Mean daily protein delivery was 72 
± 22g (1.1g/kg), meeting 82.8 ± 19.9% of the mean target range of 1.3 – 1.5g/kg/d. The mean 
cumulative protein balance was -86.0 ± 106.9g. 
Contrary to energy delivery, there were no gender differences in overall protein delivery. Mean 
daily protein delivery was not significantly influenced by the APACHE II score on admission to ICU.  
A significant negative correlation was found between nutritional status (BMI) on admission to ICU 
and mean daily protein delivery expressed as g/kg/d (n=71, R=-0.256313, p=0.030960). Hence the 
higher the BMI, the lower the weight-based mean daily protein delivery (g/kg/d).  
As with energy delivery, a significant association was found between the time (hours) to initiation of 
NT and mean daily protein delivery (g/d: n=71, R= -0.344892, p=0.003225; g/kg/d: n=71, R=-
0.298222, p=0.011536). Hence the longer it takes to initiate NT, the lower the overall mean daily 
protein delivery. This was similar to energy delivery and emphasizes the need to initiate feeds early 
if possible. 
Table 4-19 Breakdown of protein delivery parameters 
Variables Mean ± SD (median) Range 
CALCULATED PROTEIN TARGET 
Minimum target 
  
    Total grams
A
 475.6 ± 121.2 (480.0) 240.0 – 785.4 
    g/kg/d 1.3 ± 0.2 (1.2) 0.8 – 2.0 
Maximum target   
    Total grams 560.0 ± 143.7 (556.8) 300.0 – 981.7 
    g/kg/d 1.5 ± 0.2 (1.5) 1.2 – 2.5  
ACTUAL PROTEIN DELIVERY   
    Total grams 406.759 ± 143.923 (401.000) 119.770 – 852.96 
    Mean g/d 71.543 ± 21.505 (75.035) 20.830 – 134.678 
    Mean g/kg/d 1.114 ± 0.341 (1.115) 0.331 – 2.172 
ACTUAL DELIVERY VERSUS TARGET   
    Mean percent target
B
 82.751 ± 19.857 (88.589) 23.510 – 103.341 
    Cumulative balance  -85.991 ± 106.907 (-45.015) -546.275 – 11.725 
Data are presented as mean ± SD (median) and ranges. 
A
Total grams: Cumulative protein delivery over entire study period 
B
Mean percent target: Refer to section 3.8.3. for calculation of mean percent target 
Abbreviations: g: grams 
Stellenbosch University  http://scholar.sun.ac.za
  
90 
 
4.7 Contribution of non-nutritional IV fluids to energy and macronutrient delivery 
4.7.1 Energy 
On average NT contributed 89.9 ± 7.5 % to TED, whereas the remaining 10.1 ± 7.5 % was derived 
from non-nutritional IV fluids prescribed by the ICU physician or administered as part of standard 
therapeutic ICU protocols (Table 4-17). Figure 4-10 shows the mean percentage contribution of 
NNES to TED across all study participants (n=71). The majority of participants (73%) received 
more than 5% of their total energy intake from NNES.  
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Figure 4-10 Percentage contribution of non-nutritional IV fluids to total energy delivery 
Table 4-20 shows the mean daily energy delivery from all NNES. On average, NNES provided 
156kCal/d. IVFT in the form of dextrose-containing crystalloids and starch-containing colloids (i.e. 
HES) provided 102kCal/d (n=65). Energy delivery via polygam infusions (sucrose used as 
stabilizer) prescribed in the treatment of Guillian-bare syndrome (n=3) provided 101kCal/d. 
Propofol, a lipid-based sedative used in the treatment of status epilepticus (n=7), provided 
approximately 139kCal/d. The use of 5% dextrose water in the dilution of IV drugs, a routine 
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practice seen in hypernatraemic patients and in the dilution of certain medications (Amiodarone, 
Amphotericin B), provided approximately 42kCal/d. Furthermore the use of 50% dextrose water in 
the treatment of hypoglycaemia and hyperkalemia provided an additional 36kCal/d. 
 
Table 4-20 Daily energy contribution (kCal/d) of different NNES 
Variables n-size Mean ± SD (median) Range 
All NNES 71 156.3 ± 114.2 (133.0)  0 – 561.3 
Crystalloids 45 85.3 ± 63.2 (65.6)  5.1 – 258.9 
Colloids
 
(HES) 56 49.8 ± 35.9 (41.3) 8.9 – 135.8 
Polygam 3 101.3 ± 54.6 (97.8)  48.5 – 157.5 
Propofol 7 139.0 ± 120.8 (88.2)  31.2 – 316.6 
IV drug dilution 41 41.9 ± 30.0 (37.4)  4.5 – 112.2 
50% dextrose water 41 36.1 ± 25.1 (29.2)  6.1 – 109.8 
Data are presented as mean ± SD (ranges). 
 
Abbreviations: HES: Hydroxy-ethyl starch 
 
Table 4-21 shows a detailed breakdown of energy delivery according to the different nutritional and 
non-nutritional energy sources. Non-nutritional energy delivery were mostly derived from 
carbohydrate sources, i.e. dextrose via fluid therapy crystalloids (5.4% to TED), dextrose via drug 
dilution (2.9% to TED), starch via HES infusion (3.5% to TED), sucrose via polygam infusion (4.9% 
to TED) and dextrose administered in the treatment of hypoglycemia and hyperkalemia (2.3% to 
TED). Energy delivery from non-nutritional protein sources were negligible since IV albumin 
infusion was prescribed to only one study participant (n=1). Energy delivery from non-nutritional 
lipid sources was derived from the IV infusion of propofol, contributing 7.2% to TED (n=7). 
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Table 4-21 Breakdown of energy delivery according to nutritional and non-nutritional sources 
Variables N-
size 
Cumulative delivery (kCal) % of TED 
  Mean ± SD (median) Range Mean ± SD (median) Range 
CONTRIBUTION NON-NUTRITIONAL SOURCES      
   % Nutrition therapy  71 - - 89.9 ± 7.5 (91.8) 70.9 – 100.0 
   % NNES 71 - - 10.1 ± 7.5 (8.2) 0.00 – 29.1 
NUTRITION THERAPY BREAKDOWN  - -   
 Intravenous 16 4995.6 ± 3081.7 (4273.7) 430.7 – 10000.0 58.8 ± 32.1 (68.8) 2.6 – 96.4 
 Enteral 67 7584.7 ± 3364.0 (7657.4) 423.5 – 14385.5 81.0 ± 23.2 (88.9) 4.0 – 100.0 
 Oral  7 270.8 ± 188.0 (294.9) 41.3 – 500.0 2.9 ± 2.1 (3.3) 0.3 – 5.8 
NON-NUTRITIONAL SOURCES BREAKDOWN      
Carbohydrate sources      
    Dextrose via crystalloid infusion 45 496.9 ± 380.9 (409.2) 28.6 – 1628.7 5.4 ± 3.9 (4.2)  0.3 – 13.4 
    Dextrose via IV drug dilution 41 236.6 ± 169.5 (226.1) 22.0 – 648.9 2.9 ± 2.2 (2.3) 0.3 – 8.0  
    Starch via HES infusion   56 278.1 ± 205.5 (240.0) 60.0 – 780.0 3.5 ± 3.0 (2.3) 0.4 – 12.7 
    Sucrose via Polygam infusion 3 556.6 ± 213.6 (655.9) 311.5 – 702.5 4.9 ± 2.0 (4.7) 3.1 – 7.0 
    Dextrose via other routine practices
A
 41 207.3 ± 151.0 (160.0) 40.0 – 700.0  2.3 ± 1.9 (1.7) 0.3 – 9.4 
Protein sources      
    Albumin via Albusol infusion 1 184.0  - 1.644  - 
Lipid sources      
    Lipid via Propofol infusion 7 735.2 ± 635.2 (540.0) 117.0 – 1990.8 7.2 ± 6.6 (3.8)  1.9 – 18.1 
Data are presented as mean ± SD (median) and ranges. 
A
Dextrose via other routine practices: 50% Dextrose water in the treatment of hyperkalemia and hypoglycemia  
Abbreviations: HES: Hydroxy-ethyl starch  
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 4.7.2 Carbohydrates  
On average, carbohydrate containing IV fluids contributed 18% to total cumulative carbohydrate 
delivery. Table 4-22 shows a breakdown of total carbohydrate (CHO) delivery according to 
nutritional and non-nutritional sources. Total carbohydrate delivery refers to the cumulative 
carbohydrate delivery over the entire study period, i.e. from ICU admission until study exit. 
4.7.3 Protein 
The overall contribution of NNES to total protein delivery was negligible. Only one study participant 
(n=1) received additional protein from an IV albumin infusion and was therefore not considered for 
statistical analyses. IV glutamine administration (n=16) was considered a component of NT and 
was mostly derived from glutamine-containing parenteral nutrition regimens (n=13). Only three 
participants (n=3) received glutamine supplementation in the form of dipeptiven. Table 4-23 shows 
a breakdown of total protein delivery according to nutritional and non-nutritional sources. Total 
protein delivery refers to the cumulative protein delivery over the entire study period, i.e. from ICU 
admission until study exit. 
4.7.4 Lipid 
Propofol, the lipid-based sedative used in the treatment of status epilepticus, contributed 18% to 
total lipid delivery (n=7). Table 4-24 shows a breakdown of total lipid delivery according to 
nutritional and non-nutritional sources. Total lipid delivery refers to the cumulative lipid delivery 
over the entire study period, i.e. from ICU admission until study exit. 
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Table 4-22 Breakdown of carbohydrate delivery according to nutritional and non-nutritional sources 
Variables N-
size 
Cumulative delivery (grams)  % of total carbohydrate delivery 
  Mean ± SD (median) Range Mean ± SD (median) Range 
CONTRIBUTION NON-NUTRITIONAL SOURCES      
   % Non-nutritional sources 71 - - 17.6 ± 12.4 (14.6) 0 – 46.4 
   % Nutrition therapy  71 - -  82.4 ± 12.4 (85.4) 53.6 - 100 
NUTRITION THERAPY BREAKDOWN      
 Intravenous 14 611.4 ± 335.3 (616.5) 194.4 – 1213.9 57.4 ± 28.1 (60.5) 15.8 – 93.8 
 Enteral 67 865.3 ± 403.0 (813.0) 57.0 – 1731.9 75.1 ± 22.6 (81.4) 5.2 - 100 
 Oral  7 28.4 ± 18.5 (24.8) 6.8 – 50.0 2.2 ± 1.3 (2.2) 0.5 – 3.9 
NON-NUTRITIONAL SOURCES BREAKDOWN      
    Dextrose via crystalloids 45 124.4 ± 95.0 (102.3) 7.2 – 407.2 10.1 ± 6.9 (8.6) 0.6 – 26.9 
    Dextrose via drug dilution 41 59.2 ± 42.4 (56.5) 5.5 – 162.2 5.3 ± 3.7 (4.4) 0.6 – 13.9 
    Starch via HES infusion   56 69.5 ± 51.4 (60.0) 15.0 – 195.0 6.5 ± 5.3 (4.8) 0.7 – 19.9 
    Sucrose via Polygam infusion 3 139.2 ± 53.4 (164.0) 77.9 – 175.6 9.8 ± 4.8 (7.8) 6.3 – 15.3 
    Dextrose via other routine practices
A
 41 51.8 ± 37.7 (40.0) 10.0 – 175.0 5.1 ± 5.6 (3.3) 0.6 – 33.0 
Data are presented as mean ± SD (median) and ranges. 
A
Dextrose via other routine practices: 50% Dextrose water in the treatment of hyperkalemia and hypoglycemia 
Abbreviations: CHO: Carbohydrates; HES: Hydroxy-ethyl starch 
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Table 4-23 Breakdown of protein delivery according to nutritional and non-nutritional sources 
Variables N-size Cumulative delivery (grams) % of total protein 
  Mean ± SD (median) Range Mean ± SD (median) Range 
CONTRIBUTION NON-NUTRITIONAL SOURCES      
   % Nutrition therapy  71 - - 99.9 ± 0.9 (100.0) 92.1 – 100 
   % Non-nutritional sources 71 - - 0.1 ± 0.9 (0) 0 – 7.9 
NUTRITION THERAPY ENERGY BREAKDOWN      
 Intravenous
A
 16 242.7 ± 126.3 (190.8) 79.2 – 463.9 68.4 ± 30.6 (76.3) 12.6 - 100 
   Glutamine
B
 16 47.1 ± 38.0 (29.3) 3.6 – 118.4 12.5 ± 10.8 (11.7) 1.7 – 49.1 
 Enteral 67 371.1 ± 174.3 (375.5) 16.8 – 745.3 89.2 ± 25.6 (100) 4.1 - 100 
 Oral  7 12.1 ± 8.1 (14.0)  0.6 – 20.0 3.1 ± 2.4 (3.5) 0.1 – 6.5 
NON-NUTRITIONAL ENERGY BREAKDOWN      
 Albumin
C
 1 46.0 - 7.9 - 
Data are presented as mean ± SD (median) and ranges. 
A
Intravenous: Includes total nitrogen content of PN regimens, as well as additional IV glutamine supplementation; 
B
Glutamine: Includes glutamine derived from glutamine-containing PN regimens, as well as additional IV glutamine supplementation 
C
Albumin: Albusol 20% 
Abbreviations: PN: Parenteral nutrition 
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Table 4-24 Breakdown of lipid delivery according to nutritional and non-nutritional sources 
Variables N-size Cumulative grams % of total lipid 
  Mean ± SD (median) Range Mean ± SD (median) Range 
CONTRIBUTION NON-NUTRITIONAL SOURCES      
   % Nutrition therapy  71 - - 98.2 ± 6.9 (100)  58.0 – 100 
   % Non-nutritional sources 71 -  - 1.8 ± 6.9 (0) 0 – 42.0 
NUTRITION THERAPY LIPID BREAKDOWN      
 Intravenous 14 239.4 ± 130.6 (210.5) 90.0 – 495.1 76.0 ± 26.2 (89.6) 36.2 - 100 
 Enteral 67 283.6 ± 131.3 (280.3) 14.3 – 599.3 87.8 ± 25.9 (100) 2.8 - 100 
 Oral  7 12.1 ± 10.0 (9.8) 0.3 – 25.0 4.1 ± 3.5 (4.1) 0.1 – 9.9 
NON-NUTRITIONAL LIPID BREAKDOWN      
 Propofol 7 81.7 ± 70.6 (60.0) 13.0 – 221.2 17.9 ± 14.9 (12.6) 4.6 – 42.0 
Data are presented as mean ± SD (median) and ranges. 
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4.7.5 Subgroup analyses 
No significant correlation was found between the percentage contribution of NNES to TED 
and the following variables: 
(1) Gender 
(2)  Severity of illness (APACHE II score) on admission to ICU  
(3)  Nutritional status (BMI) on admission to ICU 
(4)  Admission category 
(5) Primary admission diagnosis 
(6)  Presence of severe sepsis or septic shock 
(7)  Total study hours  
(8) Hours to initiation of NT 
 
4.7.5.1 Acute kidney injury (AKI) 
Patients with AKI-ND (no dialysis, n=15) had the highest percentage contribution from NNES 
compared to patients with AKI-D (dialysis, n=16) and normal renal function (n=40) (16.4 ± 
10.0 vs 8.5 ± 5.5 vs 8.2 ± 6.0, p=0.02 respectively). The daily provision of non-nutritional 
calories to AKI-ND was significantly higher compared to patients with AKI-D and normal 
renal function (p=0.04, non-parametric Kruskal-Wallis test) (Figure 4-11).  
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Renal function; LS Means
Current effect: F(2, 68)=6.8140, p=<0.01 Kruskal-Wallis p=0.04
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 4-11 Daily non-nutritional energy provision according to renal function 
 
The above finding can be ascribed to a significantly higher mean daily administration of 
glucose solutions, i.e. 5 % dextrose water, to patients with AKI-ND (n=11) compared to AKI-
D (n=7) and normal renal function (n=21) (0.6 ± 0.4 vs 0.2 ± 0.1 vs 0.3 ± 0.2 L/d respectively, 
p=0.03). Table 4-25 shows a breakdown of the percentage contribution of different NNES to 
total energy and carbohydrate delivery according to the presence of AKI. 
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Table 4-25 Percentage contribution of NNES to TED according to renal function 
 NRF  N AKI-no 
dialysis  
N AKI-
dialysis 
N P-
value 
Energy        
   IV fluid therapy 6.0 ± 3.4  35 10.7 ± 7.2 15 4.5 ± 2.9 15 0.04 
      Crystalloids 4.8 ± 3.3  24 8.6 ± 4.5 11 3.0 ± 1.8 10 <0.01 
      Colloids 2.9 ± 2.7 31 5.0 ± 3.7 13 3.1 ± 2.4 12 0.17 
   Drug dilution  3.4 ± 2.7  12 2.1 ± 1.7  10 2.9 ± 2.0  19 0.367 
Carbohydrates        
   IV fluid therapy 11.7 ± 6.3 35 19.9 ± 12.1 14 8.3 ± 4.8 15 0.01 
      Crystalloids 9.5 ± 6.1 24 15.6 ± 8.2  11 5.7 ± 2.8 10 <0.01 
      Colloids 5.9 ± 5.2 31 8.8 ± 6.2  13 5.7 ± 4.3 12 0.24 
   Drug dilution  5.6 ± 3.6  19 6.0 ± 4.3  12 3.9 ± 2.9 10 0.38 
Abbreviations: NRF: Normal renal function; AKI: Acute kidney injury; IV: Intravenous  
 
4.7.5.2 Hypernatremia 
Table 4-26 shows the spearman rank correlation analyses between “hypernatremia days” 
and energy delivery parameters. “Hypernatremia days” were defined as the number of days 
a study participant’s serum sodium concentration exceeded 149 mmol/L; i.e. cut-off point 
above which 5% dextrose water is used for IV drug dilution and the feeding prescription is 
changed to a sodium-restricted feed. 
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Table 4-26 Correlation analyses between hypernatremia days & energy delivery 
parameters 
  Total cumulative delivery % of total delivery 
Variables n-size R p-value R p-value 
ENERGY DELIVERY      
Total cumulative 71 0,025081 0,835526 - - 
Mean daily g/d 71 0,002027 0,986614 - - 
Mean daily g/kg/d 71 -0,057423 0,634315 - - 
Non-nutritional energy sources      
   IV fluid therapy 65 0.418 0.001 0.370 0.002 
      Crystalloids 45 0,262358 0,081672 0.301 0.045 
         Glucose solutions 38 0.401 0.013 - - 
   IV drug dilution 41 0.747 0.000000 0.598548 0.000036 
Energy parameters      
   Mean percent goal 71 -0,079364 0,510603 - - 
   Cumulative energy balance 71 -0,091518 0,447823 - - 
CARBOHYDRATE DELIVERY      
Total cumulative 71 0,125830 0,295743 - - 
Mean daily g/d 71 0,154929 0,197021 - - 
Mean daily g/kg/d 71 0,107302 0,373107 - - 
Non-nutritional CHO sources      
   IV fluid therapy 64 0.421011 0.000532 0.378555 0.002039 
        Crystalloids 45 0,258186 0,086824 0,291347 0,052164 
              Glucose solutions 38 0.395124 0.014082 - - 
   IV drug dilution 41 0.746849 0.000000 0.638783 0.000007 
Abbreviations: R: Spearman rank correlation coefficient 
 
A significant positive correlation was found between the number of hypernatraemia days and 
the percentage contribution of NNES to total energy and carbohydrate delivery. This is 
because hypernatraemia frequently developed as a consequence of free water losses for 
which the administration of 5% dextrose water is clearly warranted.57 Interestingly, there was 
no significant association between the number of hypernatremia days and total cumulative 
energy delivery, mean daily energy delivery, cumulative energy balance, mean percent goal 
or the percentage contribution of carbohydrates to total energy delivery. This indicates that 
the increase in non-nutritional calorie provision was accompanied by a simultaneous 
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reduction in calorie provision from NT. This could be explained by the use of sodium-
restricted enteral feeding prescriptions that is often calorie-restricted. 
4.8 Total energy and protein delivery in relation to estimated targets 
4.8.1 Mean percent target 
Overall study participants (n=71) had a mean percent target of 93.6 ± 17.7 % and 82.8 ± 
19.9% (range 23.5 – 103.3) for energy and protein delivery respectively. 
There was no significant correlation between energy or protein mean percent target and 
severity of illness (APACHE II score) on admission, total study hours or study duration post 
initiation of NT. There was no significant association between gender or route of feeding and 
the mean percent target for energy and protein. Contrary to energy delivery a significant 
inverse correlation was found between the protein mean percent target and BMI (n=71, R= -
0.268453, p=0.023599) on admission to ICU. Hence the higher the BMI, the lower the 
protein mean percent target. 
There was a significant negative correlation between the energy and protein mean percent 
target and time (hours) to initiation of NT (energy: n=71, R= -0.280370, p=0.017874; protein: 
n=71, R= -313428, p= 0.007778). Hence the longer the time to initiation of NT, the lower the 
energy and protein mean percent target. Figure 4-12 uses the mean percent target to 
classify patients as either energy/protein underfed (<90% of minimum target), energy/protein 
targets met (90% - 110% of target range) and energy/protein overfed (>110% of maximum 
target).  
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Figure 4-12 Energy and protein mean percent target  
Forty-four (62%) of the seventy-one study participants achieved the energy target range, 
whereas only thirty-five (49%) achieved the protein target range. Only nineteen study 
participants (27%) were energy underfed whereas thirty-six (51%) were protein underfed. 
Although eight patients (11%) exceeded the maximum energy target, none exceeded the 
maximum protein target. 
4.8.2 Cumulative balance 
Overall study participants (n=71) had a mean cumulative energy and protein balance of -
674.0 ± 1866.1kCal and -86.0 ± 106.9g protein (range -546.3 – 11.7) respectively.  
There was no significant correlation between cumulative energy and protein balance and 
severity of illness (APACHE II score) on admission, total study hours or study duration post 
initiation of NT. There was no significant association between gender or route of NT and 
cumulative balance for energy and protein. Contrary to energy delivery a significant 
correlation was found between cumulative protein balance and BMI on admission to ICU 
(n=71, R=-0.286704, p=0.015348). Hence the higher the BMI, the lower the cumulative 
protein balance. 
There was a significant negative correlation between cumulative energy and protein balance 
and the time (hours) to initiation of NT (energy: n=71, R= -0.283345, p=0.016647; protein: 
n=71, R= -0.324926, p= 0.005697). Hence the longer the time to initiation of NT, the greater 
the cumulative energy and protein debt. 
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4.8.3 Subgroup analyses  
Table 4-27 shows a breakdown of the mean percent target and cumulative balance 
according to the primary admission diagnosis. Gastrointestinal patients, presumably mainly 
surgery participants, had a significantly lower mean percent target and cumulative balance 
for both energy and protein delivery. This can be ascribed to longer NPO periods prior to 
initiation of NT, as well decreased EN tolerance. 
Table 4-27 Mean percent target & cumulative balance based on primary admission 
diagnosis 
 GIT  
(n=10) 
Sepsis  
(n=20) 
Neuro  
(n=13) 
Resp  
(n=17) 
Other  
(n=11) 
P 
value 
MPT       
Energy 79.9 ± 24.6 93.6 ± 19.7 100.6 ± 9.6 99.2 ± 13.5 89.3 ± 13.2 0.030 
Protein 68.2 ± 25.8 78.3 ± 22.0 89.1 ± 11.1 92.8 ± 15.2 81.1 ± 15.8  0.02 
CB       
Energy - 2048.0 ± 
2727.6 
-749.6 ± 
2017.1  
49.7 ± 
1041.4 
-61.8 ± 
1355.0 
-1089.1 ± 
1518.7 
0.03 
Protein -143.1 ± 119.6 -123.2 ± 140.5 -52.1 ± 53.0 -32.2 ± 69.5 -89.6 ± 78.0 0.023 
Data are presented as mean ± SD. Statistical analyses based on One-Way Analysis of Variance F-
test/Kruskal-Wallis test. Abbreviations: MPT: Mean percent target; CB: Cumulative balance; Neuro: 
Neurological; Resp: Respiratory 
 
Table 4-28 shows a breakdown of the mean percent target and cumulative balance for 
energy and protein according to the presence of AKI. Patients with AKI-ND had a 
significantly lower energy and protein mean percent target and greater cumulative energy 
and protein debt. 
Table 4-28 Mean percent target and cumulative balance based on renal function 
 Normal (n=40) AKI-no dialysis (n=15) AKI-dialysis (n=16) P value 
MPT     
   Energy 96.2 ± 17.9 88.2 ± 15.8 92.4 ± 18.5 0.04 
   Protein 89.3 ± 17.2 68.6 ± 17.2 79.6 ± 21.6 0.001 
CB     
   Energy -442.8 ± 1900.4 -1122.6 ± 1500.7 -831 ± 2095.1 0.04 
   Protein -49.4 ± 81.5 -144.3 ± 79.0 -122.7 ± 147.7 <0.01 
Data are presented as mean ± SD.  Statistical analyses based on One-Way Analysis of Variance F-
test/Kruskal-Wallis test. Abbreviations: MPT: Mean percent target; CB: Cumulative balance; AKI: 
Acute kidney injury 
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4.8.4 Impact of NNES on mean percent target and cumulative balance 
There was no significant association between daily non-nutritional energy provision (kCal/d) 
and energy target group; i.e. underfed vs energy targets met vs overfed (p=0.91, data not 
shown). However, further analysis showed a significant variation between daily crystalloid-
derived non-nutritional energy provision (kCal/d) and the energy target group (p=0.04) 
(Figure 4-13). Participants who were overfed received a significantly higher amount of 
calories from crystalloids. 
Energy target group; LS Means
Current effect: F(2, 42)=1.8190, p=0.17 Kruskal-Wallis p=0.04
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 4-13 Mean daily crystalloid delivery according to energy target group 
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Participants who were underfed had a significantly higher percentage contribution of NNES 
to TED (p=0.020) (Table 4-29). The percentage contribution of NNES to TED will therefore 
be higher in ICUs where underfeeding is more prevalent.  
 
Table 4-29 Percentage contribution of NNES according to energy target group 
Energy target group n-size Mean ± SD 
(median) 
Range p-value*  p- variances 
All groups 71 10.1 ± 7.5 (8.2) 0 – 29.1  - - 
Meeting energy target*  44 9.1 ± 6.5 (7.4) 0.4 – 27.7  0.149 0.088 
Underfeeding* 19 13.1 ± 9.6 (12.9) 0 – 29.1 0.036 0.020 
Overfeeding* 8 8.3 ± 5.3 (8.9) 0 – 15.9 0.486 0.292 
*p-value: Based on T-test for independent samples (groups); Meeting energy target: Meeting 90 – 
110% of the energy target range; Underfeeding: Meeting less than 90% of the minimum energy 
target; Overfeeding: Meeting more than 110% of the maximum energy target.  
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5.1 Baseline characteristics and presence of severe sepsis, septic shock 
and AKI 
This study retrospectively reviewed the total fluid, electrolyte, energy and macronutrient 
intake of 71 critically ill adult patients admitted to a medical/surgical ICU. Approximately two-
thirds (68%) of the study sample were medical admissions and study participants were 
mostly admitted for sepsis (28%), respiratory (24%), neurological (18%) and gastrointestinal 
(14%) conditions. Patients in our study were younger (mean age 49) than previously 
published single- and multicenter observational studies in which the average age ranged 
between 55 and 68 years.12,33-34,68,74,76,91-92 This may be a reflection of the lower life 
expectancy in developing countries, such as South Africa, compared with first-world 
countries where previous studies were mostly undertaken (e.g. Canada, USA, 
Netherlands).The average BMI on admission to ICU was 28.5 kg/m2 and is similar to a 
prospective, multicentre, observational study by Heyland DK (2011) conducted in three 
medical/surgical ICUs. In this study, as in ours, approximately two-thirds (Heyland: 73%; this 
study: 68%) were medical admissions.91  
The high prevalence of pre-obesity (28%) and obesity (32%) on admission to ICU reflects 
the increasing prevalence of overnutrition in the South African population. More than half of 
the study participants (60%) had a BMI >25 kg/m2 and is similar to the study by Caesar et al 
(2011) in which 57% were either pre-obese or obese. According to McClave et al 78 based 
on U.S. and worldwide trends, the prevalence of obesity in the critical care setting is 
expected to increase over the next 10 years which is of concern since assessment of 
nutritional status and nutrient provision is problematic in this specific subgroup of patients.77 
Obese critically ill patients may experience greater losses of LBM with a greater risk of 
protein malnutrition.28,78  
One should however bear in mind that in this study BMI was based on the anthropometrical 
measurements (weight and height) recorded on the study participants’ ICU charts on 
admission to ICU. Firstly, on its own, BMI is not an accurate indicator of the presence of 
protein energy malnutrition (PEM), especially in obese patients who may have low muscle 
stores and subsequent PEM, as well as elderly patients who may suffer from age-related 
muscle atrophy (sarcopenia).  The relationship between BMI and LBM is further hampered 
by systemic inflammation, sodium retention, and fluid resuscitation causing an artificial 
increase in body weight (and hence BMI).93 Secondly, it is expected that patients with a 
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normal or high BMI on admission will develop subsequent PEM with a prolonged ICU stay, 
due to a number of factors, some intrinsic to the patient and some iatrogenic.94 
A large proportion of the study sample (82%) presented with severe sepsis, either on 
admission (28%) or later on during the study period (54%). This is in line with the 
prospective observational study in a medical-surgical ICU by Allingstrup et al in whom 89%, 
on average, presented with severe sepsis.92 Almost half of the study sample (44%) 
presented with AKI. This is slightly higher than the reported incidence of 25 – 40% reported 
by Fiaccadori 95, but in line with previous authors reporting an incidence of approximately 30 
(33) – 60 (66%) in critical illness.96-97 The high prevalence of AKI is concerning, since these 
patients have a significantly higher morbidity and mortality and managing their fluid and 
electrolyte status is particularly challenging.2 In our study a significant association was found 
between the severity of illness (APACHE II score) on admission to ICU and the presence of 
AKI. This is expected since markers of AKI; i.e. raised serum levels of creatinine and 
potassium, form part of the physiological variables used for rating a patient’s APACHE II 
score. According to Fiaccadori et al 95 AKI can be seen as an indicator of the severity of 
illness since it usually forms part of multi-organ failure secondary to severe sepsis/SIRS, 
with mortality rates reaching 50% of patients.  
5.2 Fluid delivery 
Fluids were mostly administered via the IV route (63%). The greatest contributor to total IV 
fluid delivery was in the form of crystalloids, colloids and blood products (52%) followed by 
IV drug administration (35%). In this study IV drug administration took into account the 
volume of all liquid drugs, as well as fluids used for reconstitution and dilution purposes. If 
data pertaining to drug administration were not charted (e.g. flushing of IV lines, 
reconstitution of powdered drugs, IV drug dilution) a standardized procedure (Addendum B) 
was followed to estimate the given fluid volume accurately. This standardized procedure was 
based on the precise administration policy as indicated on the drug’s package insert or as 
per standard ICU protocol for the administration of drugs. 
The mean daily IVFT volume of 1.1L/day reflects the use of a more restrictive fluid therapy 
regimen. This is in line with the recommendation by Hilton et al 35 suggesting the use of a 
more restrictive approach instead of the “fixed 3 L per day” prescription for maintenance fluid 
requirements. More recently Brettner et al 4 strongly suggested against excessive IV fluid 
administration due to the vast body of evidence linking it to the shedding of the endothelial 
glycocalyx with a subsequent increase in vascular permeability and interstitial oedema.  
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However, despite the relatively low daily administration of crystalloids, colloids and blood 
products (32% of total fluid delivery), total fluid delivery was considerably higher (3.2 L/day) 
due to additional IV fluid delivery; especially IV drug administration which contributed a 
further 21% to total fluid delivery. To our knowledge this is the first study to accurately take 
into account the volume of all liquid drugs, fluids used for reconstitution and dilution 
purposes, as well as flushing of IV lines. Our study therefore confirms the recommendation 
by Rassam et al 39 that the volume of multi-drug infusions, PN, EN or antibiotics requiring 
large volume infusions should be added to the maintenance fluid regimen such that an 
accurate balance is recorded. Additional fluids given to provide adequate nutrition and drugs 
should also be compensated for in the prescription of fluid removal in patients receiving 
CRRT for AKI.10   
Balanced electrolyte solutions (e.g. Balsol/Plasmalyte B, Hartman’s solution/Ringer’s 
Lactate) were the crystalloid of choice for IVFT. Non-hypertonic LMW 130/0.4 KD HES was 
prescribed for the treatment of acute hypovolemia, while the use of albumin and gelatins was 
practically negligible (0.6%). The choice of IV fluids in this unit are in line with recent 
publications suggesting the use of balanced tetrastarch iso-oncotic colloids to restore 
cardiac output, whilst restricting the use of balanced crystalloid solutions to the replacement 
of extracellular losses or dehydration.3-4,20 The concept of “demand-oriented perioperative 
infusion therapy” suggested by Brettner et al also supports this approach to IVFT.4 On the 
other hand international regulatory bodies issued recent statements that HES IV fluids 
should be withdrawn from clinical use; (2) its clinical use reviewed; or (3) used with extreme 
caution in ICU, cardiac surgery and patients with known kidney disease or coagulopathy.52-54 
These recommendations are however based on studies that administered outdated HES in 
excessive amounts over prolonged periods of time 50 and in elderly, critically ill septic 
patients.45-46 In our study unit the use of HES was restricted to non-hypertonic LMW 130/0.4 
KD HES with a relatively low mean daily volume of 0.2 ± 0.1 litres administered to a 
relatively young patient group (mean age 49 years). 
Surgical participants (n=23) had a significantly higher mean daily fluid delivery (p<0.01), with 
a significantly higher percentage contribution from IVFT (p<0.01), compared to their medical 
counterparts (n=48). This can be explained by a higher need for post-operative fluid 
replacement for the following reasons:3-4,20 
 Higher colloid and blood product delivery to treat acute hypovolemia caused 
by intraoperative blood loss. 
Stellenbosch University  http://scholar.sun.ac.za
  
110 
 
 Higher crystalloid delivery to replace ECF losses caused by preoperative 
fasting, especially in patients who received bowel preparation, as well as 
insensible losses during surgery, especially in major abdominal surgery. 
Non-dialysed AKI participants (p=0.01) had a significantly higher mean daily fluid delivery, 
with a significantly higher percentage contribution from IVFT (p=0.003), compared to their 
dialysed counterparts and those with normal renal function. This can be explained on the 
basis of the Acute Dialysis Quality Initiative (ADQI) consensus definition of AKI, denoted by 
the acronym RIFLE. This acronym classifies AKI into three stages of increasing severity- 
risk, injury and failure- and two outcome classes- loss and end-stage renal disease. AKI in 
ICU is often associated with pre-renal failure secondary to hypovolemia.98 In our study, the 
non-dialysed AKI patients most probably represented stage 2 (Injury) of the RIFLE acronym. 
During this stage IVFT forms the cornerstone of management to correct a state of volume 
depletion in order to avoid further exacerbation of renal injury. Renal replacement therapy 
(RRT) is only initiated once AKI has reached stage 3 (Failure). Therefore, in our study, study 
participants who received dialysis most probably represented stage 3 (failure).98 Fluid 
overload in the presence of AKI is also a common indication for dialysis.99 Dialysed patients 
are therefore more likely to present with some degree of fluid overload with the use of more 
restrictive IV fluid regimens.99 This might further explain the lower IVFT volume in this 
subgroup (AKI-dialysis) compared to their non-dialysed (AKI-ND) counterparts. 
5.3 Electrolyte delivery  
Our study confirmed that IV electrolyte supplementation is a routine ICU practice 8 and that 
nearly all patients will receive some form of IV electrolyte supplementation during the first 
week of ICU care. Potassium salts were the most frequently prescribed IV electrolyte 
supplement and were administered to 91% of the study participants. This is in line with Todd 
et al 8 who reported hypokalemia as the most common electrolyte disturbance in hospitalized 
patients. Potassium supplementation for the treatment of hypokalemia was administered 
according to a standard ICU protocol, as previously suggested for improving overall 
electrolyte replacement and its effectiveness.8  
5.4 Contribution of non-nutritional fluids to total fluid and electrolyte 
delivery 
Sodium and chloride delivery was mostly derived from non-nutritional fluids (>80%). Non-
nutritional sodium sources included sodium-containing crystalloids, hydroxyl-ethyl starches, 
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blood derivatives (i.e. Hemosolvex, Polygams), sodium bicarbonate supplementation and the 
administration of fleet enemas. Non-nutritional chloride sources included chloride-containing 
crystalloids, HES, polygam infusions and potassium chloride supplementation. Factors that 
could have contributed to the high contribution of non-nutritional sources versus NT to total 
sodium and chloride delivery include: 
 In this ICU the use of PN is predominantly restricted to electrolyte-free 
regimens, hence not contributing to total sodium and chloride delivery. 
 The routinely used IVFT products, i.e. electrolyte solutions and HES, both 
contain sodium and chloride. 
 Almost half (45%) of the study participants who received EN presented with 
hypernatremia (s-Na ≥ 149) and therefore received sodium- and chloride 
restricted EN formulae. 
The significantly lower contribution of IVFT to total chloride delivery among patients with 
higher APACHE II scores on admission to ICU could be due the prescription of chloride-
restricted or chloride-free crystalloids to more severely ill patients due to an increased 
incidence of hypernatremia (5% dextrose water), AKI and metabolic acidosis (sodium 
bicarbonate added to 5% dextrose water). 
Calcium, magnesium and phosphate delivery was determined to a large extent by the 
delivery of NT with 88%, 85% and 75% of total intake derived from NT respectively. This can 
firstly be ascribed to the fact that IVFT products are generally low in these electrolytes. 
Secondly, 94% of the study participants received EN, either on its own or in combination with 
PN or oral nutrition. EN formulae are high in calcium, magnesium and phosphate. On the 
other hand PN regimens provide little or no calcium, magnesium and phosphate. 
Overall, NT was the largest contributor to potassium, calcium, magnesium and phosphate 
delivery, whereas non-nutritional fluids were the largest contributor to total fluid, sodium and 
chloride delivery. The frequent use of low sodium- and chloride feeding prescriptions may 
have contributed to this finding. Important to note is that the electrolyte content of the 
prescribed drugs, e.g. sodium-containing antimicrobial agents, were not taken into account 
and would have further contributed to total electrolyte intake.  
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5.5 Energy and nutrient delivery 
5.5.1 Impact of NNES to total energy and macronutrient delivery: 
Table 5-1 shows a summary of the NNES that were taken into account by previously 
published studies assessing energy intake in ICU. It includes studies published both prior to, 
as well as after the data collection phase of our study (2005 – 2013). This table is based on 
the NNES that were reported by the respective authors.  
 
Table 5-1 NNES taken into account by previously published observational studies 
 IV fluid therapy Drug 
dilution 
50% 
dextrose 
water 
Propofol Polygam 
Crystalloids HES Albumin     
Villet 2005 
33
 X - - X - X - 
Hise 2007 
34
 X - - - - X - 
Alberda 2009 
74
 - - - - - X - 
Tsai 2011 
68
 X  - - - -  - 
Arabi et al 2011 
70
 X - - - - X - 
Weijs 2012 
76
 X - - - - X - 
Allingstrup 2012 
92 
 - - X - - X - 
Singer P 2012 
72
    (X) 
A
 - - - - X - 
Heidegger 2013 
32
 - - - X - X - 
This study X X X X X X X 
A 
Singer P 2012 (TICACOS): The authors did not specify the type of IV fluids taken into consideration; 
the assumption is made (based on previous studies) that at least dextrose-containing crystalloids 
were included in their calculation of energy intake. 
  
These studies did not take into account all of the existing NNES. To our knowledge, this is 
the first study to take into account the energy content of HES, polygam infusions, as well as 
the administration of 50% dextrose water used in routine ICU practices, for example, in the 
management of hypoglycemia and hyperkalemia. 
In this study, NNES contributed 10% to total energy delivery (mean), ranging from 0 – 29% 
across all study participants. The percentage contribution was greater than 10% in 39% of 
the study participants and was the highest among underfed patients, since they had the 
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lowest overall energy intake. The percentage contribution of NNES might therefore be 
substantially higher in ICUs where underfeeding is more prevalent compared to our study 
unit in whom only 27% of the study participants were energy underfed.   
In this study, daily energy delivery from NNES was 156kCal/day (mean), ranging from 0 – 
561 kCal across all study participants. It was previously reported that NNES contribute 
approximately 125 kCal/d and 250kCal/d in medical and surgical patients, respectively.34 
Villet et al 33 also reported an additional 150 – 600kCal/d delivery from glucose and sedative 
lipids on days without feeding. In a randomised trial by Arabi et al 70 the average daily caloric 
intake derived from propofol and dextrose infusions was 34kCal/day and 116kCal/d 
respectively. The authors did not specify the sources of dextrose energy that were 
evaluated. Hence it is unknown whether dextrose energy derived from IV drug dilution and 
50% dextrose water were included in the calculation of total energy intake. Our study results 
are in agreement with Heidegger et al 32 stating that NNES contribute 100 – 400kCal per day 
(based on the authors’ experience). In the recently published tight calorie control study 
(TICACOS) by Singer et al, 61 energy intake guided by repeated indirect calorimetry 
measurements (study group) was associated with an increased length of ventilation, length 
of ICU stay and risk of infection, compared to a standard 25kCal/kg feeding prescription 
(control group).  According to Heidegger et al 32 this could have been the result of systematic 
overfeeding, as evidenced by a significant positive cumulative energy balance in the study 
group (study group: 2008 ± 2177; control group: -3.550 ± 4.591; p= 0.01). Although the 
investigators did not take into account non-nutritional energy delivery in their target feeding 
prescriptions, they included it in their calculation of energy balances.61 This speaks to the 
fact that targeting full energy needs, as determined by indirect calorimetry, without taking 
NNES into account may lead to systematic overfeeding.  It also shows that systematic 
overfeeding is associated with potentially detrimental outcomes that may be even worse 
than that of underfeeding.  
Non-nutritional energy delivery was mostly derived from carbohydrate-containing IV fluids, 
whereas in the study by Hise et al 34 more than 50% of the non-nutritional energy was 
derived from propofol. In the latter study 70% of the surgical patients received propofol which 
is not a routinely used sedative agent in our unit and use was restricted to only 10% of the 
study sample who presented with status epilepticus. In this specific sub-group of patients 
(n=7) propofol provided an additional 139kCal/d, contributing 7% to total energy delivery and 
18% to total lipid delivery. Our study therefore confirms previous studies by Hise et al 34 and 
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Taylor et al 86 recommending close supervision of propofol administration as an additional 
lipid source. 
In the study by Hise et al 34 surgical patients received significantly more dextrose-containing 
IV fluids compared to medical patients (p=0.013) whereas in our study there was no 
significant difference between these groups with regard to the contribution of dextrose-
containing IV fluids to total energy delivery. In the study by Hise et al differences in ICU and 
physician practices could have influenced the prescription of these fluids since medical and 
surgical patients were from different ICU’s. 
Interestingly, in our study the administration of crystalloids played a significant role in 
overfeeding. Patients who were overfed (n=8) received a significantly higher amount of 
calories from carbohydrate-containing crystalloids compared to those who were not overfed 
(n=63) (p=0.04). This confirms the need for dieticians to take into account non-nutritional 
energy delivery, including energy derived from crystalloids, when calculating feeding 
prescriptions. 29,31-32 The prescription of calorie-restricted feeds to compensate for additional 
NNES may however contribute to protein underfeeding due to the low protein to non-protein 
energy ratio of currently available EN products.72,93 The dietician is therefore faced with a two 
pronged dilemma: Using a patient’s total energy intake as a limiting factor may lead to 
protein underfeeding whereas the use of a protein target as the limiting factor may lead to 
overfeeding. Protein underfeeding is problematic, since more and more evidence suggests 
protein intake to be an important factor in outcome. 60,72,76,92-93  
In this study, the contribution of NNES to total protein delivery was negligible. However, 
intravenous albumin infusions are not a routine practice in this particular unit and may also 
significantly influence total protein intake in units where it is routinely used. The prospective 
observational study by Allingstrup et al 92 stated that the protein derived from albumin 
infusions was included in the calculation of total protein intake. However the authors did not 
give feedback on the actual amount of albumin that was given and its contribution to total 
protein intake. 
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This study identified four patient subgroups in which close supervision of non-nutritional 
energy provision might be warranted: 
 Gullian-bare syndrome (GBS): 
These patients often receive high-dose immunoglobulin therapy through a 
continuous Polygam infusion. In our study only three study participants presented 
with GBS and hence precluded any statistical inferences. 
 AKI not receiving dialysis: 
This subgroup represents the “Injury” stage of the RIFLE criteria for AKI. IVFT in the 
form of glucose or gluco-saline solutions are often prescribed to these patients to 
reverse renal ischemia and/or increase renal perfusion.98,100 These patients also 
tend to have higher serum sodium levels as free water clearance is increased. This 
patient subgroup therefore received a significantly higher administration of glucose-
containing crystalloids (p=0.03) and a higher delivery of non-nutritional calories 
(kCal/d) (p=0.04).  
 Hypernatremia: 
Free water in the form of 5% dextrose water is clearly warranted in the treatment of 
hypernatremia.57 In our study the longer a patient presented with severe 
hypernatremia; i.e. serum sodium exceeding 149mmol/L, the greater the 
contribution of carbohydrate-containing IV fluids to total energy and carbohydrate 
delivery. 
 Status epilepticus: 
Propofol administration used in the treatment of status epilepticus adds to total 
energy and lipid intake and should therefore be closely monitored in order to 
prevent overfeeding.  
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5.5.2 Energy and protein delivery in relation to estimated requirements 
Table 5-2 shows a breakdown of the mean energy and protein delivery compared to 
previously published studies. 
Table 5-2 Mean energy and protein delivery compared to previous studies 
 Energy (kCal)
A
 NPE (kCal) Protein (g) N2 (g) NPE:N  
Alberda 2009 
74
 
 
1034 846 47 7.5 112:1 
Strack van Schijndel 2009 
101
 1730 (males) 
1536 (females) 
1429 
1268 
75 (males) 
67 (females) 
12.1 
10.7 
119:1 
118:1 
Weijs 2011 
76
 
 
1728 1424 76 12.2 117:1 
Singer 2012 
61
 
 
2086 1782 76 12.2 147:1 
Allingstrup 2012 
92
 
 
1875 1537 84.7 13.5 114:1 
Heidegger 2013 
32
 
 
1949 
B 
1625 81 
C
 13.0 125:1 
Our study 
 
1613 1325 72 11.5 115:1 
A
Refer to table 5-1 for a breakdown of the NNES taken into account by the respective studies; 
B
Based on 28kCal/kg reported; 
C
Based on 1.2g/kg reported  
Abbreviations: NPE: Non-protein energy; N2: Nitrogen; NPE:N: Non-protein energy to nitrogen ratio; 
BW: Body weight  
 
Study participants had a mean daily energy intake of 25kCal/kg derived from both nutritional 
and non-nutritional energy sources and achieved 94% of the mean target range. More than 
two-thirds of the study sample (73%) received more than 90% of the estimated energy target 
range. Since 80% of the study participants were fed via the enteral route (including the 4% 
who received additional oral nutrition) and only 14% received a combination of EN and PN, 
shows that energy targets can be met without routine supplemental PN in a predominantly 
medical ICU, given the employment of a dedicated nutrition team, including a registered 
dietician, practicing individualized and goal-directed NT.  
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
117 
 
Factors that could have contributed to our good energy delivery results include: 
(1) Earlier initiation of NT compared to previous studies with poorer outcomes. 
Early initiation of NT is seen as the first step in reducing a growing energy and 
protein deficit.29 
(2) Accurate calculation of energy delivery from NNES compared to previous 
studies. Actual energy delivery in previous studies could have been underreported 
due to a failure to take NNES into account.29 
(3) Active role of dietician in writing individualized feeding prescriptions, the use 
of a combination of EN formulae, as well as delivering prescribed feeds to 
bed-side nursing staff on a daily basis. According to Kiss et al 102 routine 
nutritional assessment by a dietician or designated nutrition support team leads to 
improved energy and protein delivery. Weijs et al 76 reports that their good energy 
and protein results were partly due to the use of individualized nutrition regimens 
with a combination of EN formulae aimed at reaching energy and protein targets. 
Interestingly, the energy and protein intake in the Weijs study was very similar to 
that of our study (Table 5-2).  
(4) Implementation of an enteral feeding protocol. The use of enteral feeding 
protocols increases the overall percentage of goal calories provided.67 
(5) Awareness among physicians about the importance of early and optimal NT. 
According to Singer and Cohen (2013), a recent Brazilian study by Gouveia Casto 
et al (2012) showed that providing nutrition education to intensive care physicians 
caused a significant increase in the early introduction of EN and the amount of 
energy delivered.72  
 
Our study found a significant correlation between the time to initiation of NT and the mean 
percent target and cumulative balance for energy and protein delivery. On average, NT was 
initiated within fourteen hours of ICU admission and is substantially earlier than in recently 
published multicenter observational studies (45 hours on average).12,91 Our study therefore 
confirms the importance of early initiation of NT in order to prevent a growing energy/protein 
debt.29,33 However, despite the good results achieved with energy targets in our study, 
protein delivery was less favourable. It therefore seems that early initiation of NT with 
currently available EN formulae is insufficient to ensure adequate protein delivery and 
indicates an urgent need for alternative measures to optimise protein delivery during the first 
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week of ICU care, particularly since recently published observational studies have shown 
that achieving adequate protein delivery in ICU is paramount. Weijs et al 76 showed that 
meeting protein and energy targets is associated with a 50% decrease in 28-day mortality, 
whereas reaching only the energy targets is not associated with a similar mortality benefit. 
Furthermore, Allingstrup et al 92 found that provision of more protein and amino acids in 
critically illness was associated with a lower mortality, which was not the case for the 
provision of energy alone, measured resting energy expenditure or energy or nitrogen 
balances. However, until now the importance of protein intake has been grossly neglected 
with the primary focus revolving around meeting energy targets.72,93 In reality most critically 
ill patients receive less than 50% of the most common protein recommendation (1.5g/kg per 
day) during their ICU stay and protein intake seldom exceeds 0.8 – 1.0g/kg/d.72,93 Study 
participants had a mean daily protein delivery of 72g (1.1g/kg/d) and a mean percent target 
of 83%. Figure 5-1 shows previously published studies with the best protein delivery results; 
i.e. equal to or greater than 1.0 g/kg protein per day. 
 
 
Figure 5-1 Protein delivery compared to previous studies 
These studies utilised labour-intensive procedures for meeting their targeted energy and 
protein intake. Singer et al 61 and Heidegger et al 32 utilised supplemental PN; whereas Weijs 
et al 76 utilised a computer algorithm with a combination of EN formulae. Although these 
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studies had a favourable energy intake (>85% of target), protein delivery was less 
favourable. This confirms that current EN and PN products fail to provide sufficient protein 
such that the most commonly recommended target of 1.5g/kg/day cannot be achieved.  
Even labour-intensive procedures as described above fall short of the optimum time frame 
and rate of protein provision, which could well be 2g/kg/d or more for a large proportion of 
critically ill patients.93 According to a recent systematic review by Hoffer and Bistrian 103 most 
critically ill patients could actually require more than 1.5g protein/kg and they strongly 
suggest that 2.0 – 2.5g protein/kg is safe and could be the optimum. 
In this study only 49% of the study participants achieved an adequate protein intake (i.e. > 
90% of minimum protein target). Figure 5-2 shows the percentage of patients in each energy 
target category who achieved at least 90% of the minimum protein target.  
 
 
Figure 5-2 Percentage of patients receiving ≥90% of minimum protein target according 
to energy target group 
Only 5% of those that were “energy underfed” and 59% of those that met energy targets 
achieved an adequate protein intake. However, all the overfed patients had an adequate 
protein delivery. Overfed patients are therefore most likely to have their protein targets met. 
This once again indicates the necessity for new EN formulations with a higher protein and 
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lower non-protein energy content, especially in the light of NNES primarily contributing to 
energy intake in the form of carbohydrates. Hoffer and Bistrian 93 agree that conventional EN 
generally fails to exceed 50% of a patient’s protein target and that achieving adequate 
protein delivery will simultaneously result in an excess delivery of non-protein energy, the 
toxic effects of which are well recognized in critical illness. Hoffer and Bistrian further 
recommend the use of routine supplemental PN as a means of bridging this protein 
shortfall.93 This study suggests that the routine use of lower-calorie, high-protein EN 
products during the first week of ICU care may offer a more cost-effective and safe way of 
optimising protein delivery in a predominantly medical ICU. 
Stellenbosch University  http://scholar.sun.ac.za
  
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6  
CONCLUSION AND RECOMMENDATIONS 
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6.1 Strengths and limitations 
This is the first study in South Africa to determine the contribution that IV fluid and electrolyte 
administration make to total fluid, electrolyte, energy and macronutrient intake in critically ill 
patients. Furthermore, to our knowledge, this is the first study that takes into account: 
 The energy content of HES, immunoglobulin therapy (polygam) and the 
administration of 50% dextrose water in calculating total energy intake. 
 The contribution of IV line flushes, the volume of liquid drugs, as well as fluids 
used for reconstitution and dilution purposes, in calculating total fluid intake. 
Study participants’ total energy and protein intake were compared to estimated energy and 
protein requirements and standardized according to evidence-based recommendations 
made by international organizations. 
 
There are some limitations in the current study. Given the nature of the design of this study, 
data was obtained through a retrospective review of study participants’ ICU charts. Data on 
fluid, electrolyte and nutrient intake was hence fully reliant on the accuracy of charted data. 
During our pilot study it was noted that certain required data was not routinely or accurately 
charted by nursing staff; i.e. flushing of IV lines, drug dilution (diluent agent and volume), and 
specification of the EN formula or PN regimen. To ensure data accuracy and validity the 
principal investigator trained all nursing staff prior to data collection with regard to accurate 
charting of all relevant data. An attendance register was completed (available on request) 
and signed by all nursing staff who received training.  An information sheet was also handed 
out during the training session (Appendix D). The principal investigator trained the clinical 
facilitator of the unit to reinforce training on a regular basis to all nursing staff and to train all 
new staff introduced to the unit with regard to accurate recording on ICU charts.  
The assumption was made that the delivery of NT was accurately charted. However, the true 
accuracy in the charting of short feeding interruptions (e.g. the time delay between an EN 
bag running empty and the bedside nurse changing the bag, measuring of residual volumes, 
administration of medications via the enteral feeding tube, and short procedures requiring 
the patient to be supine or flat, e.g. skin care, bathing the patient) is unknown.  
Given the nature of the study design, no statistical inferences can be drawn on the relation 
between fluid or nutrient delivery and patient outcomes. Although our study identified higher 
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fluid delivery among certain patient subgroups, e.g. surgical and AKI patients (no dialysis), 
cumulative fluid balance was not determined and might be of greater value in terms of 
patient outcomes. Lastly, groups that were compared in the sub-group analyses (e.g. 
surgical vs medical) were not always equal in sample size, thereby reducing the strength of 
statistical inferences.  
6.2 Recommendations 
Post-hoc analysis determining fluid balance and its relation to patient outcomes in surgical 
and AKI patients is recommended. Post-hoc investigation of the relationship between 
energy/protein mean percent goals and patient outcomes, e.g. ventilator-free days, infection 
rates, ICU mortality, hospital mortality and six-month mortality should also be considered.  
Similar studies with a prospective observational design and with equal numbers of 
subgroups to be compared (e.g. surgical vs medical patients) are recommended. Even more 
so, adequately powered randomized clinical trials to establish cause-effect relationships 
between fluid-, energy- and protein balance and patient outcomes, with total fluid and energy 
delivery calculated in a similar fashion to our study, is highly recommended. 
Lastly, adequately powered, randomized clinical trials assessing the impact of low-calorie, 
high protein EN formulae on total energy and protein delivery, whilst taking nutritional and 
non-nutritional energy sources into account, are recommended. This is especially warranted 
among the “at risk” patient groups identified in our study, namely gastrointestinal, obese and 
non-dialysed AKI patients.  
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6.3 Conclusion 
Our study revealed that even in the presence of a restrictive IV fluid therapy regimen, total 
fluid delivery is considerably higher due to additional IV fluid delivery; especially from IV drug 
administration. The crystalloid and colloid of choice for IV fluid therapy were balanced 
electrolyte solutions and hypertonic LMW 130/0.4 KD hydroxyethyl starches respectively. 
Potassium-salts were the most frequently prescribed IV electrolyte supplement.  
In this study NNES contributed 10% to total energy delivery, but the percentage contribution 
might be substantially higher in other ICUs where underfeeding is more prevalent.  Non-
nutritional energy provision was mostly derived from carbohydrate-containing IV fluids. 
Four patient subgroups were identified in whom close supervision of non-nutritional energy 
provision might be warranted, namely (1) gullian-bare syndrome receiving polygam, (2) 
status epilepticus receiving propofol, (3) non-dialysed AKI receiving high volumes of IV fluid 
therapy in the form of dextrose-containing crystalloids, and (4) hypernatraemic patients 
receiving a free water infusion in the form of 5% dextrose water.  
Our study showed that energy targets can be met without routine supplemental PN in a 
predominantly medical ICU, given the employment of a dedicated nutrition team practicing 
individualized and goal-directed NT. However, it seems that early initiation of NT with 
currently available energy-rich EN formulae is not sufficient to ensure adequate protein 
delivery. The dietician is therefore faced with a dilemma: Using a patient’s protein target as 
the limiting factor when prescribing conventional EN products may lead to overfeeding on 
calories which will then be further worsened by additional energy delivery from NNES. 
Conversely, using the energy target as the limiting factor to avoid overfeeding may lead to 
protein underfeeding. Both overfeeding and protein underfeeding have been associated with 
unfavourable patient outcomes and should be avoided.  
In conclusion, although targeting of full energy and protein requirements are associated with 
positive outcomes in ICU, 32,61,68,74-76,91-92 it is essential to include NNES in the calculation of 
feeding prescriptions to avoid the harmful effects of overfeeding. Furthermore, this study 
stresses the need for new EN formulae with a more favourable nitrogen to non-protein 
energy ratio, especially in the light of the fact that NNES contribute mainly to carbohydrate 
intake. The routine use of such feeds may offer a more cost-effective and safer solution to 
the optimisation of protein delivery compared to routine supplementation of inadequate EN 
with PN. 
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CHOOSE CONFIDENCE LEVEL 95 99
Alpha 5,00% 1,00%
Z = 1,959964 2,575829
p 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5 0,5
Precision 3 4 5 6 7 8 9 10 11 12 13 14
N 95% 1068 601 385 267 196 151 119 97 80 67 57 49
N 99% 1844 1037 664 461 339 260 205 166 138 116 99 85
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STANDARDISED DATA COLLECTION PROTOCOL
Stellenbosch University  http://scholar.sun.ac.za
  
138 
 
576 GENERAL ICU (CMJAH) 
 
CLINICAL NUTRITION RESEARCH 
 
STANDARDISED DATA COLLECTION PROTOCOL 
 
1. General information: 
 
Research project 
title: 
The Impact of Intravenous Fluid and Electrolyte Administration on Total Fluid, 
Electrolyte and Energy intake in Critically Ill Adult Patients.  
 
Researcher: Lizl Veldsman  
 
Study leaders: Prof GA Richards 
Prof R Blaauw 
 
Contact details Lizl Veldsman 
c: +2782 414 5084 
w: (011) 488 4348  
lizlveld@gmail.com 
 
 
2. Screening 
 
1.   You will consecutively enrol patients in the study. Beginning on the first day of data collection, record all 
patients discharged from ICU or who demised on or after that day in the screening log (Appendix I).  
2.   Screening log columns represent eligibility criteria for purposes of data collection. Place a  in each 
column where a patient meets the eligibility criteria, or an  if the patient does not meet that criteria.  A 
research number should be allocated to each eligible patient and recorded on the screening log.  
Research numbers should be allocated consecutively from R1 to R70 as patients are entered into the 
study. Collect data on all patients who meet all eligibility criteria. If charts are missing and you are 
unable to collect all of the required data for a patient, please exclude this patient and include the next 
eligible patient. Screening should be continued until a minimum of 70 consecutive eligible patients have 
been reached. 
Note: Consecutive means the very next patient that meets the criteria, instead of picking and choosing 
patients.  
3.   If a patient you collected data on is later readmitted to the ICU, do not include the patient a 2nd time. 
4.   Use additional pages of the screening log as necessary. 
5.   Record each patient’s hospital number on the screening log. 
6.   Each eligible patient’s research number (e.g. R4) will be recorded on the screening log. 
7.   Please keep the screening log to help track down which patient corresponds to which research number 
in case there are data queries at a later date. 
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Enrol all patients meeting the following eligibility criteria: 
Inclusion Exclusion 
- Adults (≥ 18 years of age) 
- Must have been admitted to the general ICU (576) 
of CMJAH.   
- APACHE II score ≥10 on admission to ICU. 
- Must have received nutrition therapy (i.e. enteral 
nutrition and/or parenteral nutrition) for at least 72 
hours. 
- Must have had an ICU length of stay of at least 72 
hours. 
- Skeletal abnormalities, contractures and spinal 
cord injuries (quadriplegia and paraplegia). 
 
- Nutrition therapy discontinued within 72 hours 
after ICU admission. 
 
- Discharged from ICU or death within 72 hours 
after ICU admission.  
 
 
 
3. Case Report Forms 
 
1.   A case report form (CRF) (Appendix II) must be completed for each study participant. 
2.   All data requested in the CRF is to be taken retrospectively from the original source documents, i.e. the 
patient’s ICU chart/s or hospital file. 
3.   Collect data retrospectively from the day of ICU admission until discharge from ICU, discontinuation of 
nutrition therapy or death, whichever occurred first. If a patient remained in ICU for more than 7 days 
data should only be collected until day 7 in ICU. 
4.   Please ensure that the CRFs of each patient are complete. 
5.   All data fields should be completed 
o    Please indicate if any given data is not charted on the patient’s records. 
o    Asteriks (*) denote required fields. If required data is not charted on the patient’s records, 
exclude this patient and include the next eligible patient. 
6.   All dates must be recorded in the format YYYY-MM-DD. 
7.   All times must be recorded using the 24 hour (military) clock (HH:MM). Midnight will be 00:00 hr. 
8.   Anywhere in the CRF that “Other, specify” is indicated and/or has been selected, there must be an 
entry on the line provided further describing what “other” means. 
9.   Day 1 is the date of admission to ICU. 
10. Study days are defined according to ICU chart days (i.e. 07:00-06:59 hrs). Study days therefore 
begin and end at 07:00am. This will ease data collection.  
oDay 1 might not be a full 24 hour period. 
oThe last day in the ICU might not be a full 24 hour period.  
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a. Patient Information 
Sex* Place a  in the appropriate box (male or female) 
Age* Record patient’s age (year and months) 
ICU 
Admission 
Date/Time* 
Enter the date and time the patient was admitted to 576 ICU.  
If the patient has been admitted to the ICU multiple times, use the most recent admission. If a 
patient is transferred from another ICU enter the date of admission to 576 ICU. 
Type of 
admission* 
Place a  in only one of the following categories: 
Medical: defined as a patient admitted to the ICU for treatment without any surgical intervention 
(includes patients admitted from a cardiology/ radiology unit)  
Surgical: defined as (1) a patient admitted to the ICU from the operating room directly or a 
recovery unit following a planned surgical procedure or (2) a patient admitted to the ICU from the 
operating room or a recovery unit following an unplanned surgical procedure. 
Note: If a surgical patient develops a medical complication and is transferred to the ICU from the 
ward, this would be a “medical” admission type. 
Primary ICU 
diagnosis* 
Identify and write down the most pertinent diagnosis that resulted in the patient’s admission to 
ICU. Only one diagnosis can be chosen. Remember, symptoms are not an admission diagnosis 
(e.g. respiratory distress, hypotension, etc.) Example: A patient was admitted to hospital for an 
elective cholecystectomy. Post-operatively the patient developed septic shock on the ward and 
was subsequently admitted to the ICU. The patient would be classified as medical admission 
type, and septic shock as the primary ICU diagnosis. 
APACHE II 
score* 
The APACHE II score must be calculated using Appendix III.  
Note: For each APACHE variable, use the single worst value out of all values from the first 24 
hours after ICU admission. If variables are not available from the first 24 hours, go outside the 24 
hour window and use data closest to ICU admission.  
Renal 
function* 
Review the patient’s ICU charts for the presence of AKI. The presence of AKI should be based on 
the charted diagnoses by the attending physician. If a patient presented with AKI, please indicate 
whether the patient received renal replacement therapy. 
Presence of 
sepsis* 
Review the patient’s ICU charts for the presence of sepsis. The presence of severe sepsis/ SIRS 
or septic shock should be based on the charted diagnoses and/or according to the presence of 
sepsis criteria as indicated in the table below.  
Sepsis diagnostic criteria 
SIRS Presence of two or more of the following features: 
Temperature  < 36˚C or > 38˚C; (2) Tachycardia > 90 beats per minute; 
(3) Respiratory rate > 20 breaths per minute or PaCO2 < 32 mmHg;   
(4) WCC > 12 X 10
9
/L or < 4 X 10
9
/L 
Sepsis SIRS occurring in the presence of an infection 
Severe sepsis Sepsis with evidence of one or more organ dysfunctions, such as: 
Acute kidney injury (oligouria), thrombocytopenia, secondary acute 
respiratory distress syndrome (ARDS), hypotension (requiring inotropes), 
lactic acidosis 
Septic shock Severe sepsis with hypotension (systolic BP* < 90mmHg) despite adequate 
fluid resuscitation 
Critical illness 
classification* 
Based on the primary ICU diagnosis, choose the most pertinent critical illness classification 
(subdivided under medical or surgical) for each patient. 
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b. Medical follow-up: 
Review study participants’ ICU charts and chart the following:   
- Medication/s 
- Tests/procedures 
- Laboratory blood values 
- Arterial blood gas values 
- Fluid balance 
- Gastric aspirates 
- Vomiting 
- Stools 
- Clinical presentation 
 
 
c. Baseline nutritional assessment  
Height* Record the patient’s height charted on his/her ICU chart.  
 
Weight* Record the patient’s weight charted on his/her ICU chart. When applicable also record the 
adjustment of body weight for oedema or amputations (if charted).  
 
Body mass 
index (BMI) 
Calculate and indicate the patient’s BMI according to the charted weight and height. 
 
Nutritional 
status 
Indicate the patient’s nutritional status according to the BMI classification system. 
 
Calculation 
of ideal body 
weight 
Ideal body weight must be calculated for all patients according to the following sex-specific 
guideline: 
 
Males: Height2 (m) X 20 – 25 
Females: Height2 (m) X 19 – 24 
 
Note: Use the height and weight recorded on the patient’s ICU chart/s. 
The “ideal body weight” does not necessarily refer to the weight used in the calculation of 
energy and protein targets. 
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d. Daily Feeding Prescription 
 
Daily feeding prescriptions are routinely calculated and charted for all ICU patients (charted daily on ICU 
charts). Review each study participant’s daily feeding prescription from the day of ICU admission until ICU 
discharge, discontinuation of nutrition therapy or death, whichever occurred first. If no RD feeding 
prescription is charted for a given patient, the patient’s attending physician will write a feeding prescription 
(e.g. over weekends). Use the patient’s daily feeding prescriptions (as charted on his/her ICU charts) to 
record the following information. Please indicate on the CRF if any particular information was not charted 
on the patient’s records. Remember Asteriks (*) denote required fields. If required data is not charted on 
the patient’s records, exclude this patient and include the next eligible patient. 
 
Person responsible 
for writing daily 
feeding prescription* 
Indicate the person/s who calculated/wrote the patient’s daily feeding 
prescription/s; e.g. registered dietician, attending registrar, consultant or chief 
physician of the ICU.  
Weight used in 
calculation of feeding 
prescription 
 
Indicate the weight used in the calculation of the feeding prescription.  
 
 
Prescribed route of 
nutrition therapy at 
initial assessment* 
 
Indicate the route of nutrition therapy prescribed at initial assessment. 
Nutrition therapy 
Initiation Date/Time* 
Enter the date/time EN and/or PN was initiated in the ICU, or indicate “EN and/or 
PN initiated prior to ICU admission”. Specify the initial route of nutrition therapy; 
i.e. EN and/or PN. 
 
Feeding prescription* Indicate the charted feeding prescription/s for each day (Name of EN formula/PN 
regimen and goal rate). If more than one feeding prescription was charted on a 
particular day, chart all prescriptions for that given day. 
 
Calculation of 
nutritional targets 
Indicate the method/formula used to calculate nutritional requirements.  
  
Prescribed energy 
and protein intake 
Indicate the charted daily energy and protein target. If no energy and/or protein 
target is charted, refer to Section E: Standardization of energy/protein targets. 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
143 
 
 
e. Standardization of energy and protein targets 
 
Use the criteria below to retrospectively standardise each patient’s energy and protein targets for each day.  
Standardized procedure for estimating daily energy targets 
Pathologies  Energy requirement A 
(kCal/kg/d actual BW) 
Acute and initial phase whatever the underlying disease 
   With severe undernutrition 25 – 30 
   Without undernutrition 
 
20 – 25 (female) 
25 – 30 (male) 
   With obesity 20 – 25B 
   With overweight 20 – 25C 
   Except for  
        Burns 
 
40 
Recovery or post-acute phase whatever the underlying disease 
   With severe undernutrition 30 – 35 
   Without undernutrition 25 - 30  
   With obesity 20 – 25  
   With overweight 20 – 25  
     Except for  
        Burns 
        Severe sepsis/polytrauma 
        Necrotizing pancreatitis 
        Open abdomen 
        Guillian bare syndrome 
        Toxic epidermal necrosis 
        Liver failure (hepatic encephalopathy) 
        Acute renal failure 
           -Conservative management 
           -Daily dialysis 
 
40 - 45 
30 – 35 
35 – 40 
30 – 35  
30 – 35  
35 - 40 
30 - 35 
 
25 – 30  
30 – 35 
Other factors taken into account: glucose control, presence of pyrexia, hypercapnia 
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Standardized procedure for estimating daily protein targets 
Pathologies Protein requirement (g/kg/d actual BW)* 
General ICU patient 1.2 – 1.5  
Except for:  
  Parenteral nutrition 1.3 – 1.5  
  Liver failure with hepatic encephalopathy 0.8 – 1.2   
  Burns 2 – 2.5  
  Open abdomen  1.5 – 2  
  Toxic epidermal necrosis 1.5 – 2  
  Guillian-bare syndrome 1.5 
  Acute kidney injury  
     Conservative management 1.2  
     Daily dialysis/SLED 1.5 – 1.7  
     CVVHD 1.5 – 2  
 * Use ideal body weight if overweight and adjusted ideal body weight if obese.  
Abbreviations: BW: Body weight; SLED: Sustained low-efficiency dialysis; CVVHD: Continuous venovenous  
Hemofiltration 
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Weight used for calculations 
Nutritional status Weight used for calculations 
 
With undernutrition 
 
Lower range of ideal BWA 
With severe undernutrition 
 
Median of actual BW and lower range of ideal BWB 
Without undernutrition 
 
Actual BW 
With overweight 
 
Ideal BWC 
With obese 
 
Adjusted ideal BWD 
A Lower range of ideal BW: Body mass index of 18.5 kg/m2 
B Median of actual BW and lower range of ideal BW: {(Actual BW – Ideal BW) X 0.5} + actual BW  
C Ideal BW: Males: Height2 (m) X 20 – 25; Females: Height2 (m) X 19 – 24  
D Adjusted ideal BW (25% correction factor): {(Actual BW – Ideal BW) X 0.25} + Ideal BW 
Abbreviations: BW: Body weight  
 
 
f.  Retrospective Progress Report 
 
Review the patient’s ICU charts and write down short and concise daily progress reports. 
 
 
4. Daily Fluid and Nutritional Data 
 
Use Appendix IV (Daily Fluid and Nutritional Flow Chart) to retrospectively record the daily fluid and 
nutritional intake of each study participant, from ICU admission until discharge, discontinuation of nutrition 
therapy or death, whichever occurred first. Retrospective review of ICU charts should be done on 
consecutive days following ICU admission, even if the patient did not receive nutrition (e.g. NPO for 
surgery). If a patient remained in ICU for more than 7 days data should only be collected until day 7 in ICU. 
Use additional pages of the flow chart as necessary.   
 
Study day 1 is from ICU admission until 07:00am the next morning. This might be less than 24 hours. Day 2 
and subsequent days are labelled according to ICU chart days (i.e. 07:00am to 06:59am). This will ease 
data collection.  
 
Example: A patient was admitted on March 2nd at 15:33. Day 1 begins at 15:33 and ends March 3rd at 
06:59am (Day 1 is only 15hrs, 26 min long). Day 2 begins at 07:00 am, March 3rd, and ends at 06:59am on 
March 4th. 
Note: The patient should have remained in ICU for at least 72 hours to be included in the study.  
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It is crucial to record all fluids taken in via the intravenous, enteral and/or oral route. Space is provided 
on the patient’s fluid and nutritional flow chart to indicate the type and volume of each fluid taken in.   
 
If the following data is not accurately charted, please follow the standardised procedure (Appendix V) to 
accurately estimate the type and volume of fluid administered:  
- Intravenous line flushing 
- Reconstitution of powdered drugs 
- Intravenous drug dilution 
- Administration of drugs via an enteric tube 
- Swallowing of tablets 
 
Please take note of the following: 
 
- Intravenous line flushing: 
Add an additional 72ml (3ml/hr) of normal saline to compensate for the routine automatic heparin-saline 
flushing of IV lines (driven by an infusible pressure bag). 
 
- Drugs administered subcutaneously or intramuscularly: 
Ignore the volume of drugs administered subcutaneously (e.g. Clexane, Recormin) or intramuscularly (e.g. 
Tetanis immunoglobulin/anti-tetanis toxoid; i.e. ATT) since this is regarded negligible and will not be taken 
into account during the calculation of total fluid intake.  
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Appendix I: 
 
Screening Log  
 
(Part of standardised data collection protocol) 
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SCREENING LOG   
 
Please use additional copies of this page as necessary.  
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d
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1             
 
2             
 
3             
 
4             
 
5             
 
6             
 
7 
 
            
8 
 
            
9 
 
            
10 
 
            
11 
 
            
12 
 
            
13 
 
            
14 
 
            
15 
 
            
16 
 
            
17 
 
            
18 
 
            
 
TOTAL ELIGIBLE: _______________                                
ICU 576 
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Appendix II: 
 
Case Report Form 
 
 
(Part of standardised data collection protocol) 
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Case Report Form                    Patient Hospital No:______________       Research number: ___________ 
 
A. PATIENT INFORMATION 
 
Sex*:           Male               Female                                         Age* (year & months): __________________           
 
ICU Admission Date*: (YYYY-MM-DD):_______________  Time: (HH:MM, 24h): ___________________  
 
Type of admission:              Medical                  Surgical 
 
Primary ICU diagnosis*: 
_____________________________________________________________________________________ 
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________ 
 
Other comorbidities or medical/nutritional problems: 
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________ 
Medical history: 
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________ 
 
APACHE II SCORE:*____________________________________________________________________ 
 
RENAL FUNCTION*:            Normal renal function                AKI, no dialysis                 AKI, dialysis  
 
SEPSIS*:            No sepsis           Sepsis/SIRS              Severe sepsis/SIRS                   Septic shock 
 
 
Critical illness classification (based on primary ICU diagnosis):  
 
Medical: 
 
        Cardiovascular/vascular                 Respiratory               Gastrointestinal             Neurologic 
 
        Sepsis                                             Trauma                     Metabolic                       Hematologic 
 
        Other medical disease, 
specify_____________________________________________________________________________ 
 
Surgical: 
 
       Cardiovascular/vascular                  Respiratory               Gastrointestinal             Neurologic 
 
        Trauma                                           Renal                        Gynaecologic                Orthopaedic 
 
        Other surgical condition, specify______________________________________________________ 
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B. MEDICAL FOLLOW-UP 
 
Medication 
Medication Dose Date 
       
         
         
         
         
         
         
Tests/procedures 
Date Test/ 
Procedure 
Results 
   
   
Laboratory blood values  
Parameter Normal range 
 
Date 
       
WCC 4.0 –10X10
9
/L        
Hb 12.0 – 15.0g/dL        
Plt 178-40X10
9
/L        
CRP <10        
PCT <0.5        
Na 135- 145        
K 3.3 – 5.3        
Cl 99 – 113        
Co2 18 – 29        
Urea 2.6 – 7.0        
Creat 60 – 100        
Ca 2.05 – 2.56        
Mg 0.65 – 1.1        
P 0.8 – 1.4        
Glucose 3 – 10mmol/L        
Other         
Arterial blood gas  
pH 7.35 – 7.45        
pCO2 35-45 mm Hg        
pO2 80-100 mmHg         
HCO3 21-28 mEq/L        
BE -4 - +2        
O2 saturation 95% - 100%        
Other parameters 
Fluid 
balance 
Intake*         
Output*         
Balance*         
Gastric aspirates <200mL        
Stools <400mL        
Urine output         
Vomiting         
Clinical presentation 
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C. BASELINE NUTRITIONAL ASSESSMENT 
 
 
Date recorded on ICU chart:____________________ (Day of ICU stay: ____) 
 
 
Height (metres):*____________                       Weight (kg):*_______________                 Actual 
                                                                                                                                               Estimated 
 
 
Weight adjusted for oedema?*          Yes             No                Not charted 
 
If yes, indicate degree of oedema:              Mild             Moderate             Severe            Not charted     
 
If yes, show calculations (if charted): 
___________________________________________________________________________________ 
Dry weight: _________kg              Not charted 
 
 
 
Weight adjusted for amputations?*         Yes             No                Not charted 
 
If yes, indicate body parts amputated: _________________________________            Not charted  
 
If yes, show calculations (if charted): 
___________________________________________________________________________________ 
 
Adjusted weight: _________kg              Not charted 
 
 
 
Body mass index:*______________kg/m2               Actual     
                                                                                    Estimated                                                                                         
 
 
 
 
Nutritional status* (tick the appropriate block): 
                                                                                                                                                                                                 
Calculation of ideal body weight: 
Males: Height2 (m) X 20 – 25 
Show calculations:____________________________________________________________________ 
 
Females: Height2 (m) X 19 - 24 
Show calculations:____________________________________________________________________                                                           
 Undernourished Grade I 17 ≤ BMI < 18.5 
 Grade II 16 ≤ BMI < 17 
 Grade III  BMI < 16 
 Normal 18.5 ≤ BMI < 25 
 Overweight 25 ≤ BMI < 30 
 Obese Class I 30 ≤ BMI < 35  
 Class II 35 ≤ BMI < 40 
 Class III (Morbid obesity) BMI ≥ 40 
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D. NUTRITIONAL PRESCRIPTION 
 
 
Indicate the body weight (BW) used in the calculation of nutritional targets*: 
 
Tick 
appropriate 
block 
 
Weight 
 
Indication for use 
  
Actual BW 
 
Underweight  
(at risk of refeeding syndrome) 
 
 
 
 
(ActuaI BW + ideal BW based on a BMI 18.5 kg/m
2
) X 0.5 
 
Underweight  
(no risk of refeeding syndrome) 
 
 
 
Actual BW 
 
 
 
Normal weight 
 
 
 
Ideal BW  
 
Overweight 
 
 
 
(Actual BW – ideal BW) X 0.25} + ideal BW 
 
Obese  
 
 
BW used for calculations not charted, specify: 
 
 
 
 
 
 
 
 
Prescribed route of nutrition therapy at initial assessment by doctor/RD*: 
 
                      EN                                      PN                                 EN & PN 
 
If EN, indicate route (tick appropriate block): 
 
 Nasogastric 
 
 Orogastric 
 Gastrostomy/PEG 
 
 Jejunostomy 
 
 
Other,specify:________________________ 
 
 
 
 
If PN, indicate access route (tick appropriate block): 
 
 Central 
 
 Peripheral 
 
 
When was nutrition therapy first initiated?* 
           
          Initiated prior to ICU admission 
 
          Initiated in ICU: Date (YYYY-MM-DD):_______________________ Time: (HH:MM, 24 hr)_________ 
 
Indicate initial route of nutritional therapy (tick appropriate block)*:  
 
 EN  PN  Combination of EN & PN 
 
Comments:___________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________ 
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Calculation of nutritional targets   (Use extra copies of this sheet as needed)  
Date Energy* PROT* HO Lipid Feeding script 
 
Date: 
 
 
Day of ICU 
stay: 
_____________ 
 
Responsible 
person: 
_____________ 
 
 
    
 
Product*: 
 
 
Volume/24hr*: 
________________ 
 
Rate/hr*:_________ 
 
Prescribed energy 
intake (kcal/day): 
________________ 
 
Prescribed protein 
intake (g/day): 
________________ 
 
 
Date: 
 
 
Day of ICU 
stay: 
_____________ 
 
Reason for  
changing 
prescription: 
_____________ 
 
Responsible 
person: 
______________ 
    
 
Product*: 
 
 
Volume/24hr*: 
_______________ 
 
Rate/hr:*_________ 
 
Prescribed energy 
intake (kcal/day): 
________________ 
 
Prescribed protein 
intake (g/day): 
________________ 
 
 
Date: 
 
 
Day of ICU 
stay: 
_____________ 
 
Reason for  
changing 
prescription: 
_____________ 
 
Responsible 
person: 
______________ 
    
 
Product*: 
 
 
Volume/24hr*: 
_______________ 
 
Rate/hr:*_________ 
 
Prescribed energy 
intake (kcal/day): 
________________ 
 
Prescribed protein 
intake (g/day): 
________________ 
 
 
Date: 
 
 
Day of ICU 
stay: 
_____________ 
 
Reason for  
changing 
prescription: 
_____________ 
 
 
Responsible 
person: 
______________ 
    
 
Product*: 
 
 
Volume/24hr*: 
________________ 
 
Rate/hr*:_________ 
 
Prescribed energy 
intake (kcal/day): 
________________ 
 
Prescribed protein 
intake (g/day): 
________________ 
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E. PROGRESS REPORT 
 
Date Follow-up notes 
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Appendix III: 
APACHE II scoring system 
 
(Part of standardised data collection protocol) 
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The APACHE II severity of disease classification system: 
 
 +4 +3 +2 +1 0 +1 +2 +3 +4 
Temperature (rectal) >40.9 39-
40.9 
 38.5-
38.9 
36.38.4 34-
35.9 
32-
33.9 
30-
31.9 
<30 
Mean arterial pressure 
(mmHg) 
>159 130-
159 
110-
129 
 70-109  50-69  <50 
Heart rate (ventricular) >179 140-
179 
110-
139 
 70-109  55-69 40-54 <40 
Respiratory rate >49 35-49  25-34 12-24 10-11 6-9  <6 
Oxygenation 
FiO2 <0.5 record Pa-O2 
FiO2 >0.5 record A-aDO2 
>499 350-
499 
200-
349 
 >70 
<200 
61-70  55-60 <55 
Arterial pH >7.69 7.6-
7.69 
 7.5-
7.59 
7.33-
7.49 
 7.25-
7.32 
7.15-
7.24 
<7.15 
If no ABG – serum HCO3 
(mmol/L) 
>51.9 41-
51.9 
 32-
40.9 
22-
31.9 
 18-
21.9 
15-
17.9 
<15 
Serum Sodium (mmol/L) >179 160-
179 
155-
159 
150-
154 
130-
149 
 120-
129 
111-
119 
<111 
Serum Potassium 
(mmol/L) 
>6.9 6-6.9  5.5-5.9 3.5-5.4 3-3.4 2.5-2.9  <2.5 
Serum Creatinine 
(umol/L) 
Double score for acute 
renal failure 
>299 170-
299 
130-
169 
 50-129  <50   
Haematocrit (%) >59.9  50-
59.9 
46-
49.9 
30-
45.9 
 20-
29.9 
 <20 
White cell count 
(1000/m
3
) 
>39.9  20-
39.9 
15-
19.9 
3-14.9  1-2.9  <1 
 
Total score              = (15 – GCS) + APACHE score + Age points + Chronic health points 
 
APACHE II SCORE =                   +                           +                   +                                   =______________ 
 
Age points: Age (years) Points 
 <45 0 
 45-55 2 
 55-64 3 
 65-74 5 
 >74 6 
 
Chronic health points: 
If a patient has a history of severe organ system insufficiency or is immune-compromised assign points as follows: 
g. For non-operative or emergency post-operative patients -> 5 points 
h. For elective post-operative patients -> 2 points 
 
Definitions: 
Organ insufficiency or immune-compromised state must have been evident prior to this hospital admission and 
conform to the following criteria: 
    Liver: Biopsy proven cirrhosis and documented portal hypertension; episodes of past upper GIT   bleeding 
attributed to portal hypertension. 
    Cardovascular: New York Heart Association Class IV 
    Respiratory: Chronic Restrictive, Obstructive, or Vascular disease resulting in severe exercise restriction, i.e.  
unable to climb stairs or perform household duties; or documented chronic hypoxia, hypercapnia, secondary 
polycythemia, severe pulmonary hypertension (>40mmHg), or respiratory dependency. 
    Renal: Receiving chronic dialysis 
    Immuno-compromised: the patient has received therapy that suppresses resistance to infection, e.g. Immuno-
suppression, chemotherapy, radiation, long term or recent high dose steroids, or has a disease that is 
sufficiently advances to suppress resistance to infection, e.g. leukaemia, lymphoma and AIDS. 
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Appendix IV 
Daily Fluid & Nutritional Flow Chart 
 
(Part of standardised data collection protocol) 
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DAILY FLUID AND NUTRITIONAL DATA* 
 
 Day 1 
 
ICU Bed no:____________ 
Date:_________________ 
Day 2 
 
ICU Bed no:__________ 
Date:_______________ 
Day 3 
 
ICU Bed no:___________ 
Date:________________ 
Day 4 
 
ICU Bed no:___________ 
Date:________________ 
 
Day 5 
 
ICU Bed no:___________ 
Date:________________ 
 
Day 6 
 
ICU Bed no:___________ 
Date:________________ 
 
Day 7 
 
ICU Bed no:___________ 
Date:________________ 
 
1. INTRAVENOUS 
1.1.Fluid support 
1.1.1  
Crystalloids 
             Y                  N 
 
 
             Y                  N            Y                 N                 Y                   N                 Y                  N                Y                    N                Y                    N 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
 
 
             
 
 
             
              
 
 
 
             
1.1.2 
Colloids 
 
 
               Y                    N 
 
 
               Y                   N 
 
 
               Y                    N 
 
 
               Y                    N 
 
 
               Y                   N 
 
 
                Y                  N 
 
 
               Y                   N 
 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
 
 
 
 
            
  
 
            
  
 
            
              
 
1.1.3. 
Blood 
products 
 
 
 
               Y                    N                Y                   N                Y                    N                Y                    N                Y                   N                Y                   N                Y                   N 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
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DAILY FLUID AND NUTRITIONAL DATA 
 
 Day 1 
Date:______________ 
Day 2 
Date:_________________ 
Day 3 
Date:________________ 
Day 4 
Date:__________________ 
Day 5 
Date:______________ 
Day 6 
Date:__________________ 
 
Day 7 
Date:_______________ 
1.2. IV drug & supplement dilution (*Obtain this data from the Daily IV Drug & Supplement Dilution Data Form) 
 
 
               Y                    N 
 
               Y                    N                 Y                   N                 Y                  N                Y                   N                Y                    N                Y                   N 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
              
              
 
              
1.3. Flushing of IV lines 
                Y                    N 
 
 
 
               Y                    N 
 
 
 
               Y                    N 
 
 
 
               Y                    N 
 
 
 
               Y                   N 
 
 
 
               Y                   N 
 
 
 
               Y                   N 
 
 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
              
              
1.4. IV electrolyte supplements 
                Y                    N 
 
 
 
               Y                    N 
 
 
 
               Y                    N 
 
 
 
               Y                    N 
 
 
 
               Y                   N 
 
 
 
               Y                    N 
 
 
 
               Y                   N 
 
 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
 
 
             
            
 
  
 
 
             
1.5. Nutritional prescription 
1.5.1. PN                Y                    N 
 
               Y                    N 
 
               Y                    N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                    N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
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DAILY FLUID AND NUTRITIONAL DATA 
 
 Day 1 
Date:______________ 
Day 2 
Date:_________________ 
Day 3 
Date:_______________ 
Day 4 
Date:__________________ 
Day 5 
Date:______________ 
Day 6 
Date:__________________ 
 
Day 7 
Date:_______________ 
1.5.2  
Dipeptivan 
               Y                    N 
 
               Y                    N 
 
               Y                    N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                    N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
              
 
1.5.3.  
Vitamin/ 
trace 
element 
suppl. 
 
 
               Y                    N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                   N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
 
 
             
              
1.6. Other (e.g. propofol; dextrose water infusion for hypoglycaemia) 
                Y                   N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                   N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
              
              
2. ENTERAL 
 
2.1 EN                Y                    N  
 
               Y                    N 
 
               Y                    N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                    N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
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DAILY FLUID AND NUTRITIONAL DATA 
 
 
 
Day 1 
Date:______________ 
Day 2 
Date:_________________ 
Day 3 
Date:_______________ 
Day 4 
Date:__________________ 
Day 5 
Date:______________ 
Day 6 
Date:__________________ 
 
Day 7 
Date:_______________ 
2.2. 
Flushing of 
Feeding 
tube  
                Y                   N 
 
               Y                   N 
 
               Y                    N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
              Y                    N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
              
 
              
 
2.3. Other 
(e.g. 
vitamin/ 
trace 
element 
suppl; 
mixing 
crushed 
meds with 
water) 
               Y                    N  
 
               Y                   N 
 
               Y                    N  
 
               Y                   N 
 
               Y                   N 
 
               Y                    N  
 
               Y                   N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
Type: Volume/ 
24h (L): 
         
 
     
 
 
             
         
 
     
3. ORAL 
3.1. 
Nutrition 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                    N 
 
               Y                   N 
 
               Y                    N 
 
               Y                   N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
              
 
 
 
             
3.2. Other 
(incl. 
water) 
               Y                    N 
 
               Y                    N                Y                    N 
 
               Y                    N 
 
               Y                    N 
 
               Y                    N 
 
               Y                    N 
 
Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: Specify below: 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
Purpose: Volume/ 
24h (L): 
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Appendix V: 
 
Standardised procedure for drug administration & 
 IV line flushing 
 
(Part of standardised data collection protocol) 
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Standardised procedure for drug administration & IV line flushing 
 
1. IV LINE FLUSHING 
a. Automatic flush 
A heparin-saline solution (hep-saline) is routinely used for the flushing of IV lines. Hep-saline 
consists of a 1000 IU (1ml) of heparin added to 999ml of normal saline to allow a 1:1 titration. The 
“infusible pressure bag” is maintained at a constant pressure of 300mmHg to allow an automatic 
hep-saline flush of 3ml/hr. 
b. Manual flush 
Arterial lines are manually flushed with approximately 5ml of hep-saline after administration of 
“push-in” drugs, including the “push-in” administration of insulin (sliding scale). 
 
2. RECONSTITUTION OF POWDERED DRUGS PRIOR TO INTRAVENOUS ADMINSTRATION 
Sterile saline is routinely used for the reconstitution of powdered drugs, except for drugs with its 
own reconstitution liquid enclosed in its packaging.  
 
3. IV DRUG DILUTION 
a. Type of diluent 
 Drugs are mixed with normal saline, unless: 
o     A given drug is incompatible with normal saline  
o     A patient’s serum sodium level exceeds 149mmol/L, in which case 5% dextrose 
water is used for drug dilution (unless the given drug is incompatible with 5% 
dextrose water). 
 The following drugs are routinely mixed with 5% dextrose water:  
o    Amphotericin B 
o    Amiodarone 
 The following drugs are strictly mixed with normal saline only:  
o     Epanutin 
 
b. Diluent volume 
 Adding drugs to a saline/dextrose water bag: 
It is a fixed unit protocol for the prescribed drug volume to be removed from the given diluent’s IV 
bag prior to adding the drug (e.g. remove 12ml from a 200ml normal saline bag before adding 12 
amps adrenaline). The assumption was therefore made that all drugs were routinely mixed 
according to this procedure. 
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 Antimicrobial committee antibiotic injection guidelines: 
All “push-in” drugs must be diluted in 10ml sterile saline unless otherwise stated and given through 
a freely running IV line over a period of not less than 3 minutes: 
Aminoglycosides, Amikacin, Tobramycin, Gentamycin, Cephalosporins (incl Cefazolin, Cefuroxime, 
Cefotaxime, Ceftriaxone, Ceflazidime), Cephamycins (incl Cefozitin, Penicillin, Ampicillin, 
Cloxacillin, Amoxid) 
 
Drugs indicated as “per protocol” should not be given as “push in”. Check package insert for a 
precise administration policy. Some of these drugs require specific dilution or are pre-diluted by the 
manufacturer and require a specific infusion time:  
Amphotericin B, Ciprofloxacillin, Clindamycin, Diethanolamine, Fusidate, Erythromycin, Imipenem, 
Meropenem, Ofloxacin, Piperacillin, Tazobactam, Vancomycin  
 
If the flushing of IV lines, reconstitution of powdered drugs or drug dilution are inaccurately charted 
by the nursing staff, a standardised procedure (Table 1) will be followed to estimate the given fluid 
volume. This standardised procedure is based on the precise administration policy as indicated on 
the package insert or on standard ICU protocols for the administration of drugs. 
 
4. STANDARDISED PROCEDURE FOR THE ADMINISTRATION OF DRUGS VIA AN ENTERIC 
TUBE 
a. Drugs in tablet form: 
 Drugs are crushed and mixed with approximately 10ml of water prior to administration.  
b. Drugs in liquid form: 
 Ulsanic: 5ml = 1 gram 
Tegretol: 5ml = 500mg 
The enteric tube is flushed with approximately 10ml of water after the administration of drugs. 
 
5. STANDARDISED PROCEDURE FOR SWALLOWING OF TABLETS 
The assumption is made that tablets are swallowed with approximately 30ml of water
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Table 1: Intravenous drug administration 
Drug 
 
Method 
Often prescribed dose 
Reconstitution Dilution NS flush 
Name Form Grams/volume Fluid Volume Diluent Volume Volume 
Analgesics/sedatives 
Morphine Liquid 1ml amp = 15mg Push 1 - 4 mg prn NS 15mg (1ml) to 14ml 
(1:1 titration) 
None None 5ml 
CI As prescribed  None None NS/D5W 45mg (3ml) to 47ml  
(1:1 titration) 
None 
Serenace Liquid 2ml amp = 20mg Push 2.5/5mg tds None None None None 5ml 
Dormicum 
  
Liquid 
  
3ml = 15mg 
  
Push 1 - 4mg prn NS 15mg (3ml) to 12ml 
(1:1 titration) 
None None 5ml 
CI As prescribed  None None NS/D5W 100mg (10ml) to 90ml 
(1:1 titration) 
None 
Tramadol/Tramal Liquid 2ml amp = 100mg Push 50mg bd  None None  None None 5ml 
Ampicilllin/Ranamp Powder 1 vial = 500mg IM 250mg/500mg/1g None None NS/D5W 50ml None 
Phenergen/Promethazine HCl Liquid 1ml amp = 25mg Push As prescribed  None None None None 5ml 
Perfalgon Liquid 100ml bottle = 1g IM 1g tds/qid None None None None None 
Ulcer prohylaxis 
Pantoloc Powder 1 vial = 40/80mg IM 40mg dly/bd/tds NS 10ml NS/D5W 50ml None 
CI 40mg/80mg dly None None NS/D5W Add prescribed dose to 
200ml, run at 8ml/hr 
None 
Antithrombotic   
Heparin Liquid 1ml amp = 
1000/5000IU 
CI As prescribed  None None NS only Add amount of heparin to 
be given per hour X 12 to 
100mls minus heparin 
volume, run at 8ml/hr 
over 12 hours 
 
 
None 
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Table 1: Intravenous drug administration 
Drug 
 
Method 
Often prescribed dose 
Reconstitution Dilution NS flush 
Name Form Grams/volume Fluid Volume Diluent Volume Volume 
Corticosteroids    
Solucortef Powder 1 vial = 100mg Push 100mg tds/qid NS 2ml None None 5ml 
Solumedrol Powder 1 vial = 
40/125/500mg 
Push 500mg dly WFI 500mg to 8ml None None 5ml 
Decadron Liquid 4ml Amp = 8mg Push 8mg tds None None None None 5ml 
Prokinetics  
Maxolon/Metoclopramide Liquid 2ml amp = 10mg Push 10 mg tds None None None None 5ml 
Erythromycin Powder 1 vial = 1g IM 250mg tds/1g dly NS 5ml NS/D5W 50ml None 
Diuretics                   
Lasix/Furosemide Liquid 2ml amp = 20mg Push 5mg tds None None None None 5ml 
CI As prescribed None None NS/D5W 100mg (10ml) to 90ml 
(1:1 titration) 
None 
Neuro-related drugs  
Rivotril Powder 1 vial = 1g Push 1g tds Own SW 2ml None None 5ml 
Epilim/ Sodium Valproate Powder 1 vial = 400mg IM 400mg tds Own SW  4ml  
(total volume= 
5ml) 
NS/D5W 100ml None 
Epanutin/Phenytoin Liquid 5ml Amp = 250mg IM 300mg/750mg/1g None None Only NS 50/100/100 None 
CI As prescribed  None None Only NS 200ml minus drug volume  None 
Muscle relaxants  
Vencuronium bromide/ 
Norcuron 
Powder 1 vial = 10mg Push 20mg stat for intubation NS 5ml  
(hence 2mg/ml) 
None None 5ml 
Pancuronium bromide/ Pavulon Liquid 2ml amp = 40mg Push As prescribed  None None 
 
None None 5ml 
Etomidate  Liquid 5ml amp =  10mg Push 10mg for intubation None None None None 5ml 
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Table 1: Intravenous drug administration 
Drug 
 
Method 
Often prescribed dose 
Reconstitution Dilution NS flush 
Name Form Grams/volume Fluid Volume Diluent Volume Volume 
Glucose control  
Actrapid/Humulin R Liquid 1ml = 100U Push Sliding scale NS 2ml None None 5ml 
CI As prescribed  None None NS/D5W 1ml (100U) to 99ml None 
Cardiac-related drugs   
Digoxin/Lanoxin Liquid 2ml amp = 0.5mg  Push As prescribed  None None None None 5ml 
Inotropic support  
Dobutrex* Liquid 20ml amp = 250mg CI APP None None NS/D5W 1g (80ml) in 120ml  None 
Adrenaline* Liquid 1ml amp = 1mg CI APP None None NS/D5W 6 amps (6ml) to 194ml None 
12 amps (12ml) to 188ml None 
24 amps (24ml) to 176ml None 
48 amps (48ml) to 152ml None 
Phenylephrine* Liquid 1 ml amp = 10mg CI APP None None NS/D5W 10 mg (1 amp) to 199 ml None 
40mg (4ml) to 196ml None 
80mg (8ml) to 192ml None 
Amiodarone/Corderone* Liquid 3ml = 150mg CI 600/1200mg None None Only D5W Loading dose: 5mg/kg in 
100ml over 30min 
 
None 
Then 1200mg over 24 hrs: 
Add 600mg (4 amps) to 
188ml, run at 17ml/hr 
over 12hrs 
 
 
 
 
None 
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Table 1: Intravenous drug administration 
Drug 
 
Method 
Often prescribed dose 
Reconstitution Dilution NS flush 
Name Form Grams/volume Fluid Volume Diluent Volume Volume 
Antibiotics  
Ampicillin Powder 1 vial = 500mg Push 250mg/500mg/1g NS 10ml None None 5ml 
Amikacin Liquid 2ml vial = 500mg Push 500mg/1000mg dly NS 10ml None None 5ml 
IM 500mg/1000mg dly None None NS/D5W 50/100ml None 
Augmentin  Powder 600mg/1200mg IM 600/1200mg tds None None NS/D5W 50ml None 
Azithromycin/Zithromax Powder 1 vial = 500mg IM 500mg dly/bd Own SW 4.8ml  
(Total volume= 
5ml) 
NS/D5W 100ml (50ml if RF) None 
Bactrim Liquid 1 amp = 3ml IM 4 amps (12ml) qid None None NS/D5W 4 amps (12ml) to 38ml None 
Clarithromycin/Klacid Powder 1 vial = 500mg IM  As prescribed  None None NS/D5W 100ml None 
Cefazolin/Ranzol/Kefzol/ 
Keftaz 
Powder 1 vial = 1g Push 500mg/1g/2g dly NS 10ml None None 5ml 
IM 500mg/1g/2g dly None None NS/D5W 50ml None 
Cefepime/Maxapime 
  
Powder 
  
1 vial = 
500mg/1g/2g 
  
IM As prescribed  None None NS/D5W 50ml None 
CI 3g/4g dly None None NS/D5W 3g to 100ml/4g to 200ml, 
run at 12.5 ml/hr 
None 
Cefotaxime Na/ 
Claforan/Tazocef 
Powder 1 vial = 1g Push 500mg/1g bd NS 10ml None None 5ml 
IM 500mg/1g bd None None NS/D5W 50ml None 
Ceflazidime/Taziject Powder 500mg/1g/2g Push As prescribed NS 10ml None None 5ml 
IM As prescribed  None None NS/D5W 50ml None 
Rocephin/Ceftriaxone/Kocef-
1000 
Powder 250mg/500mg/1g Push 250mg/500mg/1g bd NS 10ml None None 5ml 
IM 250mg/500mg/1g bd NS 5ml/5ml/10ml NS/D5W 50/50/100ml None 
Cefuroxime/Zinacef Powder 1 vial = 750mg Push 750mg qid NS 10ml None None 5ml 
IM 750mg qid None None NS/D5W 50ml None 
Cimetidine/Ranitidine/Zantac Liquid  2ml amp = 50mg IM 150mg bd None None NS/D5W 50ml 
 
None 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
  
170 
 
Table 1: Intravenous drug administration 
Drug 
 
Method 
Often prescribed dose 
Reconstitution Dilution NS flush 
Name Form Grams/volume Fluid Volume Diluent Volume Volume 
Ciprofloxacillin/Ciprobay/ 
Ciprocina 
Liquid 100ml bottle = 
200mg 
IM 200mg dly None None None None None 
Clindamycin Liquid 4ml amp = 600mg IM 300/600/900/1200mg/d None None NS/D5W 50/100/150/200ml None 
Cloxacillin Powder 1 vial = 500mg Push As prescribed NS 10ml None None 5ml 
IM As prescribed  None None NS/D5W 50ml None 
Ertapenem Powder 1 vial = 1g IM 500mg bd None None NS/D5W 50ml None 
Flagyl Liquid 100ml bottle = 
500mg 
IM 500mg tds None None None None None 
Gentamycin Liquid 2ml amp = 80mg IM 80/120mg dly None None NS/D5W 50ml None 
Imipenem Powder 1 vial = 500mg IM 1g tds None None NS/D5W 100ml None 
Linezolid/zyvoxid Liquid 300ml bag = 600mg IM 600mg tds None None NS/D5W 50ml None 
Meropenem Powder 1 vial = 
500mg/1000mg 
IM 250/500/1000mg dly None None NS/D5W 50ml None 
Tazocin/Piptaz Powder 1 vial = 4.5g IM 4.5g None None NS/D5W 50ml None 
CI 9/18g dly None None NS/D5W 200ml None 
Tobramycin Liquid 2ml amp = 80mg Push 240mg bd NS 10ml None None 5ml 
IM 240mg bd None None NS/D5W 50ml None 
Teicoplanin/Targocid 200 Liquid 10ml vial = 200mg 
 
IM As prescribed  None None NS/D5W 50ml None 
Vancomycin 
  
Powder 
  
1 vial = 500mg/1g 
  
IM 500mg/1g stat None None NS/D5W 50ml/100ml None 
CI 2g dly None None NS/D5W 2g to 200ml, run at 8ml/hr None 
Antifungal   
Amphothericin B/Fungizone* Powder 1 vial = 50mg CI 40mg dly None None D5W only 40mg to 200ml, run at 
8ml/hr 
 
None 
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Table 1: Intravenous drug administration 
Drug 
 
Method 
Often prescribed dose 
Reconstitution Dilution NS flush 
Name Form Grams/volume Fluid Volume Diluent Volume Volume 
Fluconazole Liquid 100ml bottle = 
200mg 
IM 200mg tds None None None None None 
Voriconazole Powder 1 vial = 200mg IM 600mg dly None None NS/D5W 50ml None 
Antiviral  
Acyclovir/Zovirax Powder 
 
1 vial = 250mg IM As prescribed None None NS/D5W 100ml None 
Glanciclovir/Cymevene  Powder 
 
1 vial = 500mg IM 250mg tds None None NS/D5W 100ml None 
Metronidazole Liquid 
 
100ml bag = 500mg IM As prescribed None None None None None 
Antiprotozoal  
Artesunate/Artesun Powder 1 vial = 60mg IM As prescribed Own 5% 
NaHCO3 
1 ml   
(Total volume = 
6ml) 
NS/D5W 50ml None 
Quinine Liquid 1 ml amp = 300mg CI As prescribed None None D5W only 600mg (2ml) to 198ml  None 
Antifibrinolytic  
Cyclokapron Liquid 5ml amp = 500mg IM 500mg tds None None NS/D5W 50ml None 
Other                   
Acetylcysteine/Parvolex 
  
Liquid 
  
10ml amp = 2g 
  
IM 600mg (3ml) tds None None NS/D5W 50ml  None 
CI As prescribed None None NS/D5W 200ml minus drug 
volume, run at 8ml/hr 
None 
Lignocaine Liquid 5ml amp = 0.1g IM As prescribed None None NS/D5W 50ml None 
Salbutamol Liquid 5ml amp = 5mg Push 5mg/10mg  NS 5ml None None 5ml 
Aminophylline Liquid 10ml amp = 250mg IM 175mg (7ml) stat None None NS/D5W 43ml None 
400mg (16ml) stat None None NS/D5W 84ml None 
CI 1g dly None None NS/D5W 1g (40ml) to 160ml None 
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Table 1: Intravenous drug administration 
Drug 
 
Method 
Often prescribed dose 
Reconstitution Dilution NS flush 
Name Form Grams/volume Fluid Volume Diluent Volume Volume 
TNT/Nitroglycerine* Liquid 10ml = 25mg CI APP None None NS/D5W 50mg (20ml) to 180ml, 
run at 8ml/hr 
None 
Precedex/Dexmedetomidine Liquid 2ml amp = 200mcg CI APP None None NS/D5W 1 amp (2ml) to 48ml, run 
at 1 - 18ml/hr 
  
Atropine* Liquid 10ml amp = 10mg CI APP None None NS/D5W 10mg (10ml) to 190ml 
(1:1 titration) 
None 
1ml amp = 0.5mg CI APP None None NS/D5W 10mg (20ml) to 180ml 
diluent (1:1 titration) 
None 
DDAVP* Liquid 1ml amp = 4mcg CI APP None None NS/D5W 6 amps (6ml) to 194ml None 
Trandate/Labatol Liquid 1 ml amp = 5mg CI As prescribed None None NS/D5W 200mg (40ml) to 160ml  None 
Haemosolvex Factor IX Powder 1 vial =500 IU  Push As prescribed Own WFI 10ml None None 5ml 
Polygam Powder 6g/12g/24g CI As prescribed None None Own NS 6g to 200ml/12g to 
400ml/24g to 800ml 
None 
Propofol 1% Liquid 10mg/ml CI As prescribed/APP None None None None None 
Robinul Liquid 1ml amp = 0.2mg CI APP None None NS/D5W 10 amps (10ml) to 190ml, 
run at 10ml/hr 
None 
Ketamine* Liquid 10ml vial = 1000mg 
 
 
 
 
CI As prescribed  None None NS/D5W 10mg (0.1ml drug) to 
30ml (induction dose) 
None 
50mg (0.5ml drug) to 
49.5ml 
None 
100mg (1ml drug) to 99ml None 
150mg (1.5ml drug) to 
148.5ml 
None 
400mg (4ml) to 196ml None 
Somatostatin* Liquid 1ml amp = 
0.05mg/0.1mg 
CI APP None None NS/D5W 10 amps (10ml) to 190ml, 
run at 10ml/hr 
None 
Remifentanyl/Ativan Liquid 1ml amp = 2mg C APP None None NS/D5W 2mg (1ml) to 49ml None 
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Table 1: Intravenous drug administration 
Drug 
 
Method 
Often prescribed dose 
Reconstitution Dilution NS flush 
Name Form Grams/volume Fluid Volume Diluent Volume Volume 
Electrolyte supplementation  
Potassium chloride 15%  Liquid 10ml amp = 1.5g  
 
IM APP None None NS/D5W 20mmol (10ml) to 50ml None 
40mmol (20ml) to 100ml None 
60mmol (30ml) to 150ml None 
Potassium phosphate Liquid 10ml amp = 2.14g 
 
IM APP None None NS/D5W 20mmol (10ml) to 50ml None 
40mmol (20ml) to 100ml None 
60mmol (30ml) to 150ml None 
Calcium chloride 10% Liquid 10ml amp = 1g  
 
IM 10ml stat None None NS/D5W 10ml to 50ml None 
Calcium gluconate 10% Liquid 10ml amp IM 10ml stat None None NS/D5W 10ml to 50ml None 
Magnesium sulphate Liquid 2ml = 1g  IM 2g (4ml) stat None None NS/D5W 2g (4ml) to 100ml None 
10g None None NS/D5W 10g (20ml) to 180ml, run 
at 20ml/hr 
None 
Sodium bicarbonate 8.5% Liquid 50ml bag IM As prescribed None None None None None 
Vitamin supplementation  
Vitamin C Liquid 5ml amp = 500mg Push 1g dly None None None None 5ml 
Vitamin K Liquid 1ml amp = 10mg Push Once dly or bd None None None None 5ml 
Thiamine Liquid 10ml vial = 100mg Push 100mg/300mg dly None None None None 5ml 
*Dobutrex, adrenaline, phenylephrine, amiodarone, amphotericin B, TNT, Precedex, Atropine, DDAVP, Robinul, Ketamine, Somatostatin; Epidural protocol: Standard ICU protocols 
Abbreviations: NS: Normal saline; IM: Intermittent infusion; CI: Continuous infusion; APP: As per protocol; D5W: 5% dextrose water; WFI: Water for injection. 
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APPENDIX C 
 
 
GENERAL ICU (CMJAH) GUIDELINES  
FOR ADJUSTING WEIGHT FOR OEDEMA/AMPUTATIONS 
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GICU (CMJAH) GUIDELINES FOR ADJUSTING WEIGHT FOR  
FLUID RETENTION AND AMPUTATIONS 
 
I. WEIGHT ADJUSTMENT FOR VISIBLE OEDEMA 
Degree of oedema Correction factor 
Mild Actual/estimated body weight – 1 kg 
Moderate Actual/estimated body weight – 5 kg 
Severe Actual/estimated body weight – 10 kg 
II. WEIGHT ADJUSTMENT FOR AMPUTATIONS 
Body Part Contribution to body weight (%)
A 
Entire arm 6.5 
Upper arm 3.5 
Forearm 2.3 
Hand 0.8 
Entire leg 18.5 
Upper leg 11.6 
Lower leg 5.3 
Foot 1.8 
Adjusted BW = (Estimated or current body weight/100 - % of amputation) X 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX D 
 
 
PRE-STUDY NURSING STAFF TRAINING HAND-OUT 
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576 GENERAL ICU (CMJAH) 
 
CLINICAL NUTRITION RESEARCH 
 
GENERAL INFORMATION 
Research Study: The Impact of Intravenous Fluid and Electrolyte Administration on Total Fluid, 
Electrolyte and Energy intake in Critically Ill Adult Patients.  
 
Investigator: Lizl Veldsman  
 
Co-
investigators: 
Prof GA Richards 
Prof R Blaauw 
 
Contact details Lizl Veldsman 
c: +2782 414 5084 
w: (011) 488 4348  
lizlveld@gmail.com 
 
AIM & OBJECTIVES 
AIM: 
 
To determine the nutritional content / contribution of IV fluid and electrolyte 
administration on the total feeding prescription of ICU patients.   
OBJECTIVES: 
 
(1) To determine the volume and types of IV fluids most often prescribed 
to ICU patients. 
(2) To determine the IV electrolyte supplements (type and dosing) most 
often prescribed to ICU patients.  
(3) To determine the contribution of the following routine ICU practices to 
a patient’s total fluid, electrolyte, energy and macronutrient intake: 
-Crystalloids, colloids and blood products used for IV fluid and 
volume management 
-Crystalloids used for IV drug dilution and flushing of IV lines 
-Lipids delivered with sedatives (propofol)  
-IV electrolyte replacement 
(4) To compare a patient’s total energy and macronutrient intake with 
his/her individualized feeding prescription. 
Data Collection 
Data will be collected retrospectively from the patients’ ICU charts once they are discharged from 
ICU. The following data will be collected from the day of ICU admission until a maximum of 7 
days:  
- Type and volume of IV fluids used for fluid support 
- Type and volume of IV fluids used for IV drug dilution 
- Type and volume of IV fluids used for flushing of IV lines 
- Type and dosing of IV electrolyte replacement (if prescribed) 
- Dose of propofol and/or dipeptivan infused (if prescribed) 
- Type and volume of enteral and/or parenteral nutrition delivered to the patient. 
- Type and volume of fluids and/or feeds taken orally (if applicable) 
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This study is based on a retrospective review of patients’ ICU charts. 
THEREFORE the success of this study largely depends on how accurate patients’ 
information is recorded on their ICU charts. 
 
THEREFORE ALL OF YOU PLAY A CRUCIAL ROLE IN THE SUCCESS OF THIS 
STUDY! 
 
Will you please ensure that the following information is accurately recorded on the ICU 
charts of all patients in ICU: 
Arterial blood gas values 
- Haematocrit %  
 
Fluid support: 
- Name of IV solution used (e.g. Ringer’s Lactate) 
- Rate of administration (e.g. 80mL/hr) 
 
IV drug dilution: 
Please chart the following information every time an IV drug or -electrolyte (e.g. KCl) is 
diluted: 
- Name of IV solution used (e.g. D5W, N/S) 
NB:  Please indicate if D5W was used instead of N/S. 
- Volume used (e.g. 40mmoL KCL diluted in 200mL N/S) 
 
Flushing of IV lines: 
Please chart the following every time an IV line is flushed: 
- NAME OF IV SOLUTION used for flushing IV lines (e.g. N/S) 
NB:  Please indicate if D5W was used instead of N/S. 
- Approximate VOLUME used for flushing of IV lines (e.g. 3mL) 
 
IV electrolyte administration: 
- Please indicate the TYPE (e.g. KCl, KPO4) and DOSE (e.g. 40 mmol) administered. 
Propofol/dipeptivan infusion: 
- If propofol or dipeptivan is prescribed to a patient, please chart the RATE at which it is 
administered to the patient. 
Crushing of medications given via the NGT/OGT: 
- Please indicate the VOLUME (e.g. 10mL) of water mixed with the crushed meds. 
If a fluid other than water was used (e.g. saline), please chart what fluid has been used. 
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Enteral nutrition: 
- Accurately chart the NAME OF THE FEED (e.g. Nutrison Low Sodium) and the RATE (e.g. 
60mL/hr) OF ADMINISTRATION. 
- If a patient’s feeding prescription is changed (e.g. changed from Osmolite to Fresubin 1200 
Complete), please indicate on the fluid chart the exact time at which the feed has been 
changed. 
- If a patient’s feeding prescription is as follows:  
 
 
 
 
 
 
60mL/hr X 24hr  
 
1440mL per day (±1.5L per day) 
 
 
             1 bottle Osmolite (1 litre)             1 bag Supportan (500mL)    
Parenteral nutrition 
Please chart the following on the patient’s ICU chart: 
- The ITN regimen (e.g. ITN8004XA) 
- Every time a new TPN bag is started, please record the name of the TPN bag (e.g. Kabiven 
or ITN8003XA) as well as the rate of infusion on the patient’s ICU chart. 
E.g. At 10h00 patient X is started on Kabiven @ 60mL/hr. At 17h00 that afternoon the Kabiven 
bag is discarded and the prescribed ITN bag (e.g. ITN 8804XA) is started.  
Chart the following: 10h00 =  KABIVEN 60mL/hr 
                                   17h00 = ITN8804A 60mL/hr.  
Oral feeds: 
Accurately chart the type and volume of oral feeds taken in by the patient. This includes: 
- Sips of water 
- Tea 
- Porridge 
- Sipfeeds 
- Jelly 
 
Alternate Osmolite with Supportan @ 60 mL/hr 
(1 bottle Osmolite  + 1 bag Supportan per day) 
THIS MEANS: 
Stellenbosch University  http://scholar.sun.ac.za
